{
	"0": {"data": {"text": "Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.\n", "entity1": "lindane", "entity2": "neurotoxicity", "span1": [10, 17], "span2": [108, 121]}, "bert_text": "Effect of <e1> lindane </e1> on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced <e2> neurotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"1": {"data": {"text": "Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.\n", "entity1": "lindane", "entity2": "neurotoxicity", "span1": [92, 99], "span2": [108, 121]}, "bert_text": "Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in <e1> lindane </e1> induced <e2> neurotoxicity </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"2": {"data": {"text": "Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.\n", "entity1": "Dexrazoxane", "entity2": "myelosuppression", "span1": [0, 11], "span2": [29, 45]}, "bert_text": "<e1> Dexrazoxane </e1> protects against <e2> myelosuppression </e2> from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"3": {"data": {"text": "Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.\n", "entity1": "etoposide", "entity2": "myelosuppression", "span1": [84, 93], "span2": [29, 45]}, "bert_text": "Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs <e1> etoposide </e1> <e2> myelosuppression </e2> from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"4": {"data": {"text": "Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.\n", "entity1": "daunorubicin", "entity2": "myelosuppression", "span1": [98, 110], "span2": [29, 45]}, "bert_text": "Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and <e1> daunorubicin </e1> <e2> myelosuppression </e2> from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"5": {"data": {"text": "Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.\n", "entity1": "doxorubicin", "entity2": "myelosuppression", "span1": [119, 130], "span2": [29, 45]}, "bert_text": "Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not <e1> doxorubicin </e1> <e2> myelosuppression </e2> from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"6": {"data": {"text": "Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.", "entity1": "methamphetamine", "entity2": "Aggressive behaviors", "span1": [114, 129], "span2": [0, 20]}, "bert_text": "Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in <e1> methamphetamine </e1> <e2> Aggressive behaviors </e2> have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"7": {"data": {"text": "Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.", "entity1": "methamphetamine", "entity2": "psychiatric disorders", "span1": [114, 129], "span2": [73, 94]}, "bert_text": "Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in <e1> methamphetamine </e1> <e2> psychiatric disorders </e2>, and are common in methamphetamine (METH) abusers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"8": {"data": {"text": "Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.", "entity1": "METH", "entity2": "Aggressive behaviors", "span1": [131, 135], "span2": [0, 20]}, "bert_text": "Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (<e1> METH </e1> <e2> Aggressive behaviors </e2> have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"9": {"data": {"text": "Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.", "entity1": "METH", "entity2": "psychiatric disorders", "span1": [131, 135], "span2": [73, 94]}, "bert_text": "Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (<e1> METH </e1> <e2> psychiatric disorders </e2>, and are common in methamphetamine (METH) abusers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"10": {"data": {"text": "In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.", "entity1": "AMN082", "entity2": "catalepsy", "span1": [13, 19], "span2": [64, 73]}, "bert_text": "In addition, <e1> AMN082 </e1> reduces the duration of haloperidol-induced <e2> catalepsy </e2> in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"11": {"data": {"text": "In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [44, 55], "span2": [64, 73]}, "bert_text": "In addition, AMN082 reduces the duration of <e1> haloperidol </e1>-induced <e2> catalepsy </e2> in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"12": {"data": {"text": "The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).", "entity1": "quetiapine", "entity2": "akathisia", "span1": [52, 62], "span2": [17, 26]}, "bert_text": "The incidence of akathisia was low and similar with <e1> quetiapine </e1> <e2> akathisia </e2> was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"13": {"data": {"text": "The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).", "entity1": "QTP", "entity2": "akathisia", "span1": [111, 114], "span2": [17, 26]}, "bert_text": "The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with <e1> QTP </e1> <e2> akathisia </e2> was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"14": {"data": {"text": "The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).", "entity1": "Li", "entity2": "akathisia", "span1": [117, 119], "span2": [17, 26]}, "bert_text": "The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + <e1> Li </e1> <e2> akathisia </e2> was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"15": {"data": {"text": "The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).", "entity1": "Li", "entity2": "akathisia", "span1": [141, 143], "span2": [17, 26]}, "bert_text": "The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + <e1> Li </e1> <e2> akathisia </e2> was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"16": {"data": {"text": "The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).", "entity1": "DVP", "entity2": "akathisia", "span1": [120, 123], "span2": [17, 26]}, "bert_text": "The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/<e1> DVP </e1> <e2> akathisia </e2> was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"17": {"data": {"text": "The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).", "entity1": "DVP", "entity2": "akathisia", "span1": [144, 147], "span2": [17, 26]}, "bert_text": "The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/<e1> DVP </e1> <e2> akathisia </e2> was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"18": {"data": {"text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.", "entity1": "anthracyclines", "entity2": "myelosuppression", "span1": [13, 27], "span2": [186, 202]}, "bert_text": "PURPOSE: The <e1> anthracyclines </e1> daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <e2> myelosuppression </e2> and cardiac toxicity limit their use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"19": {"data": {"text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.", "entity1": "anthracyclines", "entity2": "cardiac toxicity", "span1": [13, 27], "span2": [207, 223]}, "bert_text": "PURPOSE: The <e1> anthracyclines </e1> daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <e2> cardiac toxicity </e2> limit their use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"20": {"data": {"text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.", "entity1": "daunorubicin", "entity2": "myelosuppression", "span1": [28, 40], "span2": [186, 202]}, "bert_text": "PURPOSE: The anthracyclines <e1> daunorubicin </e1> and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <e2> myelosuppression </e2> and cardiac toxicity limit their use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"21": {"data": {"text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.", "entity1": "daunorubicin", "entity2": "cardiac toxicity", "span1": [28, 40], "span2": [207, 223]}, "bert_text": "PURPOSE: The anthracyclines <e1> daunorubicin </e1> and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <e2> cardiac toxicity </e2> limit their use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"22": {"data": {"text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.", "entity1": "doxorubicin", "entity2": "myelosuppression", "span1": [45, 56], "span2": [186, 202]}, "bert_text": "PURPOSE: The anthracyclines daunorubicin and <e1> doxorubicin </e1> and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <e2> myelosuppression </e2> and cardiac toxicity limit their use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"23": {"data": {"text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.", "entity1": "doxorubicin", "entity2": "cardiac toxicity", "span1": [45, 56], "span2": [207, 223]}, "bert_text": "PURPOSE: The anthracyclines daunorubicin and <e1> doxorubicin </e1> and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <e2> cardiac toxicity </e2> limit their use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"24": {"data": {"text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.", "entity1": "epipodophyllotoxin", "entity2": "myelosuppression", "span1": [65, 83], "span2": [186, 202]}, "bert_text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the <e1> epipodophyllotoxin </e1> etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <e2> myelosuppression </e2> and cardiac toxicity limit their use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"25": {"data": {"text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.", "entity1": "epipodophyllotoxin", "entity2": "cardiac toxicity", "span1": [65, 83], "span2": [207, 223]}, "bert_text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the <e1> epipodophyllotoxin </e1> etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <e2> cardiac toxicity </e2> limit their use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"26": {"data": {"text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.", "entity1": "etoposide", "entity2": "myelosuppression", "span1": [84, 93], "span2": [186, 202]}, "bert_text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin <e1> etoposide </e1> are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <e2> myelosuppression </e2> and cardiac toxicity limit their use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"27": {"data": {"text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.", "entity1": "etoposide", "entity2": "cardiac toxicity", "span1": [84, 93], "span2": [207, 223]}, "bert_text": "PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin <e1> etoposide </e1> are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <e2> cardiac toxicity </e2> limit their use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"28": {"data": {"text": "CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.", "entity1": "Methadone", "entity2": "QT prolongation", "span1": [13, 22], "span2": [42, 57]}, "bert_text": "CONCLUSIONS: <e1> Methadone </e1> is associated with <e2> QT prolongation </e2> and higher reporting of syncope in a population of heroin addicts.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"29": {"data": {"text": "CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.", "entity1": "Methadone", "entity2": "syncope", "span1": [13, 22], "span2": [82, 89]}, "bert_text": "CONCLUSIONS: <e1> Methadone </e1> is associated with QT prolongation and higher reporting of <e2> syncope </e2> in a population of heroin addicts.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"30": {"data": {"text": "CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.", "entity1": "heroin", "entity2": "QT prolongation", "span1": [109, 115], "span2": [42, 57]}, "bert_text": "CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of <e1> heroin </e1> <e2> QT prolongation </e2> and higher reporting of syncope in a population of heroin addicts.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"31": {"data": {"text": "CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.", "entity1": "heroin", "entity2": "syncope", "span1": [109, 115], "span2": [82, 89]}, "bert_text": "CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of <e1> heroin </e1> <e2> syncope </e2> in a population of heroin addicts.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"32": {"data": {"text": "Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.", "entity1": "imipenem/cilastatin", "entity2": "cerebral vascular accident", "span1": [179, 198], "span2": [46, 72]}, "bert_text": "Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of <e1> imipenem/cilastatin </e1> <e2> cerebral vascular accident </e2> (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"33": {"data": {"text": "Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.", "entity1": "imipenem/cilastatin", "entity2": "CVA", "span1": [179, 198], "span2": [74, 77]}, "bert_text": "Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of <e1> imipenem/cilastatin </e1> <e2> CVA </e2>) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"34": {"data": {"text": "Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.", "entity1": "imipenem/cilastatin", "entity2": "head trauma", "span1": [179, 198], "span2": [82, 93]}, "bert_text": "Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of <e1> imipenem/cilastatin </e1> <e2> head trauma </e2> and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"35": {"data": {"text": "Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.", "entity1": "imipenem/cilastatin", "entity2": "renal disease", "span1": [179, 198], "span2": [113, 126]}, "bert_text": "Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of <e1> imipenem/cilastatin </e1> <e2> renal disease </e2> developed seizures while receiving maximum doses of imipenem/cilastatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
	"36": {"data": {"text": "Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.", "entity1": "imipenem/cilastatin", "entity2": "seizures", "span1": [179, 198], "span2": [137, 145]}, "bert_text": "Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of <e1> imipenem/cilastatin </e1> <e2> seizures </e2> while receiving maximum doses of imipenem/cilastatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"37": {"data": {"text": "This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).", "entity1": "methadone", "entity2": "pain", "span1": [118, 127], "span2": [36, 40]}, "bert_text": "This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in <e1> methadone </e1> <e2> pain </e2> tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"38": {"data": {"text": "Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.", "entity1": "steroid", "entity2": "tetanic", "span1": [43, 50], "span2": [111, 118]}, "bert_text": "Half-relaxation time was prolonged in both <e1> steroid </e1> groups, and time to peak tension was longer with M, whereas <e2> tetanic </e2> tensions were similar.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"39": {"data": {"text": "Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.", "entity1": "M", "entity2": "tetanic", "span1": [100, 101], "span2": [111, 118]}, "bert_text": "Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with <e1> M </e1>, whereas <e2> tetanic </e2> tensions were similar.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"40": {"data": {"text": "The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.", "entity1": "timolol", "entity2": "hypokalemia", "span1": [35, 42], "span2": [66, 77]}, "bert_text": "The beta adrenergic blocking drug, <e1> timolol </e1>, tended to correct the <e2> hypokalemia </e2> of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"41": {"data": {"text": "The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.", "entity1": "bendrofluazide", "entity2": "hypokalemia", "span1": [92, 106], "span2": [66, 77]}, "bert_text": "The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term <e1> bendrofluazide </e1> <e2> hypokalemia </e2> of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"42": {"data": {"text": "In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.", "entity1": "CB 3717", "entity2": "breast cancer", "span1": [31, 38], "span2": [66, 79]}, "bert_text": "In early clinical studies with <e1> CB 3717 </e1>, activity has been seen in <e2> breast cancer </e2>, ovarian cancer, hepatoma, and mesothelioma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"43": {"data": {"text": "In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.", "entity1": "CB 3717", "entity2": "ovarian cancer", "span1": [31, 38], "span2": [81, 95]}, "bert_text": "In early clinical studies with <e1> CB 3717 </e1>, activity has been seen in breast cancer, <e2> ovarian cancer </e2>, hepatoma, and mesothelioma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"44": {"data": {"text": "In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.", "entity1": "CB 3717", "entity2": "hepatoma", "span1": [31, 38], "span2": [97, 105]}, "bert_text": "In early clinical studies with <e1> CB 3717 </e1>, activity has been seen in breast cancer, ovarian cancer, <e2> hepatoma </e2>, and mesothelioma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"45": {"data": {"text": "In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.", "entity1": "CB 3717", "entity2": "mesothelioma", "span1": [31, 38], "span2": [111, 123]}, "bert_text": "In early clinical studies with <e1> CB 3717 </e1>, activity has been seen in breast cancer, ovarian cancer, hepatoma, and <e2> mesothelioma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"46": {"data": {"text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "entity1": "steroids", "entity2": "atrophy", "span1": [64, 72], "span2": [183, 190]}, "bert_text": "We conclude that (1) short-term treatment with massive doses of <e1> steroids </e1> induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb <e2> atrophy </e2>, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"47": {"data": {"text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "entity1": "steroids", "entity2": "atrophy", "span1": [64, 72], "span2": [324, 331]}, "bert_text": "We conclude that (1) short-term treatment with massive doses of <e1> steroids </e1> induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb <e2> atrophy </e2> was not caused by acute nutritional deprivation alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"48": {"data": {"text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "entity1": "steroids", "entity2": "muscle necrosis", "span1": [64, 72], "span2": [294, 309]}, "bert_text": "We conclude that (1) short-term treatment with massive doses of <e1> steroids </e1> induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused <e2> muscle necrosis </e2>; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"49": {"data": {"text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "entity1": "steroids", "entity2": "atrophy", "span1": [143, 151], "span2": [183, 190]}, "bert_text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of <e1> steroids </e1> induced predominantly type IIb <e2> atrophy </e2>, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"50": {"data": {"text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "entity1": "steroids", "entity2": "atrophy", "span1": [143, 151], "span2": [324, 331]}, "bert_text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of <e1> steroids </e1> induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb <e2> atrophy </e2> was not caused by acute nutritional deprivation alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"51": {"data": {"text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "entity1": "steroids", "entity2": "muscle necrosis", "span1": [143, 151], "span2": [294, 309]}, "bert_text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of <e1> steroids </e1> induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused <e2> muscle necrosis </e2>; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"52": {"data": {"text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "entity1": "steroid", "entity2": "atrophy", "span1": [279, 286], "span2": [183, 190]}, "bert_text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither <e1> steroid </e1> <e2> atrophy </e2>, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"53": {"data": {"text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "entity1": "steroid", "entity2": "atrophy", "span1": [279, 286], "span2": [324, 331]}, "bert_text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither <e1> steroid </e1> caused muscle necrosis; (4) type IIb <e2> atrophy </e2> was not caused by acute nutritional deprivation alone.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"54": {"data": {"text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "entity1": "steroid", "entity2": "muscle necrosis", "span1": [279, 286], "span2": [294, 309]}, "bert_text": "We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither <e1> steroid </e1> caused <e2> muscle necrosis </e2>; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"55": {"data": {"text": "Cefotetan-induced immune hemolytic anemia.\n", "entity1": "Cefotetan", "entity2": "hemolytic anemia", "span1": [0, 9], "span2": [25, 41]}, "bert_text": "<e1> Cefotetan </e1>-induced immune <e2> hemolytic anemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"56": {"data": {"text": "Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).", "entity1": "QTP", "entity2": "EPS", "span1": [43, 46], "span2": [11, 14]}, "bert_text": "Similarly, EPS-related adverse events with <e1> QTP </e1> <e2> EPS </e2>-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"57": {"data": {"text": "Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).", "entity1": "Li", "entity2": "EPS", "span1": [49, 51], "span2": [11, 14]}, "bert_text": "Similarly, EPS-related adverse events with QTP + <e1> Li </e1> <e2> EPS </e2>-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"58": {"data": {"text": "Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).", "entity1": "Li", "entity2": "EPS", "span1": [98, 100], "span2": [11, 14]}, "bert_text": "Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + <e1> Li </e1> <e2> EPS </e2>-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"59": {"data": {"text": "Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).", "entity1": "DVP", "entity2": "EPS", "span1": [52, 55], "span2": [11, 14]}, "bert_text": "Similarly, EPS-related adverse events with QTP + Li/<e1> DVP </e1> <e2> EPS </e2>-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"60": {"data": {"text": "Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).", "entity1": "DVP", "entity2": "EPS", "span1": [101, 104], "span2": [11, 14]}, "bert_text": "Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/<e1> DVP </e1> <e2> EPS </e2>-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"61": {"data": {"text": "The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist.", "entity1": "succinylcholine", "entity2": "apnoea", "span1": [35, 50], "span2": [51, 57]}, "bert_text": "The use of serum cholinesterase in <e1> succinylcholine </e1> <e2> apnoea </e2> provided considerable relief to both patient and anaesthetist.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"62": {"data": {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity1": "catecholamines", "entity2": "psychotic symptoms", "span1": [72, 86], "span2": [92, 110]}, "bert_text": "To examine the relationship between quantitative stimulant drug levels, <e1> catecholamines </e1>, and <e2> psychotic symptoms </e2>, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"63": {"data": {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity1": "catecholamines", "entity2": "psychosis", "span1": [72, 86], "span2": [217, 226]}, "bert_text": "To examine the relationship between quantitative stimulant drug levels, <e1> catecholamines </e1>, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced <e2> psychosis </e2> were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"64": {"data": {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity1": "catecholamines", "entity2": "psychiatric", "span1": [72, 86], "span2": [135, 146]}, "bert_text": "To examine the relationship between quantitative stimulant drug levels, <e1> catecholamines </e1>, and psychotic symptoms, nineteen patients in a <e2> psychiatric </e2> emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"65": {"data": {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity1": "catecholamine", "entity2": "psychotic symptoms", "span1": [327, 340], "span2": [92, 110]}, "bert_text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and <e1> catecholamine </e1> <e2> psychotic symptoms </e2>, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
	"66": {"data": {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity1": "catecholamine", "entity2": "psychosis", "span1": [327, 340], "span2": [217, 226]}, "bert_text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and <e1> catecholamine </e1> <e2> psychosis </e2> were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
	"67": {"data": {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity1": "catecholamine", "entity2": "psychiatric", "span1": [327, 340], "span2": [135, 146]}, "bert_text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and <e1> catecholamine </e1> <e2> psychiatric </e2> emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
	"68": {"data": {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity1": "amphetamine-", "entity2": "psychotic symptoms", "span1": [185, 197], "span2": [92, 110]}, "bert_text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of <e1> amphetamine- </e1> <e2> psychotic symptoms </e2>, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"69": {"data": {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity1": "amphetamine-", "entity2": "psychosis", "span1": [185, 197], "span2": [217, 226]}, "bert_text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of <e1> amphetamine- </e1> or cocaine-induced <e2> psychosis </e2> were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"70": {"data": {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity1": "amphetamine-", "entity2": "psychiatric", "span1": [185, 197], "span2": [135, 146]}, "bert_text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of <e1> amphetamine- </e1> <e2> psychiatric </e2> emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"71": {"data": {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity1": "cocaine", "entity2": "psychotic symptoms", "span1": [201, 208], "span2": [92, 110]}, "bert_text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or <e1> cocaine </e1> <e2> psychotic symptoms </e2>, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"72": {"data": {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity1": "cocaine", "entity2": "psychosis", "span1": [201, 208], "span2": [217, 226]}, "bert_text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or <e1> cocaine </e1>-induced <e2> psychosis </e2> were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"73": {"data": {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity1": "cocaine", "entity2": "psychiatric", "span1": [201, 208], "span2": [135, 146]}, "bert_text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or <e1> cocaine </e1> <e2> psychiatric </e2> emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"74": {"data": {"text": "The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.", "entity1": "methadone", "entity2": "syncope", "span1": [48, 57], "span2": [80, 87]}, "bert_text": "The association between opioid dose and QT, and <e1> methadone </e1> dose and reporting of <e2> syncope </e2> was assessed using multivariate linear regression and logistic regression, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"75": {"data": {"text": "To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).", "entity1": "SM-5887", "entity2": "cardiotoxic", "span1": [58, 65], "span2": [36, 47]}, "bert_text": "To examine a possibly deteriorating cardiotoxic effect of <e1> SM-5887 </e1> <e2> cardiotoxic </e2> effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"76": {"data": {"text": "To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).", "entity1": "SM-5887", "entity2": "cardiomyopathy", "span1": [58, 65], "span2": [77, 91]}, "bert_text": "To examine a possibly deteriorating cardiotoxic effect of <e1> SM-5887 </e1>, low-grade <e2> cardiomyopathy </e2> was induced in dogs by four courses of doxorubicin (1.5 mg/kg).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"77": {"data": {"text": "To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).", "entity1": "doxorubicin", "entity2": "cardiotoxic", "span1": [131, 142], "span2": [36, 47]}, "bert_text": "To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of <e1> doxorubicin </e1> <e2> cardiotoxic </e2> effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"78": {"data": {"text": "To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [131, 142], "span2": [77, 91]}, "bert_text": "To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of <e1> doxorubicin </e1> <e2> cardiomyopathy </e2> was induced in dogs by four courses of doxorubicin (1.5 mg/kg).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"79": {"data": {"text": "The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.", "entity1": "milrinone", "entity2": "heart failure", "span1": [48, 57], "span2": [85, 98]}, "bert_text": "The use of phosphodiesterase inhibitors such as <e1> milrinone </e1> in the treatment of severe <e2> heart failure </e2> is frequently restricted because they cause vasodilation and hypotension.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"80": {"data": {"text": "The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.", "entity1": "milrinone", "entity2": "hypotension", "span1": [48, 57], "span2": [160, 171]}, "bert_text": "The use of phosphodiesterase inhibitors such as <e1> milrinone </e1> in the treatment of severe heart failure is frequently restricted because they cause vasodilation and <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"81": {"data": {"text": "Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.\n", "entity1": "fluocinolone acetonide", "entity2": "uveitis", "span1": [59, 81], "span2": [38, 45]}, "bert_text": "Intraocular pressure in patients with uveitis treated with <e1> fluocinolone acetonide </e1> <e2> uveitis </e2> treated with fluocinolone acetonide implants.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"82": {"data": {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity1": "lindane", "entity2": "convulsions", "span1": [48, 55], "span2": [100, 111]}, "bert_text": "Similarly, when the P450-mediated metabolism of <e1> lindane </e1> was blocked by cobalt chloride incidence of <e2> convulsions </e2> was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"83": {"data": {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity1": "lindane", "entity2": "toxicity", "span1": [48, 55], "span2": [294, 302]}, "bert_text": "Similarly, when the P450-mediated metabolism of <e1> lindane </e1> was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"84": {"data": {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity1": "lindane", "entity2": "convulsions", "span1": [150, 157], "span2": [100, 111]}, "bert_text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with <e1> lindane </e1> <e2> convulsions </e2> was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"85": {"data": {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity1": "lindane", "entity2": "toxicity", "span1": [150, 157], "span2": [294, 302]}, "bert_text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with <e1> lindane </e1> indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"86": {"data": {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity1": "lindane", "entity2": "convulsions", "span1": [174, 181], "span2": [100, 111]}, "bert_text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that <e1> lindane </e1> <e2> convulsions </e2> was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"87": {"data": {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity1": "lindane", "entity2": "toxicity", "span1": [174, 181], "span2": [294, 302]}, "bert_text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that <e1> lindane </e1> per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"88": {"data": {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity1": "cobalt chloride", "entity2": "convulsions", "span1": [71, 86], "span2": [100, 111]}, "bert_text": "Similarly, when the P450-mediated metabolism of lindane was blocked by <e1> cobalt chloride </e1> incidence of <e2> convulsions </e2> was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"89": {"data": {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity1": "cobalt chloride", "entity2": "toxicity", "span1": [71, 86], "span2": [294, 302]}, "bert_text": "Similarly, when the P450-mediated metabolism of lindane was blocked by <e1> cobalt chloride </e1> incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"90": {"data": {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity1": "PB", "entity2": "convulsions", "span1": [218, 220], "span2": [100, 111]}, "bert_text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by <e1> PB </e1> <e2> convulsions </e2> was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"91": {"data": {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity1": "PB", "entity2": "toxicity", "span1": [218, 220], "span2": [294, 302]}, "bert_text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by <e1> PB </e1> or ethanol inducible P450 isoenzymes are involved in its neurobehavioral <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"92": {"data": {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity1": "ethanol", "entity2": "convulsions", "span1": [224, 231], "span2": [100, 111]}, "bert_text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or <e1> ethanol </e1> <e2> convulsions </e2> was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"93": {"data": {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity1": "ethanol", "entity2": "toxicity", "span1": [224, 231], "span2": [294, 302]}, "bert_text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or <e1> ethanol </e1> inducible P450 isoenzymes are involved in its neurobehavioral <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"94": {"data": {"text": "Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.", "entity1": "steroid", "entity2": "ventricular septal rupture", "span1": [80, 87], "span2": [28, 54]}, "bert_text": "Two cases of postinfarction ventricular septal rupture in patients on long-term <e1> steroid </e1> <e2> ventricular septal rupture </e2> in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"95": {"data": {"text": "The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.\n", "entity1": "morphine", "entity2": "spinal cord ischemia", "span1": [132, 140], "span2": [174, 194]}, "bert_text": "The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial <e1> morphine </e1> after a noninjurious interval of <e2> spinal cord ischemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"96": {"data": {"text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.", "entity1": "Myocet", "entity2": "MBC", "span1": [162, 168], "span2": [61, 64]}, "bert_text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of <e1> Myocet </e1> <e2> MBC </e2> and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"97": {"data": {"text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.", "entity1": "Myocet", "entity2": "toxicity", "span1": [162, 168], "span2": [319, 327]}, "bert_text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of <e1> Myocet </e1> (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"98": {"data": {"text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.", "entity1": "doxorubicin", "entity2": "MBC", "span1": [189, 200], "span2": [61, 64]}, "bert_text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional <e1> doxorubicin </e1> <e2> MBC </e2> and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"99": {"data": {"text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.", "entity1": "doxorubicin", "entity2": "toxicity", "span1": [189, 200], "span2": [319, 327]}, "bert_text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional <e1> doxorubicin </e1> (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"100": {"data": {"text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.", "entity1": "cyclophosphamide", "entity2": "MBC", "span1": [241, 257], "span2": [61, 64]}, "bert_text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of <e1> cyclophosphamide </e1> <e2> MBC </e2> and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"101": {"data": {"text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.", "entity1": "cyclophosphamide", "entity2": "toxicity", "span1": [241, 257], "span2": [319, 327]}, "bert_text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of <e1> cyclophosphamide </e1> (C), every 3 weeks until disease progression or unacceptable <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"102": {"data": {"text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.", "entity1": "C", "entity2": "MBC", "span1": [259, 260], "span2": [61, 64]}, "bert_text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (<e1> C </e1> <e2> MBC </e2> and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"103": {"data": {"text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.", "entity1": "C", "entity2": "toxicity", "span1": [259, 260], "span2": [319, 327]}, "bert_text": "PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (<e1> C </e1>), every 3 weeks until disease progression or unacceptable <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"104": {"data": {"text": "The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.", "entity1": "dobutamine", "entity2": "hypertrophic cardiomyopathy", "span1": [145, 155], "span2": [46, 73]}, "bert_text": "The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with <e1> dobutamine </e1> <e2> hypertrophic cardiomyopathy </e2>, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"105": {"data": {"text": "The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.", "entity1": "dobutamine", "entity2": "biventricular failure", "span1": [145, 155], "span2": [93, 114]}, "bert_text": "The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with <e1> dobutamine </e1> <e2> biventricular failure </e2> and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"106": {"data": {"text": "The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).", "entity1": "quetiapine", "entity2": "EPS", "span1": [88, 98], "span2": [17, 20]}, "bert_text": "The incidence of EPS-related adverse events, including akathisia, was no different with <e1> quetiapine </e1> <e2> EPS </e2>-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"107": {"data": {"text": "The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).", "entity1": "quetiapine", "entity2": "akathisia", "span1": [88, 98], "span2": [55, 64]}, "bert_text": "The incidence of EPS-related adverse events, including akathisia, was no different with <e1> quetiapine </e1> <e2> akathisia </e2>, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"108": {"data": {"text": "tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.", "entity1": "CB 3717", "entity2": "cytotoxicity", "span1": [81, 88], "span2": [179, 191]}, "bert_text": "tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than <e1> CB 3717 </e1>, respectively, and their formation may, therefore, be an important determinant of CB 3717 <e2> cytotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"109": {"data": {"text": "tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.", "entity1": "CB 3717", "entity2": "cytotoxicity", "span1": [171, 178], "span2": [179, 191]}, "bert_text": "tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of <e1> CB 3717 </e1> <e2> cytotoxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"110": {"data": {"text": "The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.", "entity1": "bortezomib", "entity2": "MM", "span1": [25, 35], "span2": [176, 178]}, "bert_text": "The results suggest that <e1> bortezomib </e1> in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed <e2> MM </e2> that warrants further investigation.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"111": {"data": {"text": "The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.", "entity1": "cyclophosphamide", "entity2": "MM", "span1": [56, 72], "span2": [176, 178]}, "bert_text": "The results suggest that bortezomib in combination with <e1> cyclophosphamide </e1> at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed <e2> MM </e2> that warrants further investigation.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"112": {"data": {"text": "The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.", "entity1": "dexamethasone", "entity2": "MM", "span1": [92, 105], "span2": [176, 178]}, "bert_text": "The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and <e1> dexamethasone </e1> is an effective induction treatment for patients with newly diagnosed <e2> MM </e2> that warrants further investigation.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"113": {"data": {"text": "The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.", "entity1": "carbamazepine", "entity2": "bradyarrhythmias", "span1": [217, 230], "span2": [106, 122]}, "bert_text": "The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated <e1> carbamazepine </e1> <e2> bradyarrhythmias </e2> or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
	"114": {"data": {"text": "The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.", "entity1": "carbamazepine", "entity2": "atrioventricular conduction delay", "span1": [217, 230], "span2": [126, 159]}, "bert_text": "The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated <e1> carbamazepine </e1> <e2> atrioventricular conduction delay </e2>, associated with either therapeutic or modestly elevated carbamazepine serum levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
	"115": {"data": {"text": "Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.\n", "entity1": "oral contraceptives", "entity2": "Hepatic adenomas", "span1": [78, 97], "span2": [0, 16]}, "bert_text": "Hepatic adenomas and focal nodular hyperplasia of the liver in young women on <e1> oral contraceptives </e1> <e2> Hepatic adenomas </e2> and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"116": {"data": {"text": "Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.\n", "entity1": "oral contraceptives", "entity2": "focal nodular hyperplasia", "span1": [78, 97], "span2": [21, 46]}, "bert_text": "Hepatic adenomas and focal nodular hyperplasia of the liver in young women on <e1> oral contraceptives </e1> <e2> focal nodular hyperplasia </e2> of the liver in young women on oral contraceptives: case reports.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"117": {"data": {"text": "The transient steroid-induced IOP rise did not seem to cause functional impairment.", "entity1": "steroid", "entity2": "IOP rise", "span1": [14, 21], "span2": [30, 38]}, "bert_text": "The transient <e1> steroid </e1>-induced <e2> IOP rise </e2> did not seem to cause functional impairment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"118": {"data": {"text": "A phase II study of thalidomide in advanced metastatic renal cell carcinoma.\n", "entity1": "thalidomide", "entity2": "renal cell carcinoma", "span1": [20, 31], "span2": [55, 75]}, "bert_text": "A phase II study of <e1> thalidomide </e1> in advanced metastatic <e2> renal cell carcinoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"119": {"data": {"text": "These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.", "entity1": "RA", "entity2": "forestomach carcinogenesis", "span1": [29, 31], "span2": [68, 94]}, "bert_text": "These findings indicate that <e1> RA </e1> acted as a co-carcinogen in the BHA <e2> forestomach carcinogenesis </e2> of the rat.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"120": {"data": {"text": "These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.", "entity1": "BHA", "entity2": "forestomach carcinogenesis", "span1": [64, 67], "span2": [68, 94]}, "bert_text": "These findings indicate that RA acted as a co-carcinogen in the <e1> BHA </e1> <e2> forestomach carcinogenesis </e2> of the rat.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"121": {"data": {"text": "We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.", "entity1": "naloxone", "entity2": "overdose", "span1": [139, 147], "span2": [45, 53]}, "bert_text": "We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of <e1> naloxone </e1> <e2> overdose </e2>, manifested by marked hypotension, that resolved promptly with the administration of naloxone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"122": {"data": {"text": "We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.", "entity1": "naloxone", "entity2": "hypotension", "span1": [139, 147], "span2": [76, 87]}, "bert_text": "We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of <e1> naloxone </e1> <e2> hypotension </e2>, that resolved promptly with the administration of naloxone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"123": {"data": {"text": "Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.\n", "entity1": "diltiazem", "entity2": "asystolic cardiac arrest", "span1": [39, 48], "span2": [8, 32]}, "bert_text": "Delayed asystolic cardiac arrest after <e1> diltiazem </e1> <e2> asystolic cardiac arrest </e2> after diltiazem overdose; resuscitation with high dose intravenous calcium.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"124": {"data": {"text": "Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.\n", "entity1": "diltiazem", "entity2": "overdose", "span1": [39, 48], "span2": [49, 57]}, "bert_text": "Delayed asystolic cardiac arrest after <e1> diltiazem </e1> <e2> overdose </e2>; resuscitation with high dose intravenous calcium.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"125": {"data": {"text": "Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.\n", "entity1": "calcium", "entity2": "asystolic cardiac arrest", "span1": [100, 107], "span2": [8, 32]}, "bert_text": "Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous <e1> calcium </e1> <e2> asystolic cardiac arrest </e2> after diltiazem overdose; resuscitation with high dose intravenous calcium.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"126": {"data": {"text": "Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.\n", "entity1": "calcium", "entity2": "overdose", "span1": [100, 107], "span2": [49, 57]}, "bert_text": "Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous <e1> calcium </e1> <e2> overdose </e2>; resuscitation with high dose intravenous calcium.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"127": {"data": {"text": "In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.", "entity1": "mepivacaine", "entity2": "muscle damage", "span1": [108, 119], "span2": [15, 28]}, "bert_text": "In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to <e1> mepivacaine </e1> <e2> muscle damage </e2>, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"128": {"data": {"text": "In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.", "entity1": "lidocaine", "entity2": "muscle damage", "span1": [124, 133], "span2": [15, 28]}, "bert_text": "In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and <e1> lidocaine </e1> <e2> muscle damage </e2>, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"129": {"data": {"text": "In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.", "entity1": "epinephrine", "entity2": "muscle damage", "span1": [139, 150], "span2": [15, 28]}, "bert_text": "In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus <e1> epinephrine </e1> <e2> muscle damage </e2>, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"130": {"data": {"text": "Reversible cholestasis with bile duct injury following azathioprine therapy.", "entity1": "azathioprine", "entity2": "cholestasis", "span1": [55, 67], "span2": [11, 22]}, "bert_text": "Reversible cholestasis with bile duct injury following <e1> azathioprine </e1> <e2> cholestasis </e2> with bile duct injury following azathioprine therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"131": {"data": {"text": "Reversible cholestasis with bile duct injury following azathioprine therapy.", "entity1": "azathioprine", "entity2": "bile duct injury", "span1": [55, 67], "span2": [28, 44]}, "bert_text": "Reversible cholestasis with bile duct injury following <e1> azathioprine </e1> <e2> bile duct injury </e2> following azathioprine therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"132": {"data": {"text": "Cutaneous leucocytoclastic vasculitis associated with oxacillin.\n", "entity1": "oxacillin", "entity2": "Cutaneous leucocytoclastic vasculitis", "span1": [54, 63], "span2": [0, 37]}, "bert_text": "Cutaneous leucocytoclastic vasculitis associated with <e1> oxacillin </e1> <e2> Cutaneous leucocytoclastic vasculitis </e2> associated with oxacillin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"133": {"data": {"text": "Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.", "entity1": "Methamphetamine", "entity2": "hyperkinesia", "span1": [0, 15], "span2": [100, 112]}, "bert_text": "<e1> Methamphetamine </e1> or amphetamine levels were related to several psychopathology scores and the global <e2> hyperkinesia </e2> rating.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
	"134": {"data": {"text": "Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.", "entity1": "amphetamine", "entity2": "hyperkinesia", "span1": [19, 30], "span2": [100, 112]}, "bert_text": "Methamphetamine or <e1> amphetamine </e1> levels were related to several psychopathology scores and the global <e2> hyperkinesia </e2> rating.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
	"135": {"data": {"text": "Additional therapy with chloroquine (CQ) was started because of arthralgia.", "entity1": "chloroquine", "entity2": "arthralgia", "span1": [24, 35], "span2": [64, 74]}, "bert_text": "Additional therapy with <e1> chloroquine </e1> (CQ) was started because of <e2> arthralgia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"136": {"data": {"text": "Additional therapy with chloroquine (CQ) was started because of arthralgia.", "entity1": "CQ", "entity2": "arthralgia", "span1": [37, 39], "span2": [64, 74]}, "bert_text": "Additional therapy with chloroquine (<e1> CQ </e1>) was started because of <e2> arthralgia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"137": {"data": {"text": "Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.", "entity1": "Dexrazoxane", "entity2": "cardiotoxicity", "span1": [0, 11], "span2": [83, 97]}, "bert_text": "<e1> Dexrazoxane </e1> (ICRF-187) is recommended for protection against anthracycline-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"138": {"data": {"text": "Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.", "entity1": "ICRF-187", "entity2": "cardiotoxicity", "span1": [13, 21], "span2": [83, 97]}, "bert_text": "Dexrazoxane (<e1> ICRF-187 </e1>) is recommended for protection against anthracycline-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"139": {"data": {"text": "Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.", "entity1": "anthracycline", "entity2": "cardiotoxicity", "span1": [61, 74], "span2": [83, 97]}, "bert_text": "Dexrazoxane (ICRF-187) is recommended for protection against <e1> anthracycline </e1>-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"140": {"data": {"text": "LV may be a late-onset adverse reaction associated with warfarin therapy.", "entity1": "warfarin", "entity2": "LV", "span1": [56, 64], "span2": [0, 2]}, "bert_text": "LV may be a late-onset adverse reaction associated with <e1> warfarin </e1> <e2> LV </e2> may be a late-onset adverse reaction associated with warfarin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"141": {"data": {"text": "Tiapride in levodopa-induced involuntary movements.\n", "entity1": "Tiapride", "entity2": "involuntary movements", "span1": [0, 8], "span2": [29, 50]}, "bert_text": "<e1> Tiapride </e1> in levodopa-induced <e2> involuntary movements </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"142": {"data": {"text": "Tiapride in levodopa-induced involuntary movements.\n", "entity1": "levodopa", "entity2": "involuntary movements", "span1": [12, 20], "span2": [29, 50]}, "bert_text": "Tiapride in <e1> levodopa </e1>-induced <e2> involuntary movements </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"143": {"data": {"text": "OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.", "entity1": "fluocinolone acetonide", "entity2": "uveitis", "span1": [131, 153], "span2": [106, 113]}, "bert_text": "OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the <e1> fluocinolone acetonide </e1> <e2> uveitis </e2> treated with the fluocinolone acetonide (FA) intravitreal implant.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"144": {"data": {"text": "OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.", "entity1": "FA", "entity2": "uveitis", "span1": [155, 157], "span2": [106, 113]}, "bert_text": "OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (<e1> FA </e1> <e2> uveitis </e2> treated with the fluocinolone acetonide (FA) intravitreal implant.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"145": {"data": {"text": "The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.", "entity1": "doxorubicin", "entity2": "gastric lymphoma", "span1": [213, 224], "span2": [68, 84]}, "bert_text": "The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of <e1> doxorubicin </e1> <e2> gastric lymphoma </e2> and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"146": {"data": {"text": "The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.", "entity1": "doxorubicin", "entity2": "myotonic dystrophy", "span1": [213, 224], "span2": [89, 107]}, "bert_text": "The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of <e1> doxorubicin </e1> <e2> myotonic dystrophy </e2>, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"147": {"data": {"text": "The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.", "entity1": "doxorubicin", "entity2": "muscular dystrophy", "span1": [213, 224], "span2": [139, 157]}, "bert_text": "The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of <e1> doxorubicin </e1> <e2> muscular dystrophy </e2>, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"148": {"data": {"text": "The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.", "entity1": "doxorubicin", "entity2": "atrial fibrillation", "span1": [213, 224], "span2": [170, 189]}, "bert_text": "The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of <e1> doxorubicin </e1> <e2> atrial fibrillation </e2> following one cycle of doxorubicin-based chemotherapy in the same patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"149": {"data": {"text": "A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed.", "entity1": "steroid", "entity2": "septal rupture", "span1": [31, 38], "span2": [77, 91]}, "bert_text": "A possible association between <e1> steroid </e1> therapy and subsequent postinfarction <e2> septal rupture </e2> is discussed.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
	"150": {"data": {"text": "The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.", "entity1": "retinyl acetate", "entity2": "forestomach tumorigenesis", "span1": [34, 49], "span2": [101, 126]}, "bert_text": "The potential modifying effect of <e1> retinyl acetate </e1> (RA) on butylated hydroxyanisole (BHA)-induced rat <e2> forestomach tumorigenesis </e2> was examined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"151": {"data": {"text": "The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.", "entity1": "RA", "entity2": "forestomach tumorigenesis", "span1": [51, 53], "span2": [101, 126]}, "bert_text": "The potential modifying effect of retinyl acetate (<e1> RA </e1>) on butylated hydroxyanisole (BHA)-induced rat <e2> forestomach tumorigenesis </e2> was examined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"152": {"data": {"text": "The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.", "entity1": "butylated hydroxyanisole", "entity2": "forestomach tumorigenesis", "span1": [58, 82], "span2": [101, 126]}, "bert_text": "The potential modifying effect of retinyl acetate (RA) on <e1> butylated hydroxyanisole </e1> (BHA)-induced rat <e2> forestomach tumorigenesis </e2> was examined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"153": {"data": {"text": "The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.", "entity1": "BHA)-induced", "entity2": "forestomach tumorigenesis", "span1": [84, 96], "span2": [101, 126]}, "bert_text": "The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (<e1> BHA)-induced </e1> rat <e2> forestomach tumorigenesis </e2> was examined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"154": {"data": {"text": "Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.", "entity1": "5-HT", "entity2": "aggressive behavior", "span1": [83, 87], "span2": [123, 142]}, "bert_text": "Based on these data, it can be speculated that pubertal AAS users with low central <e1> 5-HT </e1> may be especially prone to exhibit <e2> aggressive behavior </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"155": {"data": {"text": "Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.", "entity1": "Phenobarbital", "entity2": "liver disease", "span1": [0, 13], "span2": [201, 214]}, "bert_text": "<e1> Phenobarbital </e1> (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic <e2> liver disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"156": {"data": {"text": "Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.", "entity1": "PB", "entity2": "liver disease", "span1": [15, 17], "span2": [201, 214]}, "bert_text": "Phenobarbital (<e1> PB </e1>) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic <e2> liver disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"157": {"data": {"text": "Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.", "entity1": "PB", "entity2": "liver disease", "span1": [81, 83], "span2": [201, 214]}, "bert_text": "Phenobarbital (PB) has a reputation for safety, and it is commonly believed that <e1> PB </e1>-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic <e2> liver disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"158": {"data": {"text": "CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.", "entity1": "lithium", "entity2": "thyroid illness", "span1": [99, 106], "span2": [22, 37]}, "bert_text": "CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during <e1> lithium </e1> <e2> thyroid illness </e2> is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"159": {"data": {"text": "CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.", "entity1": "lithium", "entity2": "hypothyroidism", "span1": [99, 106], "span2": [59, 73]}, "bert_text": "CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during <e1> lithium </e1> <e2> hypothyroidism </e2> and hypercalcemia during lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"160": {"data": {"text": "CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.", "entity1": "lithium", "entity2": "hypercalcemia", "span1": [99, 106], "span2": [78, 91]}, "bert_text": "CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during <e1> lithium </e1> <e2> hypercalcemia </e2> during lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"161": {"data": {"text": "Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.", "entity1": "phenytoin", "entity2": "hypothermia", "span1": [18, 27], "span2": [47, 58]}, "bert_text": "Administration of <e1> phenytoin </e1> in the presence of <e2> hypothermia </e2> may lead to an adverse cardiac event in children.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"162": {"data": {"text": "A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).", "entity1": "cyclophosphamide", "entity2": "multiple myeloma", "span1": [67, 83], "span2": [231, 247]}, "bert_text": "A clinical trial was initiated to evaluate the recommended dose of <e1> cyclophosphamide </e1> in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed <e2> multiple myeloma </e2> (MM).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"163": {"data": {"text": "A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).", "entity1": "cyclophosphamide", "entity2": "MM", "span1": [67, 83], "span2": [249, 251]}, "bert_text": "A clinical trial was initiated to evaluate the recommended dose of <e1> cyclophosphamide </e1> in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (<e2> MM </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"164": {"data": {"text": "A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).", "entity1": "bortezomib", "entity2": "multiple myeloma", "span1": [104, 114], "span2": [231, 247]}, "bert_text": "A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with <e1> bortezomib </e1> and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed <e2> multiple myeloma </e2> (MM).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"165": {"data": {"text": "A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).", "entity1": "bortezomib", "entity2": "MM", "span1": [104, 114], "span2": [249, 251]}, "bert_text": "A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with <e1> bortezomib </e1> and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (<e2> MM </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"166": {"data": {"text": "A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).", "entity1": "dexamethasone", "entity2": "multiple myeloma", "span1": [119, 132], "span2": [231, 247]}, "bert_text": "A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and <e1> dexamethasone </e1> as induction treatment before stem cell transplantation for younger patients with newly diagnosed <e2> multiple myeloma </e2> (MM).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"167": {"data": {"text": "A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).", "entity1": "dexamethasone", "entity2": "MM", "span1": [119, 132], "span2": [249, 251]}, "bert_text": "A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and <e1> dexamethasone </e1> as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (<e2> MM </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"168": {"data": {"text": "We report 4 patients with late-onset LV probably due to warfarin.", "entity1": "warfarin", "entity2": "LV", "span1": [56, 64], "span2": [37, 39]}, "bert_text": "We report 4 patients with late-onset LV probably due to <e1> warfarin </e1> <e2> LV </e2> probably due to warfarin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"169": {"data": {"text": "Gentamicin nephropathy in a neonate.\n", "entity1": "Gentamicin", "entity2": "nephropathy", "span1": [0, 10], "span2": [11, 22]}, "bert_text": "<e1> Gentamicin </e1> <e2> nephropathy </e2> in a neonate.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"170": {"data": {"text": "Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted", "entity1": "dexmedetomidine", "entity2": "bradycardia", "span1": [9, 24], "span2": [73, 84]}, "bert_text": "Although <e1> dexmedetomidine </e1> sedation was associated with a 16% incidence of <e2> bradycardia </e2>, all concomitant mean arterial blood pressures were within 20% of age-adjusted", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"171": {"data": {"text": "To our knowledge, this is the first reported case of captopril-induced hypotension treated with naloxone.", "entity1": "naloxone", "entity2": "hypotension", "span1": [96, 104], "span2": [71, 82]}, "bert_text": "To our knowledge, this is the first reported case of captopril-induced hypotension treated with <e1> naloxone </e1> <e2> hypotension </e2> treated with naloxone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"172": {"data": {"text": "Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).", "entity1": "Thallium-201", "entity2": "hyperemia", "span1": [0, 12], "span2": [103, 112]}, "bert_text": "<e1> Thallium-201 </e1> SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced <e2> hyperemia </e2>; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"173": {"data": {"text": "Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).", "entity1": "dipyridamole", "entity2": "hyperemia", "span1": [82, 94], "span2": [103, 112]}, "bert_text": "Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during <e1> dipyridamole </e1>-induced <e2> hyperemia </e2>; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"174": {"data": {"text": "This increase in aggressiveness was not secondary to METH-induced hyperactivity.", "entity1": "METH", "entity2": "aggressiveness", "span1": [53, 57], "span2": [17, 31]}, "bert_text": "This increase in aggressiveness was not secondary to <e1> METH </e1> <e2> aggressiveness </e2> was not secondary to METH-induced hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"175": {"data": {"text": "This increase in aggressiveness was not secondary to METH-induced hyperactivity.", "entity1": "METH", "entity2": "hyperactivity", "span1": [53, 57], "span2": [66, 79]}, "bert_text": "This increase in aggressiveness was not secondary to <e1> METH </e1>-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"176": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "pilocarpine", "entity2": "arrhythmias", "span1": [29, 40], "span2": [72, 83]}, "bert_text": "The current data showed that <e1> pilocarpine </e1> significantly delayed onset of <e2> arrhythmias </e2>, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"177": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "pilocarpine", "entity2": "arrhythmia", "span1": [29, 40], "span2": [164, 174]}, "bert_text": "The current data showed that <e1> pilocarpine </e1> significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced <e2> arrhythmia </e2> score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"178": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "pilocarpine", "entity2": "arrhythmic", "span1": [29, 40], "span2": [217, 227]}, "bert_text": "The current data showed that <e1> pilocarpine </e1> significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of <e2> arrhythmic </e2> rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"179": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "pilocarpine", "entity2": "ventricular tachycardia", "span1": [29, 40], "span2": [114, 137]}, "bert_text": "The current data showed that <e1> pilocarpine </e1> significantly delayed onset of arrhythmias, decreased the time course of <e2> ventricular tachycardia </e2> and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"180": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "pilocarpine", "entity2": "fibrillation", "span1": [29, 40], "span2": [142, 154]}, "bert_text": "The current data showed that <e1> pilocarpine </e1> significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and <e2> fibrillation </e2>, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"181": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "pilocarpine", "entity2": "arrhythmias", "span1": [352, 363], "span2": [72, 83]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with <e1> pilocarpine </e1> <e2> arrhythmias </e2>, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"182": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "pilocarpine", "entity2": "arrhythmia", "span1": [352, 363], "span2": [164, 174]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with <e1> pilocarpine </e1> <e2> arrhythmia </e2> score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"183": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "pilocarpine", "entity2": "arrhythmic", "span1": [352, 363], "span2": [217, 227]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with <e1> pilocarpine </e1> <e2> arrhythmic </e2> rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"184": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "pilocarpine", "entity2": "ventricular tachycardia", "span1": [352, 363], "span2": [114, 137]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with <e1> pilocarpine </e1> <e2> ventricular tachycardia </e2> and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"185": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "pilocarpine", "entity2": "fibrillation", "span1": [352, 363], "span2": [142, 154]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with <e1> pilocarpine </e1> <e2> fibrillation </e2>, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"186": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "Ca(2+)](i", "entity2": "arrhythmias", "span1": [251, 260], "span2": [72, 83]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [<e1> Ca(2+)](i </e1> <e2> arrhythmias </e2>, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"187": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "Ca(2+)](i", "entity2": "arrhythmia", "span1": [251, 260], "span2": [164, 174]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [<e1> Ca(2+)](i </e1> <e2> arrhythmia </e2> score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"188": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "Ca(2+)](i", "entity2": "arrhythmic", "span1": [251, 260], "span2": [217, 227]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [<e1> Ca(2+)](i </e1> <e2> arrhythmic </e2> rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"189": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "Ca(2+)](i", "entity2": "ventricular tachycardia", "span1": [251, 260], "span2": [114, 137]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [<e1> Ca(2+)](i </e1> <e2> ventricular tachycardia </e2> and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"190": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "Ca(2+)](i", "entity2": "fibrillation", "span1": [251, 260], "span2": [142, 154]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [<e1> Ca(2+)](i </e1> <e2> fibrillation </e2>, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"191": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "aconitine", "entity2": "arrhythmias", "span1": [282, 291], "span2": [72, 83]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by <e1> aconitine </e1> <e2> arrhythmias </e2>, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"192": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "aconitine", "entity2": "arrhythmia", "span1": [282, 291], "span2": [164, 174]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by <e1> aconitine </e1> <e2> arrhythmia </e2> score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"193": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "aconitine", "entity2": "arrhythmic", "span1": [282, 291], "span2": [217, 227]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by <e1> aconitine </e1> <e2> arrhythmic </e2> rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"194": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "aconitine", "entity2": "ventricular tachycardia", "span1": [282, 291], "span2": [114, 137]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by <e1> aconitine </e1> <e2> ventricular tachycardia </e2> and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"195": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "aconitine", "entity2": "fibrillation", "span1": [282, 291], "span2": [142, 154]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by <e1> aconitine </e1> <e2> fibrillation </e2>, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"196": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "ouabain", "entity2": "arrhythmias", "span1": [295, 302], "span2": [72, 83]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or <e1> ouabain </e1> <e2> arrhythmias </e2>, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"197": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "ouabain", "entity2": "arrhythmia", "span1": [295, 302], "span2": [164, 174]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or <e1> ouabain </e1> <e2> arrhythmia </e2> score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"198": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "ouabain", "entity2": "arrhythmic", "span1": [295, 302], "span2": [217, 227]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or <e1> ouabain </e1> <e2> arrhythmic </e2> rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"199": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "ouabain", "entity2": "ventricular tachycardia", "span1": [295, 302], "span2": [114, 137]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or <e1> ouabain </e1> <e2> ventricular tachycardia </e2> and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"200": {"data": {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity1": "ouabain", "entity2": "fibrillation", "span1": [295, 302], "span2": [142, 154]}, "bert_text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or <e1> ouabain </e1> <e2> fibrillation </e2>, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"201": {"data": {"text": "Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.", "entity1": "anastrozole", "entity2": "breast cancer", "span1": [48, 59], "span2": [132, 145]}, "bert_text": "Patients participating in a randomised trial of <e1> anastrozole </e1>, tamoxifen alone or combined (ATAC) (n=94) and a group of women without <e2> breast cancer </e2> (n=35) completed a battery of neuropsychological measures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"202": {"data": {"text": "Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.", "entity1": "tamoxifen", "entity2": "breast cancer", "span1": [61, 70], "span2": [132, 145]}, "bert_text": "Patients participating in a randomised trial of anastrozole, <e1> tamoxifen </e1> alone or combined (ATAC) (n=94) and a group of women without <e2> breast cancer </e2> (n=35) completed a battery of neuropsychological measures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"203": {"data": {"text": "Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).", "entity1": "scopolamine", "entity2": "impairment in word recall", "span1": [61, 72], "span2": [81, 106]}, "bert_text": "Compared with the young group, the elderly group had greater <e1> scopolamine </e1>-induced <e2> impairment in word recall </e2> 60, 90 and 120 minutes after administration (p < 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"204": {"data": {"text": "Is phenytoin administration safe in a hypothermic child?\n", "entity1": "phenytoin", "entity2": "hypothermic", "span1": [3, 12], "span2": [38, 49]}, "bert_text": "Is <e1> phenytoin </e1> administration safe in a <e2> hypothermic </e2> child?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"205": {"data": {"text": "A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.", "entity1": "methadone", "entity2": "syncope", "span1": [15, 24], "span2": [98, 105]}, "bert_text": "A 50 mg higher <e1> methadone </e1> dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for <e2> syncope </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"206": {"data": {"text": "Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy.", "entity1": "cis-RA", "entity2": "neuroblastoma", "span1": [6, 12], "span2": [52, 65]}, "bert_text": "Since <e1> cis-RA </e1> has demonstrated clinical responses in <e2> neuroblastoma </e2> patients, it may be effective in preventing relapse after cytotoxic therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"207": {"data": {"text": "Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.", "entity1": "phenytoin", "entity2": "bradycardia", "span1": [10, 19], "span2": [71, 82]}, "bert_text": "Following <e1> phenytoin </e1> administration, the patient developed acute severe <e2> bradycardia </e2>, refractory to atropine and adrenaline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"208": {"data": {"text": "Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.", "entity1": "atropine", "entity2": "bradycardia", "span1": [98, 106], "span2": [71, 82]}, "bert_text": "Following phenytoin administration, the patient developed acute severe bradycardia, refractory to <e1> atropine </e1> <e2> bradycardia </e2>, refractory to atropine and adrenaline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"209": {"data": {"text": "Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.", "entity1": "adrenaline", "entity2": "bradycardia", "span1": [111, 121], "span2": [71, 82]}, "bert_text": "Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and <e1> adrenaline </e1> <e2> bradycardia </e2>, refractory to atropine and adrenaline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"210": {"data": {"text": "The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.", "entity1": "nitric oxide", "entity2": "convulsions", "span1": [58, 70], "span2": [166, 177]}, "bert_text": "The effects of N-nitro-L-arginine-methyl ester (L-NAME) a <e1> nitric oxide </e1> (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"211": {"data": {"text": "The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.", "entity1": "NO", "entity2": "convulsions", "span1": [72, 74], "span2": [166, 177]}, "bert_text": "The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (<e1> NO </e1>) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"212": {"data": {"text": "The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.", "entity1": "NO", "entity2": "convulsions", "span1": [113, 115], "span2": [166, 177]}, "bert_text": "The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a <e1> NO </e1> precursor, were investigated on lidocaine-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"213": {"data": {"text": "The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.", "entity1": "lidocaine", "entity2": "convulsions", "span1": [148, 157], "span2": [166, 177]}, "bert_text": "The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on <e1> lidocaine </e1>-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"214": {"data": {"text": "In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.", "entity1": "lidocaine", "entity2": "convulsions", "span1": [65, 74], "span2": [100, 111]}, "bert_text": "In contrast, the L-arginine treatment increased the incidence of <e1> lidocaine </e1> (80 mg/kg, i.p.)-induced <e2> convulsions </e2> significantly.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"215": {"data": {"text": "Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.\n", "entity1": "quetiapine", "entity2": "extrapyramidal symptoms", "span1": [62, 72], "span2": [27, 50]}, "bert_text": "Placebo-level incidence of extrapyramidal symptoms (EPS) with <e1> quetiapine </e1> <e2> extrapyramidal symptoms </e2> (EPS) with quetiapine in controlled studies of patients with bipolar mania.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"216": {"data": {"text": "Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.\n", "entity1": "quetiapine", "entity2": "EPS", "span1": [62, 72], "span2": [52, 55]}, "bert_text": "Placebo-level incidence of extrapyramidal symptoms (EPS) with <e1> quetiapine </e1> <e2> EPS </e2>) with quetiapine in controlled studies of patients with bipolar mania.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"217": {"data": {"text": "Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.\n", "entity1": "quetiapine", "entity2": "bipolar mania", "span1": [62, 72], "span2": [112, 125]}, "bert_text": "Placebo-level incidence of extrapyramidal symptoms (EPS) with <e1> quetiapine </e1> in controlled studies of patients with <e2> bipolar mania </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"218": {"data": {"text": "Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.", "entity1": "oral contraceptive", "entity2": "liver tumors", "span1": [96, 114], "span2": [47, 59]}, "bert_text": "Within the last several years, previously rare liver tumors have been seen in young women using <e1> oral contraceptive </e1> <e2> liver tumors </e2> have been seen in young women using oral contraceptive steroids.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"219": {"data": {"text": "Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.", "entity1": "steroids", "entity2": "liver tumors", "span1": [115, 123], "span2": [47, 59]}, "bert_text": "Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive <e1> steroids </e1> <e2> liver tumors </e2> have been seen in young women using oral contraceptive steroids.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"220": {"data": {"text": "Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia.\n", "entity1": "lovastatin", "entity2": "hypercholesterolemia", "span1": [29, 39], "span2": [68, 88]}, "bert_text": "Efficacy and tolerability of <e1> lovastatin </e1> in 3390 women with moderate <e2> hypercholesterolemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"221": {"data": {"text": "OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.", "entity1": "quetiapine", "entity2": "extrapyramidal symptoms", "span1": [81, 91], "span2": [24, 47]}, "bert_text": "OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with <e1> quetiapine </e1> <e2> extrapyramidal symptoms </e2> (EPS), including akathisia, with quetiapine in patients with bipolar mania.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"222": {"data": {"text": "OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.", "entity1": "quetiapine", "entity2": "EPS", "span1": [81, 91], "span2": [49, 52]}, "bert_text": "OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with <e1> quetiapine </e1> <e2> EPS </e2>), including akathisia, with quetiapine in patients with bipolar mania.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"223": {"data": {"text": "OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.", "entity1": "quetiapine", "entity2": "akathisia", "span1": [81, 91], "span2": [65, 74]}, "bert_text": "OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with <e1> quetiapine </e1> <e2> akathisia </e2>, with quetiapine in patients with bipolar mania.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"224": {"data": {"text": "OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.", "entity1": "quetiapine", "entity2": "bipolar mania", "span1": [81, 91], "span2": [109, 122]}, "bert_text": "OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with <e1> quetiapine </e1> in patients with <e2> bipolar mania </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"225": {"data": {"text": "OBJECTIVE: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia.", "entity1": "lovastatin", "entity2": "hypercholesterolemia", "span1": [50, 60], "span2": [84, 104]}, "bert_text": "OBJECTIVE: To evaluate the efficacy and safety of <e1> lovastatin </e1> in women with moderate <e2> hypercholesterolemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"226": {"data": {"text": "Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase.", "entity1": "succinylcholine", "entity2": "apnoea", "span1": [87, 102], "span2": [52, 58]}, "bert_text": "Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after <e1> succinylcholine </e1> <e2> apnoea </e2> lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"227": {"data": {"text": "These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary.", "entity1": "estrogen", "entity2": "tumor", "span1": [147, 155], "span2": [164, 169]}, "bert_text": "These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of <e1> estrogen </e1> induced <e2> tumor </e2> angiogenesis in the rat pituitary.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"228": {"data": {"text": "Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.\n", "entity1": "doxorubicin", "entity2": "renal toxicity", "span1": [24, 35], "span2": [6, 20]}, "bert_text": "Acute renal toxicity of <e1> doxorubicin </e1> <e2> renal toxicity </e2> of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"229": {"data": {"text": "Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.\n", "entity1": "adriamycin)-loaded", "entity2": "renal toxicity", "span1": [37, 55], "span2": [6, 20]}, "bert_text": "Acute renal toxicity of doxorubicin (<e1> adriamycin)-loaded </e1> <e2> renal toxicity </e2> of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"230": {"data": {"text": "Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.\n", "entity1": "cyanoacrylate", "entity2": "renal toxicity", "span1": [56, 69], "span2": [6, 20]}, "bert_text": "Acute renal toxicity of doxorubicin (adriamycin)-loaded <e1> cyanoacrylate </e1> <e2> renal toxicity </e2> of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"231": {"data": {"text": "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\n", "entity1": "warfarin", "entity2": "haemopericardium and gastrointestinal haemorrhage", "span1": [108, 116], "span2": [6, 55]}, "bert_text": "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with <e1> warfarin </e1> <e2> haemopericardium and gastrointestinal haemorrhage </e2> due to possible interaction of cranberry juice with warfarin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"232": {"data": {"text": "Quinidine hepatitis.\n", "entity1": "Quinidine", "entity2": "hepatitis", "span1": [0, 9], "span2": [10, 19]}, "bert_text": "<e1> Quinidine </e1> <e2> hepatitis </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"233": {"data": {"text": "Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.\n", "entity1": "aminoglycoside", "entity2": "Nephrotoxic", "span1": [23, 37], "span2": [0, 11]}, "bert_text": "Nephrotoxic effects of <e1> aminoglycoside </e1> <e2> Nephrotoxic </e2> effects of aminoglycoside treatment on renal protein reabsorption and accumulation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"234": {"data": {"text": "Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.", "entity1": "Haloperidol", "entity2": "akathisia", "span1": [0, 11], "span2": [68, 77]}, "bert_text": "<e1> Haloperidol </e1> induced a significantly higher incidence (p < 0.001) of <e2> akathisia </e2> (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"235": {"data": {"text": "Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.", "entity1": "Haloperidol", "entity2": "tremor", "span1": [0, 11], "span2": [99, 105]}, "bert_text": "<e1> Haloperidol </e1> induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), <e2> tremor </e2> (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"236": {"data": {"text": "Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.", "entity1": "Haloperidol", "entity2": "extrapyramidal syndrome", "span1": [0, 11], "span2": [131, 154]}, "bert_text": "<e1> Haloperidol </e1> induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and <e2> extrapyramidal syndrome </e2> (35.4% versus 5.9%) than quetiapine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"237": {"data": {"text": "Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.", "entity1": "quetiapine", "entity2": "akathisia", "span1": [180, 190], "span2": [68, 77]}, "bert_text": "Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than <e1> quetiapine </e1> <e2> akathisia </e2> (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"238": {"data": {"text": "Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.", "entity1": "quetiapine", "entity2": "tremor", "span1": [180, 190], "span2": [99, 105]}, "bert_text": "Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than <e1> quetiapine </e1> <e2> tremor </e2> (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"239": {"data": {"text": "Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.", "entity1": "quetiapine", "entity2": "extrapyramidal syndrome", "span1": [180, 190], "span2": [131, 154]}, "bert_text": "Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than <e1> quetiapine </e1> <e2> extrapyramidal syndrome </e2> (35.4% versus 5.9%) than quetiapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"240": {"data": {"text": "Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness.\n", "entity1": "Methamphetamine", "entity2": "aggressiveness", "span1": [0, 15], "span2": [115, 129]}, "bert_text": "<e1> Methamphetamine </e1> causes alterations in the MAP kinase-related pathways in the brains of mice that display increased <e2> aggressiveness </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"241": {"data": {"text": "Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.\n", "entity1": "retinyl acetate", "entity2": "carcinogenic", "span1": [26, 41], "span2": [3, 15]}, "bert_text": "Co-carcinogenic effect of <e1> retinyl acetate </e1> <e2> carcinogenic </e2> effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"242": {"data": {"text": "Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.\n", "entity1": "retinyl acetate", "entity2": "forestomach carcinogenesis", "span1": [26, 41], "span2": [45, 71]}, "bert_text": "Co-carcinogenic effect of <e1> retinyl acetate </e1> on <e2> forestomach carcinogenesis </e2> of male F344 rats induced with butylated hydroxyanisole.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"243": {"data": {"text": "Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.\n", "entity1": "butylated hydroxyanisole", "entity2": "carcinogenic", "span1": [103, 127], "span2": [3, 15]}, "bert_text": "Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with <e1> butylated hydroxyanisole </e1> <e2> carcinogenic </e2> effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"244": {"data": {"text": "Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.\n", "entity1": "butylated hydroxyanisole", "entity2": "forestomach carcinogenesis", "span1": [103, 127], "span2": [45, 71]}, "bert_text": "Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with <e1> butylated hydroxyanisole </e1> <e2> forestomach carcinogenesis </e2> of male F344 rats induced with butylated hydroxyanisole.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"245": {"data": {"text": "The use of serum cholinesterase in succinylcholine apnoea.\n", "entity1": "succinylcholine", "entity2": "apnoea", "span1": [35, 50], "span2": [51, 57]}, "bert_text": "The use of serum cholinesterase in <e1> succinylcholine </e1> <e2> apnoea </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"246": {"data": {"text": "This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.", "entity1": "OCT", "entity2": "impaired renal function", "span1": [54, 57], "span2": [119, 142]}, "bert_text": "This study was undertaken to determine the effects of <e1> OCT </e1> on serum PTH levels and bone turnover in states of normal or <e2> impaired renal function </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
	"247": {"data": {"text": "The cardiac depressant actions of phenytoin and hypothermia can be additive.", "entity1": "phenytoin", "entity2": "hypothermia", "span1": [34, 43], "span2": [48, 59]}, "bert_text": "The cardiac depressant actions of <e1> phenytoin </e1> and <e2> hypothermia </e2> can be additive.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"248": {"data": {"text": "All 4 patients presented with skin eruptions that developed after receiving warfarin for several years.", "entity1": "warfarin", "entity2": "skin eruptions", "span1": [76, 84], "span2": [30, 44]}, "bert_text": "All 4 patients presented with skin eruptions that developed after receiving <e1> warfarin </e1> <e2> skin eruptions </e2> that developed after receiving warfarin for several years.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"249": {"data": {"text": "Renal function and hemodynamics during prolonged isoflurane-induced hypotension in humans.\n", "entity1": "isoflurane", "entity2": "hypotension", "span1": [49, 59], "span2": [68, 79]}, "bert_text": "Renal function and hemodynamics during prolonged <e1> isoflurane </e1>-induced <e2> hypotension </e2> in humans.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"250": {"data": {"text": "Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.", "entity1": "tropicamide", "entity2": "impairment in word recall", "span1": [50, 61], "span2": [99, 124]}, "bert_text": "Pupil size at time points after administration of <e1> tropicamide </e1> and pilocarpine; scopolamine-induced <e2> impairment in word recall </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"251": {"data": {"text": "Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.", "entity1": "pilocarpine", "entity2": "impairment in word recall", "span1": [66, 77], "span2": [99, 124]}, "bert_text": "Pupil size at time points after administration of tropicamide and <e1> pilocarpine </e1>; scopolamine-induced <e2> impairment in word recall </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"252": {"data": {"text": "Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.", "entity1": "scopolamine", "entity2": "impairment in word recall", "span1": [79, 90], "span2": [99, 124]}, "bert_text": "Pupil size at time points after administration of tropicamide and pilocarpine; <e1> scopolamine </e1>-induced <e2> impairment in word recall </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"253": {"data": {"text": "These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.", "entity1": "puromycin aminonucleoside", "entity2": "nephrotic syndrome", "span1": [84, 109], "span2": [118, 136]}, "bert_text": "These findings suggest that thrombin plays an important role in the pathogenesis of <e1> puromycin aminonucleoside </e1>-induced <e2> nephrotic syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"254": {"data": {"text": "Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.\n", "entity1": "tramadol", "entity2": "hallucinations", "span1": [56, 64], "span2": [15, 29]}, "bert_text": "Nightmares and hallucinations after long-term intake of <e1> tramadol </e1> <e2> hallucinations </e2> after long-term intake of tramadol combined with antidepressants.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"255": {"data": {"text": "Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.", "entity1": "Reserpine", "entity2": "dyskinesia", "span1": [0, 9], "span2": [150, 160]}, "bert_text": "<e1> Reserpine </e1> (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral <e2> dyskinesia </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
	"256": {"data": {"text": "During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.", "entity1": "dipyridamole", "entity2": "hyperemia", "span1": [7, 19], "span2": [28, 37]}, "bert_text": "During <e1> dipyridamole </e1>-induced <e2> hyperemia </e2>, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"257": {"data": {"text": "During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.", "entity1": "dipyridamole", "entity2": "coronary stenosis", "span1": [7, 19], "span2": [72, 89]}, "bert_text": "During <e1> dipyridamole </e1>-induced hyperemia, 12 of the 16 dogs with a partial <e2> coronary stenosis </e2> had a visible area of hypoperfusion by contrast echocardiography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"258": {"data": {"text": "Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.", "entity1": "penicillins", "entity2": "hemolytic anemia", "span1": [110, 121], "span2": [7, 23]}, "bert_text": "Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving <e1> penicillins </e1> <e2> hemolytic anemia </e2> due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"259": {"data": {"text": "Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.", "entity1": "cephalosporins", "entity2": "hemolytic anemia", "span1": [143, 157], "span2": [7, 23]}, "bert_text": "Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation <e1> cephalosporins </e1> <e2> hemolytic anemia </e2> due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"260": {"data": {"text": "D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.", "entity1": "D-Penicillamine", "entity2": "nephrotic syndrome", "span1": [0, 15], "span2": [23, 41]}, "bert_text": "<e1> D-Penicillamine </e1> caused <e2> nephrotic syndrome </e2> in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"261": {"data": {"text": "D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.", "entity1": "D-Penicillamine", "entity2": "proteinuria", "span1": [0, 15], "span2": [77, 88]}, "bert_text": "<e1> D-Penicillamine </e1> caused nephrotic syndrome in 1 patient and milder reversible <e2> proteinuria </e2> in 3 other patients; none developed renal insufficiency.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"262": {"data": {"text": "D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.", "entity1": "D-Penicillamine", "entity2": "renal insufficiency", "span1": [0, 15], "span2": [125, 144]}, "bert_text": "<e1> D-Penicillamine </e1> caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed <e2> renal insufficiency </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
	"263": {"data": {"text": "The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.", "entity1": "amiodarone", "entity2": "pulmonary toxicity", "span1": [26, 36], "span2": [4, 22]}, "bert_text": "The pulmonary toxicity of <e1> amiodarone </e1> <e2> pulmonary toxicity </e2> of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"264": {"data": {"text": "The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.", "entity1": "amiodarone", "entity2": "hypersensitivity pneumonitis", "span1": [26, 36], "span2": [155, 183]}, "bert_text": "The pulmonary toxicity of <e1> amiodarone </e1> is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated <e2> hypersensitivity pneumonitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"265": {"data": {"text": "The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.", "entity1": "heparin", "entity2": "pelvic thrombophlebitis", "span1": [53, 60], "span2": [83, 106]}, "bert_text": "The disease occurred subsequent to the initiation of <e1> heparin </e1> therapy for suspected <e2> pelvic thrombophlebitis </e2> and cleared rapidly subsequent to its discontinuation.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"266": {"data": {"text": "A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.", "entity1": "trihexyphenidyl", "entity2": "mental slowness", "span1": [22, 37], "span2": [82, 97]}, "bert_text": "A 2.0-mg oral dose of <e1> trihexyphenidyl </e1> resulted in increased subjective ratings of <e2> mental slowness </e2> in carriers of the APOE epsilon4 allele only.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"267": {"data": {"text": "We conclude that renal compensatory mechanisms are preserved during isoflurane-induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed.", "entity1": "isoflurane", "entity2": "hypotension", "span1": [68, 78], "span2": [87, 98]}, "bert_text": "We conclude that renal compensatory mechanisms are preserved during <e1> isoflurane </e1>-induced <e2> hypotension </e2> and that renal function and hemodynamics quickly return to normal when normotension is resumed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"268": {"data": {"text": "Morphine but not nicotine induced a dose-dependent catalepsy.", "entity1": "Morphine", "entity2": "catalepsy", "span1": [0, 8], "span2": [51, 60]}, "bert_text": "<e1> Morphine </e1> but not nicotine induced a dose-dependent <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"269": {"data": {"text": "Morphine but not nicotine induced a dose-dependent catalepsy.", "entity1": "nicotine", "entity2": "catalepsy", "span1": [17, 25], "span2": [51, 60]}, "bert_text": "Morphine but not <e1> nicotine </e1> induced a dose-dependent <e2> catalepsy </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"270": {"data": {"text": "D-penicillamine in the treatment of localized scleroderma.\n", "entity1": "D-penicillamine", "entity2": "localized scleroderma", "span1": [0, 15], "span2": [36, 57]}, "bert_text": "<e1> D-penicillamine </e1> in the treatment of <e2> localized scleroderma </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"271": {"data": {"text": "Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.\n", "entity1": "anthracycline", "entity2": "cardiomyopathy", "span1": [37, 50], "span2": [112, 126]}, "bert_text": "Chronic effects of a novel synthetic <e1> anthracycline </e1> derivative (SM-5887) on normal heart and doxorubicin-induced <e2> cardiomyopathy </e2> in beagle dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"272": {"data": {"text": "Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.\n", "entity1": "SM-5887", "entity2": "cardiomyopathy", "span1": [63, 70], "span2": [112, 126]}, "bert_text": "Chronic effects of a novel synthetic anthracycline derivative (<e1> SM-5887 </e1>) on normal heart and doxorubicin-induced <e2> cardiomyopathy </e2> in beagle dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"273": {"data": {"text": "Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.\n", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [92, 103], "span2": [112, 126]}, "bert_text": "Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and <e1> doxorubicin </e1>-induced <e2> cardiomyopathy </e2> in beagle dogs.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"274": {"data": {"text": "CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.", "entity1": "dobutamine", "entity2": "myocardial ischemia", "span1": [19, 29], "span2": [94, 113]}, "bert_text": "CONCLUSION: During <e1> dobutamine </e1> stress testing, metoprolol attenuates or eliminates evidence of <e2> myocardial ischemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"275": {"data": {"text": "CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.", "entity1": "metoprolol", "entity2": "myocardial ischemia", "span1": [46, 56], "span2": [94, 113]}, "bert_text": "CONCLUSION: During dobutamine stress testing, <e1> metoprolol </e1> attenuates or eliminates evidence of <e2> myocardial ischemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"276": {"data": {"text": "Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.", "entity1": "GTN", "entity2": "headache", "span1": [86, 89], "span2": [70, 78]}, "bert_text": "Both patients and controls developed significantly stronger immediate headache on the <e1> GTN </e1> <e2> headache </e2> on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"277": {"data": {"text": "Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.", "entity1": "GTN", "entity2": "headache", "span1": [86, 89], "span2": [126, 134]}, "bert_text": "Both patients and controls developed significantly stronger immediate headache on the <e1> GTN </e1> day than on the placebo day and the <e2> headache </e2> was significantly more pronounced in patients than in controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"278": {"data": {"text": "This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing glomerulonephritis.", "entity1": "sulphasalazine", "entity2": "glomerulonephritis", "span1": [24, 38], "span2": [80, 98]}, "bert_text": "This case suggests that <e1> sulphasalazine </e1> can induce PR3-ANCA-positive necrotizing <e2> glomerulonephritis </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"279": {"data": {"text": "Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.", "entity1": "trihexyphenidyl", "entity2": "mental slowness", "span1": [63, 78], "span2": [105, 120]}, "bert_text": "Drug effects as determined by difference scores between 2.0 mg <e1> trihexyphenidyl </e1> and placebo on ratings of <e2> mental slowness </e2> significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"280": {"data": {"text": "MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.", "entity1": "cyclophosphamide", "entity2": "bladder cancer", "span1": [89, 105], "span2": [117, 131]}, "bert_text": "MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with <e1> cyclophosphamide </e1> associated <e2> bladder cancer </e2> were reviewed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"281": {"data": {"text": "This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).", "entity1": "cis-RA", "entity2": "toxicities", "span1": [117, 123], "span2": [81, 91]}, "bert_text": "This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of <e1> cis-RA </e1> <e2> toxicities </e2>, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"282": {"data": {"text": "This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).", "entity1": "cis-RA", "entity2": "neuroblastoma", "span1": [117, 123], "span2": [182, 195]}, "bert_text": "This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of <e1> cis-RA </e1> administered on an intermittent schedule in children with <e2> neuroblastoma </e2> following bone marrow transplantation (BMT).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"283": {"data": {"text": "Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.", "entity1": "doxorubicin", "entity2": "renal toxicity", "span1": [6, 17], "span2": [45, 59]}, "bert_text": "Acute <e1> doxorubicin </e1>-loaded nanoparticle (DXNP) <e2> renal toxicity </e2> was explored in both normal rats and rats with experimental glomerulonephritis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"284": {"data": {"text": "Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.", "entity1": "doxorubicin", "entity2": "glomerulonephritis", "span1": [6, 17], "span2": [120, 138]}, "bert_text": "Acute <e1> doxorubicin </e1>-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental <e2> glomerulonephritis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"285": {"data": {"text": "Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).", "entity1": "creatine", "entity2": "Myopathy", "span1": [42, 50], "span2": [0, 8]}, "bert_text": "Myopathy, defined as muscle symptoms with <e1> creatine </e1> <e2> Myopathy </e2>, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"286": {"data": {"text": "Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).", "entity1": "lovastatin", "entity2": "Myopathy", "span1": [185, 195], "span2": [0, 8]}, "bert_text": "Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of <e1> lovastatin </e1> <e2> Myopathy </e2>, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"287": {"data": {"text": "The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear.", "entity1": "thalidomide", "entity2": "renal cell carcinoma", "span1": [43, 54], "span2": [59, 79]}, "bert_text": "The dose-response relationship, if any, of <e1> thalidomide </e1> for <e2> renal cell carcinoma </e2> is unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"288": {"data": {"text": "Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.\n", "entity1": "cisapride", "entity2": "irritable bowel syndrome", "span1": [11, 20], "span2": [91, 115]}, "bert_text": "Effects of <e1> cisapride </e1> on symptoms and postcibal small-bowel motor function in patients with <e2> irritable bowel syndrome </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"289": {"data": {"text": "These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.", "entity1": "OCT", "entity2": "hypercalcemia", "span1": [40, 43], "span2": [90, 103]}, "bert_text": "These results indicate that even though <e1> OCT </e1> does not completely prevent the occurrence of <e2> hypercalcemia </e2> in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"290": {"data": {"text": "These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.", "entity1": "OCT", "entity2": "renal insufficiency", "span1": [40, 43], "span2": [130, 149]}, "bert_text": "These results indicate that even though <e1> OCT </e1> does not completely prevent the occurrence of hypercalcemia in experimental dogs with <e2> renal insufficiency </e2>, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"291": {"data": {"text": "These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.", "entity1": "OCT", "entity2": "hyperparathyroidism", "span1": [40, 43], "span2": [199, 218]}, "bert_text": "These results indicate that even though <e1> OCT </e1> does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary <e2> hyperparathyroidism </e2> because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"292": {"data": {"text": "These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.", "entity1": "OCT", "entity2": "adynamic bone disease", "span1": [40, 43], "span2": [310, 331]}, "bert_text": "These results indicate that even though <e1> OCT </e1> does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of <e2> adynamic bone disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
	"293": {"data": {"text": "Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.\n", "entity1": "dobutamine", "entity2": "Myocardial ischemia", "span1": [56, 66], "span2": [0, 19]}, "bert_text": "Myocardial ischemia due to coronary artery spasm during <e1> dobutamine </e1> <e2> Myocardial ischemia </e2> due to coronary artery spasm during dobutamine stress echocardiography.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"294": {"data": {"text": "Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.\n", "entity1": "dobutamine", "entity2": "coronary artery spasm", "span1": [56, 66], "span2": [27, 48]}, "bert_text": "Myocardial ischemia due to coronary artery spasm during <e1> dobutamine </e1> <e2> coronary artery spasm </e2> during dobutamine stress echocardiography.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"295": {"data": {"text": "It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).", "entity1": "nitric oxide", "entity2": "headache", "span1": [26, 38], "span2": [52, 60]}, "bert_text": "It has been proposed that <e1> nitric oxide </e1> (NO) induced <e2> headache </e2> in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"296": {"data": {"text": "It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).", "entity1": "nitric oxide", "entity2": "primary headaches", "span1": [26, 38], "span2": [64, 81]}, "bert_text": "It has been proposed that <e1> nitric oxide </e1> (NO) induced headache in <e2> primary headaches </e2> may be associated with release of calcitonin gene-related peptide (CGRP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"297": {"data": {"text": "It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).", "entity1": "NO", "entity2": "headache", "span1": [40, 42], "span2": [52, 60]}, "bert_text": "It has been proposed that nitric oxide (<e1> NO </e1>) induced <e2> headache </e2> in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"298": {"data": {"text": "It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).", "entity1": "NO", "entity2": "primary headaches", "span1": [40, 42], "span2": [64, 81]}, "bert_text": "It has been proposed that nitric oxide (<e1> NO </e1>) induced headache in <e2> primary headaches </e2> may be associated with release of calcitonin gene-related peptide (CGRP).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"299": {"data": {"text": "It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).", "entity1": "CGRP", "entity2": "headache", "span1": [149, 153], "span2": [52, 60]}, "bert_text": "It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (<e1> CGRP </e1> <e2> headache </e2> in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"300": {"data": {"text": "It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).", "entity1": "CGRP", "entity2": "primary headaches", "span1": [149, 153], "span2": [64, 81]}, "bert_text": "It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (<e1> CGRP </e1> <e2> primary headaches </e2> may be associated with release of calcitonin gene-related peptide (CGRP).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"301": {"data": {"text": "We describe a patient who developed anemia while receiving intravenous cefotetan.", "entity1": "cefotetan", "entity2": "anemia", "span1": [71, 80], "span2": [36, 42]}, "bert_text": "We describe a patient who developed anemia while receiving intravenous <e1> cefotetan </e1> <e2> anemia </e2> while receiving intravenous cefotetan.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"302": {"data": {"text": "Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.", "entity1": "hepatitis B surface antigen", "entity2": "Hepatitis B", "span1": [215, 242], "span2": [0, 11]}, "bert_text": "Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to <e1> hepatitis B surface antigen </e1> <e2> Hepatitis B </e2> immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"303": {"data": {"text": "Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.", "entity1": "hepatitis B surface antigen", "entity2": "type B hepatitis", "span1": [215, 242], "span2": [167, 183]}, "bert_text": "Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to <e1> hepatitis B surface antigen </e1> <e2> type B hepatitis </e2> after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
	"304": {"data": {"text": "Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.", "entity1": "HBsAG)-positive", "entity2": "Hepatitis B", "span1": [244, 259], "span2": [0, 11]}, "bert_text": "Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (<e1> HBsAG)-positive </e1> <e2> Hepatitis B </e2> immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"305": {"data": {"text": "Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.", "entity1": "HBsAG)-positive", "entity2": "type B hepatitis", "span1": [244, 259], "span2": [167, 183]}, "bert_text": "Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (<e1> HBsAG)-positive </e1> <e2> type B hepatitis </e2> after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
	"306": {"data": {"text": "All seizures were controlled with therapeutic doses of phenytoin.", "entity1": "phenytoin", "entity2": "seizures", "span1": [55, 64], "span2": [4, 12]}, "bert_text": "All seizures were controlled with therapeutic doses of <e1> phenytoin </e1> <e2> seizures </e2> were controlled with therapeutic doses of phenytoin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"307": {"data": {"text": "To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.", "entity1": "estrogen", "entity2": "tumor", "span1": [25, 33], "span2": [55, 60]}, "bert_text": "To elucidate the role of <e1> estrogen </e1> in the regulation of <e2> tumor </e2> angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"308": {"data": {"text": "On the contrary, the SM-5887 treatment did not progress the grade of cardiomyopathy.", "entity1": "SM-5887", "entity2": "cardiomyopathy", "span1": [21, 28], "span2": [69, 83]}, "bert_text": "On the contrary, the <e1> SM-5887 </e1> treatment did not progress the grade of <e2> cardiomyopathy </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
	"309": {"data": {"text": "The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.", "entity1": "E2", "entity2": "tumor", "span1": [103, 105], "span2": [9, 14]}, "bert_text": "The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the <e1> E2 </e1> <e2> tumor </e2> angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"310": {"data": {"text": "Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.", "entity1": "tramadol", "entity2": "hallucinations", "span1": [152, 160], "span2": [71, 85]}, "bert_text": "Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and <e1> tramadol </e1> <e2> hallucinations </e2> that only stopped after the withdrawal of psycho-active drugs and tramadol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
	"311": {"data": {"text": "The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.", "entity1": "propylthiouracil", "entity2": "vasculitis", "span1": [17, 33], "span2": [51, 61]}, "bert_text": "The diagnosis of <e1> propylthiouracil </e1> (PTU)-associated <e2> vasculitis </e2> was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"312": {"data": {"text": "The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.", "entity1": "PTU)-associated", "entity2": "vasculitis", "span1": [35, 50], "span2": [51, 61]}, "bert_text": "The diagnosis of propylthiouracil (<e1> PTU)-associated </e1> <e2> vasculitis </e2> was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"313": {"data": {"text": "The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.", "entity1": "PTU", "entity2": "vasculitis", "span1": [245, 248], "span2": [51, 61]}, "bert_text": "The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of <e1> PTU </e1> <e2> vasculitis </e2> was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"314": {"data": {"text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "entity1": "diltiazem", "entity2": "overdose", "span1": [63, 72], "span2": [31, 39]}, "bert_text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of <e1> diltiazem </e1> <e2> overdose </e2> including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"315": {"data": {"text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "entity1": "paracetamol", "entity2": "overdose", "span1": [74, 85], "span2": [31, 39]}, "bert_text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, <e1> paracetamol </e1> <e2> overdose </e2> including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"316": {"data": {"text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "entity1": "aspirin", "entity2": "overdose", "span1": [87, 94], "span2": [31, 39]}, "bert_text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, <e1> aspirin </e1> <e2> overdose </e2> including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"317": {"data": {"text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "entity1": "isosorbide", "entity2": "overdose", "span1": [96, 106], "span2": [31, 39]}, "bert_text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, <e1> isosorbide </e1> <e2> overdose </e2> including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"318": {"data": {"text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "entity1": "nitrate", "entity2": "overdose", "span1": [107, 114], "span2": [31, 39]}, "bert_text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide <e1> nitrate </e1> <e2> overdose </e2> including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"319": {"data": {"text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "entity1": "alcohol", "entity2": "overdose", "span1": [120, 127], "span2": [31, 39]}, "bert_text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and <e1> alcohol </e1> <e2> overdose </e2> including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"320": {"data": {"text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "entity1": "Myocet", "entity2": "cardiotoxicity", "span1": [12, 18], "span2": [91, 105]}, "bert_text": "CONCLUSION: <e1> Myocet </e1> improves the therapeutic index of doxorubicin by significantly reducing <e2> cardiotoxicity </e2> and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"321": {"data": {"text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "entity1": "Myocet", "entity2": "neutropenia", "span1": [12, 18], "span2": [118, 129]}, "bert_text": "CONCLUSION: <e1> Myocet </e1> improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 <e2> neutropenia </e2> and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"322": {"data": {"text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "entity1": "Myocet", "entity2": "MBC", "span1": [12, 18], "span2": [247, 250]}, "bert_text": "CONCLUSION: <e1> Myocet </e1> improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for <e2> MBC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"323": {"data": {"text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [53, 64], "span2": [91, 105]}, "bert_text": "CONCLUSION: Myocet improves the therapeutic index of <e1> doxorubicin </e1> by significantly reducing <e2> cardiotoxicity </e2> and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"324": {"data": {"text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "entity1": "doxorubicin", "entity2": "neutropenia", "span1": [53, 64], "span2": [118, 129]}, "bert_text": "CONCLUSION: Myocet improves the therapeutic index of <e1> doxorubicin </e1> by significantly reducing cardiotoxicity and grade 4 <e2> neutropenia </e2> and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"325": {"data": {"text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "entity1": "doxorubicin", "entity2": "MBC", "span1": [53, 64], "span2": [247, 250]}, "bert_text": "CONCLUSION: Myocet improves the therapeutic index of <e1> doxorubicin </e1> by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for <e2> MBC </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"326": {"data": {"text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "entity1": "cyclophosphamide", "entity2": "cardiotoxicity", "span1": [204, 220], "span2": [91, 105]}, "bert_text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with <e1> cyclophosphamide </e1> <e2> cardiotoxicity </e2> and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"327": {"data": {"text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "entity1": "cyclophosphamide", "entity2": "neutropenia", "span1": [204, 220], "span2": [118, 129]}, "bert_text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with <e1> cyclophosphamide </e1> <e2> neutropenia </e2> and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"328": {"data": {"text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "entity1": "cyclophosphamide", "entity2": "MBC", "span1": [204, 220], "span2": [247, 250]}, "bert_text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with <e1> cyclophosphamide </e1> as first-line therapy for <e2> MBC </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"329": {"data": {"text": "This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg.", "entity1": "amlodipine", "entity2": "hypertension", "span1": [139, 149], "span2": [84, 96]}, "bert_text": "This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of <e1> amlodipine </e1> <e2> hypertension </e2>, who was started on a combination pill of amlodipine/benazapril 10/5 mg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"330": {"data": {"text": "This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg.", "entity1": "benazapril", "entity2": "hypertension", "span1": [150, 160], "span2": [84, 96]}, "bert_text": "This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/<e1> benazapril </e1> <e2> hypertension </e2>, who was started on a combination pill of amlodipine/benazapril 10/5 mg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"331": {"data": {"text": "On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice", "entity1": "reserpine", "entity2": "tremor", "span1": [19, 28], "span2": [50, 56]}, "bert_text": "On the other hand, <e1> reserpine </e1> induced increases in <e2> tremor </e2> and catalepsy compared to control mice", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"332": {"data": {"text": "On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice", "entity1": "reserpine", "entity2": "catalepsy", "span1": [19, 28], "span2": [61, 70]}, "bert_text": "On the other hand, <e1> reserpine </e1> induced increases in tremor and <e2> catalepsy </e2> compared to control mice", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"333": {"data": {"text": "All toxicities resolved after cis-RA was discontinued.", "entity1": "cis-RA", "entity2": "toxicities", "span1": [30, 36], "span2": [4, 14]}, "bert_text": "All toxicities resolved after <e1> cis-RA </e1> <e2> toxicities </e2> resolved after cis-RA was discontinued.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"334": {"data": {"text": "Worsening of levodopa-induced dyskinesias by motor and mental tasks.\n", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [13, 21], "span2": [30, 41]}, "bert_text": "Worsening of <e1> levodopa </e1>-induced <e2> dyskinesias </e2> by motor and mental tasks.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"335": {"data": {"text": "In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated.", "entity1": "nicotine", "entity2": "catalepsy", "span1": [33, 41], "span2": [45, 54]}, "bert_text": "In the present study, effects of <e1> nicotine </e1> on <e2> catalepsy </e2> induced by morphine in mice have been investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"336": {"data": {"text": "In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated.", "entity1": "morphine", "entity2": "catalepsy", "span1": [66, 74], "span2": [45, 54]}, "bert_text": "In the present study, effects of nicotine on catalepsy induced by <e1> morphine </e1> <e2> catalepsy </e2> induced by morphine in mice have been investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"337": {"data": {"text": "PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.", "entity1": "lithium", "entity2": "bipolar disorder", "span1": [93, 100], "span2": [66, 82]}, "bert_text": "PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving <e1> lithium </e1> <e2> bipolar disorder </e2> receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"338": {"data": {"text": "Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.\n", "entity1": "thallium-201", "entity2": "coronary stenosis", "span1": [136, 148], "span2": [100, 117]}, "bert_text": "Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with <e1> thallium-201 </e1> <e2> coronary stenosis </e2>: correlation with thallium-201 single-photon emission tomography.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"339": {"data": {"text": "Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.\n", "entity1": "catecholamines", "entity2": "psychosis", "span1": [83, 97], "span2": [38, 47]}, "bert_text": "Quantitative drug levels in stimulant psychosis: relationship to symptom severity, <e1> catecholamines </e1> <e2> psychosis </e2>: relationship to symptom severity, catecholamines and hyperkinesia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"340": {"data": {"text": "Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.\n", "entity1": "catecholamines", "entity2": "hyperkinesia", "span1": [83, 97], "span2": [102, 114]}, "bert_text": "Quantitative drug levels in stimulant psychosis: relationship to symptom severity, <e1> catecholamines </e1> and <e2> hyperkinesia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"341": {"data": {"text": "OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.", "entity1": "thalidomide", "entity2": "toxicity", "span1": [53, 64], "span2": [28, 36]}, "bert_text": "OBJECTIVES: To evaluate the toxicity and activity of <e1> thalidomide </e1> <e2> toxicity </e2> and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"342": {"data": {"text": "OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.", "entity1": "thalidomide", "entity2": "renal cell cancer", "span1": [53, 64], "span2": [102, 119]}, "bert_text": "OBJECTIVES: To evaluate the toxicity and activity of <e1> thalidomide </e1> in patients with advanced metastatic <e2> renal cell cancer </e2> and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"343": {"data": {"text": "Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.", "entity1": "oral contraceptives", "entity2": "hepatic adenoma", "span1": [104, 123], "span2": [13, 28]}, "bert_text": "Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of <e1> oral contraceptives </e1> <e2> hepatic adenoma </e2> and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"344": {"data": {"text": "Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.", "entity1": "oral contraceptives", "entity2": "focal nodular hyperplasia", "span1": [104, 123], "span2": [40, 65]}, "bert_text": "Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of <e1> oral contraceptives </e1> <e2> focal nodular hyperplasia </e2> presumably associated with the use of oral contraceptives, are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"345": {"data": {"text": "The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in dipyridamole-induced hyperemia.", "entity1": "dipyridamole", "entity2": "hyperemia", "span1": [105, 117], "span2": [126, 135]}, "bert_text": "The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in <e1> dipyridamole </e1>-induced <e2> hyperemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"346": {"data": {"text": "Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.", "entity1": "prednisone", "entity2": "lethargy", "span1": [33, 43], "span2": [65, 73]}, "bert_text": "Following short exposure to oral <e1> prednisone </e1>, both boys developed <e2> lethargy </e2>, increasing somnolence, polydipsia, polyphagia, and polyuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"347": {"data": {"text": "Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.", "entity1": "prednisone", "entity2": "somnolence", "span1": [33, 43], "span2": [86, 96]}, "bert_text": "Following short exposure to oral <e1> prednisone </e1>, both boys developed lethargy, increasing <e2> somnolence </e2>, polydipsia, polyphagia, and polyuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"348": {"data": {"text": "Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.", "entity1": "prednisone", "entity2": "polydipsia", "span1": [33, 43], "span2": [98, 108]}, "bert_text": "Following short exposure to oral <e1> prednisone </e1>, both boys developed lethargy, increasing somnolence, <e2> polydipsia </e2>, polyphagia, and polyuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"349": {"data": {"text": "Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.", "entity1": "prednisone", "entity2": "polyphagia", "span1": [33, 43], "span2": [110, 120]}, "bert_text": "Following short exposure to oral <e1> prednisone </e1>, both boys developed lethargy, increasing somnolence, polydipsia, <e2> polyphagia </e2>, and polyuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"350": {"data": {"text": "Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.", "entity1": "prednisone", "entity2": "polyuria", "span1": [33, 43], "span2": [126, 134]}, "bert_text": "Following short exposure to oral <e1> prednisone </e1>, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and <e2> polyuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"351": {"data": {"text": "Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.", "entity1": "METH", "entity2": "aggressiveness", "span1": [63, 67], "span2": [92, 106]}, "bert_text": "Herein, we report that multiple (but not single) injections of <e1> METH </e1> significantly increased <e2> aggressiveness </e2> in male CD-1 mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"352": {"data": {"text": "Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril.", "entity1": "naloxone", "entity2": "hypotension", "span1": [47, 55], "span2": [75, 86]}, "bert_text": "Our experience demonstrates a possible role of <e1> naloxone </e1> in the reversal of <e2> hypotension </e2> resulting from captopril.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"353": {"data": {"text": "Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.", "entity1": "haloperidol", "entity2": "EPS", "span1": [73, 84], "span2": [26, 29]}, "bert_text": "Adverse events related to EPS occurred in 59.6% of patients treated with <e1> haloperidol </e1> <e2> EPS </e2> occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"354": {"data": {"text": "Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.", "entity1": "haloperidol", "entity2": "EPS", "span1": [73, 84], "span2": [213, 216]}, "bert_text": "Adverse events related to EPS occurred in 59.6% of patients treated with <e1> haloperidol </e1> (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to <e2> EPS </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"355": {"data": {"text": "Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.", "entity1": "lithium", "entity2": "EPS", "span1": [146, 153], "span2": [26, 29]}, "bert_text": "Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with <e1> lithium </e1> <e2> EPS </e2> occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"356": {"data": {"text": "Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.", "entity1": "lithium", "entity2": "EPS", "span1": [146, 153], "span2": [213, 216]}, "bert_text": "Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with <e1> lithium </e1> (n = 98) monotherapy experienced adverse events related to <e2> EPS </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"357": {"data": {"text": "Warfarin-induced leukocytoclastic vasculitis.\n", "entity1": "Warfarin", "entity2": "leukocytoclastic vasculitis", "span1": [0, 8], "span2": [17, 44]}, "bert_text": "<e1> Warfarin </e1>-induced <e2> leukocytoclastic vasculitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"358": {"data": {"text": "This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.", "entity1": "calcium", "entity2": "overdose", "span1": [72, 79], "span2": [108, 116]}, "bert_text": "This case suggests there is a role for aggressive high dose intravenous <e1> calcium </e1> therapy in severe diltiazem <e2> overdose </e2>, particularly with the onset of asystole.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"359": {"data": {"text": "This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.", "entity1": "calcium", "entity2": "asystole", "span1": [72, 79], "span2": [149, 157]}, "bert_text": "This case suggests there is a role for aggressive high dose intravenous <e1> calcium </e1> therapy in severe diltiazem overdose, particularly with the onset of <e2> asystole </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"360": {"data": {"text": "This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.", "entity1": "diltiazem", "entity2": "overdose", "span1": [98, 107], "span2": [108, 116]}, "bert_text": "This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe <e1> diltiazem </e1> <e2> overdose </e2>, particularly with the onset of asystole.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"361": {"data": {"text": "This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.", "entity1": "diltiazem", "entity2": "asystole", "span1": [98, 107], "span2": [149, 157]}, "bert_text": "This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe <e1> diltiazem </e1> overdose, particularly with the onset of <e2> asystole </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"362": {"data": {"text": "Myositis was suspected, and the patient was treated with steroids.", "entity1": "steroids", "entity2": "Myositis", "span1": [57, 65], "span2": [0, 8]}, "bert_text": "Myositis was suspected, and the patient was treated with <e1> steroids </e1> <e2> Myositis </e2> was suspected, and the patient was treated with steroids.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"363": {"data": {"text": "Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.", "entity1": "nimesulide", "entity2": "urticaria", "span1": [61, 71], "span2": [116, 125]}, "bert_text": "Taken together, our results confirm the good tolerability of <e1> nimesulide </e1> and paracetamol in patients who experienced <e2> urticaria </e2>/angioedema caused by NSAIDs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"364": {"data": {"text": "Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.", "entity1": "nimesulide", "entity2": "angioedema", "span1": [61, 71], "span2": [126, 136]}, "bert_text": "Taken together, our results confirm the good tolerability of <e1> nimesulide </e1> and paracetamol in patients who experienced urticaria/<e2> angioedema </e2> caused by NSAIDs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"365": {"data": {"text": "Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.", "entity1": "paracetamol", "entity2": "urticaria", "span1": [76, 87], "span2": [116, 125]}, "bert_text": "Taken together, our results confirm the good tolerability of nimesulide and <e1> paracetamol </e1> in patients who experienced <e2> urticaria </e2>/angioedema caused by NSAIDs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"366": {"data": {"text": "Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.", "entity1": "paracetamol", "entity2": "angioedema", "span1": [76, 87], "span2": [126, 136]}, "bert_text": "Taken together, our results confirm the good tolerability of nimesulide and <e1> paracetamol </e1> in patients who experienced urticaria/<e2> angioedema </e2> caused by NSAIDs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"367": {"data": {"text": "Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.", "entity1": "NSAIDs", "entity2": "urticaria", "span1": [147, 153], "span2": [116, 125]}, "bert_text": "Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by <e1> NSAIDs </e1> <e2> urticaria </e2>/angioedema caused by NSAIDs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"368": {"data": {"text": "Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.", "entity1": "NSAIDs", "entity2": "angioedema", "span1": [147, 153], "span2": [126, 136]}, "bert_text": "Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by <e1> NSAIDs </e1> <e2> angioedema </e2> caused by NSAIDs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"369": {"data": {"text": "The patients had developed transient renal failure after the intermittent administration of rifampicin.", "entity1": "rifampicin", "entity2": "renal failure", "span1": [92, 102], "span2": [37, 50]}, "bert_text": "The patients had developed transient renal failure after the intermittent administration of <e1> rifampicin </e1> <e2> renal failure </e2> after the intermittent administration of rifampicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"370": {"data": {"text": "Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.", "entity1": "doxorubicin", "entity2": "Proteinuria", "span1": [99, 110], "span2": [0, 11]}, "bert_text": "Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after <e1> doxorubicin </e1> <e2> Proteinuria </e2> appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"371": {"data": {"text": "Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.", "entity1": "DX", "entity2": "Proteinuria", "span1": [187, 189], "span2": [0, 11]}, "bert_text": "Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and <e1> DX </e1> <e2> Proteinuria </e2> appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"372": {"data": {"text": "RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.", "entity1": "OCT", "entity2": "renal insufficiency", "span1": [21, 24], "span2": [94, 113]}, "bert_text": "RESULTS: In Nx dogs, <e1> OCT </e1> significantly decreased serum PTH levels soon after the induction of <e2> renal insufficiency </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"373": {"data": {"text": "Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.", "entity1": "aminoglycosides", "entity2": "impairment of renal reabsorption", "span1": [6, 21], "span2": [93, 125]}, "bert_text": "Thus, <e1> aminoglycosides </e1> may act as nephrotoxicants at glomerular and/or tubular level inducing <e2> impairment of renal reabsorption </e2> and accumulation of proteins.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"374": {"data": {"text": "One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.", "entity1": "steroid", "entity2": "pleural effusion", "span1": [16, 23], "span2": [37, 53]}, "bert_text": "One month after <e1> steroid </e1> therapy, the <e2> pleural effusion </e2> disappeared, and PR3-ANCA titer normalized 3 months later.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"375": {"data": {"text": "Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.", "entity1": "D-penicillamine", "entity2": "localized scleroderma", "span1": [95, 110], "span2": [51, 72]}, "bert_text": "Case reports of 11 patients with severe, extensive localized scleroderma who were treated with <e1> D-penicillamine </e1> <e2> localized scleroderma </e2> who were treated with D-penicillamine are summarized in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"376": {"data": {"text": "In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "entity1": "milrinone", "entity2": "heart failure", "span1": [83, 92], "span2": [31, 44]}, "bert_text": "In patients with decompensated heart failure with hypotension after treatment with <e1> milrinone </e1> <e2> heart failure </e2> with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"377": {"data": {"text": "In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "entity1": "milrinone", "entity2": "hypotension", "span1": [83, 92], "span2": [50, 61]}, "bert_text": "In patients with decompensated heart failure with hypotension after treatment with <e1> milrinone </e1> <e2> hypotension </e2> after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"378": {"data": {"text": "In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "entity1": "milrinone", "entity2": "heart failure", "span1": [186, 195], "span2": [31, 44]}, "bert_text": "In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of <e1> milrinone </e1> <e2> heart failure </e2> with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"379": {"data": {"text": "In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "entity1": "milrinone", "entity2": "hypotension", "span1": [186, 195], "span2": [50, 61]}, "bert_text": "In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of <e1> milrinone </e1> <e2> hypotension </e2> after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"380": {"data": {"text": "In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "entity1": "vasopressin", "entity2": "heart failure", "span1": [107, 118], "span2": [31, 44]}, "bert_text": "In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of <e1> vasopressin </e1> <e2> heart failure </e2> with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"381": {"data": {"text": "In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "entity1": "vasopressin", "entity2": "hypotension", "span1": [107, 118], "span2": [50, 61]}, "bert_text": "In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of <e1> vasopressin </e1> <e2> hypotension </e2> after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"382": {"data": {"text": "A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.", "entity1": "carbamazepine", "entity2": "sinus bradycardia", "span1": [72, 85], "span2": [15, 32]}, "bert_text": "A patient with sinus bradycardia and atrioventricular block, induced by <e1> carbamazepine </e1> <e2> sinus bradycardia </e2> and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"383": {"data": {"text": "A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.", "entity1": "carbamazepine", "entity2": "atrioventricular block", "span1": [72, 85], "span2": [37, 59]}, "bert_text": "A patient with sinus bradycardia and atrioventricular block, induced by <e1> carbamazepine </e1> <e2> atrioventricular block </e2>, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"384": {"data": {"text": "Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.", "entity1": "diazepam", "entity2": "bradycardia", "span1": [42, 50], "span2": [163, 174]}, "bert_text": "Intravenous pretreatment of the rats with <e1> diazepam </e1>, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex <e2> bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"385": {"data": {"text": "Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.", "entity1": "adrenaline", "entity2": "bradycardia", "span1": [86, 96], "span2": [163, 174]}, "bert_text": "Intravenous pretreatment of the rats with diazepam, although causing no change in the <e1> adrenaline </e1>-induced pressor effect, did enhance the adrenaline-induced reflex <e2> bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"386": {"data": {"text": "Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.", "entity1": "adrenaline", "entity2": "bradycardia", "span1": [137, 147], "span2": [163, 174]}, "bert_text": "Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the <e1> adrenaline </e1>-induced reflex <e2> bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"387": {"data": {"text": "As it revealed chloroquine-induced myopathy, medication was stopped.", "entity1": "chloroquine", "entity2": "myopathy", "span1": [15, 26], "span2": [35, 43]}, "bert_text": "As it revealed <e1> chloroquine </e1>-induced <e2> myopathy </e2>, medication was stopped.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"388": {"data": {"text": "Both patients had received maximum doses of other beta-lactam antibiotics without evidence of seizure activity.", "entity1": "beta-lactam", "entity2": "seizure", "span1": [50, 61], "span2": [94, 101]}, "bert_text": "Both patients had received maximum doses of other <e1> beta-lactam </e1> antibiotics without evidence of <e2> seizure </e2> activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"389": {"data": {"text": "Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.", "entity1": "Dobutamine", "entity2": "myocardial ischemia", "span1": [0, 10], "span2": [83, 102]}, "bert_text": "<e1> Dobutamine </e1> stress echocardiography (DSE) is a useful and safe provocation test for <e2> myocardial ischemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"390": {"data": {"text": "In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.", "entity1": "mesna", "entity2": "hemorrhagic cystitis", "span1": [59, 64], "span2": [137, 157]}, "bert_text": "In contrast, two of four consecutive patients who received <e1> mesna </e1> uroprophylaxis before allogeneic bone marrow transplantation had severe <e2> hemorrhagic cystitis </e2> for at least 2 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"391": {"data": {"text": "The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.", "entity1": "etoposide", "entity2": "myocardial infarction", "span1": [84, 93], "span2": [20, 41]}, "bert_text": "The occurrence of a myocardial infarction is reported after chemotherapy containing <e1> etoposide </e1> <e2> myocardial infarction </e2> is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"392": {"data": {"text": "The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.", "entity1": "etoposide", "entity2": "coronary heart disease", "span1": [84, 93], "span2": [129, 151]}, "bert_text": "The occurrence of a myocardial infarction is reported after chemotherapy containing <e1> etoposide </e1>, in a man with no risk factors for <e2> coronary heart disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
	"393": {"data": {"text": "A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.", "entity1": "DX", "entity2": "proteinuria", "span1": [94, 96], "span2": [17, 28]}, "bert_text": "A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with <e1> DX </e1> <e2> proteinuria </e2> appeared in animals treated with DXNP than in those treated with DX.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"394": {"data": {"text": "From the analysis of these cases, two distinct forms of carbamazepine-associated cardiac dysfunction emerged.", "entity1": "carbamazepine", "entity2": "cardiac dysfunction", "span1": [56, 69], "span2": [81, 100]}, "bert_text": "From the analysis of these cases, two distinct forms of <e1> carbamazepine </e1>-associated <e2> cardiac dysfunction </e2> emerged.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"395": {"data": {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity1": "Lithium", "entity2": "tremor", "span1": [0, 7], "span2": [75, 81]}, "bert_text": "<e1> Lithium </e1> was associated with a significantly higher incidence (p < 0.05) of <e2> tremor </e2> (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"396": {"data": {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity1": "Lithium", "entity2": "tremor", "span1": [0, 7], "span2": [125, 131]}, "bert_text": "<e1> Lithium </e1> was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar <e2> tremor </e2>, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"397": {"data": {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity1": "Lithium", "entity2": "tremor", "span1": [0, 7], "span2": [222, 228]}, "bert_text": "<e1> Lithium </e1> was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of <e2> tremor </e2> in patients receiving lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"398": {"data": {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity1": "lithium", "entity2": "tremor", "span1": [168, 175], "span2": [75, 81]}, "bert_text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of <e1> lithium </e1> <e2> tremor </e2> (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"399": {"data": {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity1": "lithium", "entity2": "tremor", "span1": [168, 175], "span2": [125, 131]}, "bert_text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of <e1> lithium </e1> <e2> tremor </e2>, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"400": {"data": {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity1": "lithium", "entity2": "tremor", "span1": [168, 175], "span2": [222, 228]}, "bert_text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of <e1> lithium </e1>, may have contributed to the elevated rate of <e2> tremor </e2> in patients receiving lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"401": {"data": {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity1": "lithium", "entity2": "tremor", "span1": [251, 258], "span2": [75, 81]}, "bert_text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving <e1> lithium </e1> <e2> tremor </e2> (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"402": {"data": {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity1": "lithium", "entity2": "tremor", "span1": [251, 258], "span2": [125, 131]}, "bert_text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving <e1> lithium </e1> <e2> tremor </e2>, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"403": {"data": {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity1": "lithium", "entity2": "tremor", "span1": [251, 258], "span2": [222, 228]}, "bert_text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving <e1> lithium </e1> <e2> tremor </e2> in patients receiving lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"404": {"data": {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity1": "quetiapine", "entity2": "tremor", "span1": [95, 105], "span2": [75, 81]}, "bert_text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than <e1> quetiapine </e1> <e2> tremor </e2> (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"405": {"data": {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity1": "quetiapine", "entity2": "tremor", "span1": [95, 105], "span2": [125, 131]}, "bert_text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than <e1> quetiapine </e1> (5.6%); cerebellar <e2> tremor </e2>, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"406": {"data": {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity1": "quetiapine", "entity2": "tremor", "span1": [95, 105], "span2": [222, 228]}, "bert_text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than <e1> quetiapine </e1> (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of <e2> tremor </e2> in patients receiving lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"407": {"data": {"text": "Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.", "entity1": "cyclophosphamide", "entity2": "Hemorrhagic cystitis", "span1": [72, 88], "span2": [0, 20]}, "bert_text": "Hemorrhagic cystitis is a potentially serious complication of high-dose <e1> cyclophosphamide </e1> <e2> Hemorrhagic cystitis </e2> is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"408": {"data": {"text": "A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.", "entity1": "fentanyl", "entity2": "rigidity", "span1": [164, 172], "span2": [28, 36]}, "bert_text": "A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of <e1> fentanyl </e1> <e2> rigidity </e2> leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"409": {"data": {"text": "A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.", "entity1": "fentanyl", "entity2": "respiratory failure", "span1": [164, 172], "span2": [48, 67]}, "bert_text": "A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of <e1> fentanyl </e1> <e2> respiratory failure </e2> is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"410": {"data": {"text": "The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.", "entity1": "valsartan", "entity2": "hypertension", "span1": [19, 28], "span2": [105, 117]}, "bert_text": "The data show that <e1> valsartan </e1> is at least as effective as amlodipine in the treatment of mild to moderate <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"411": {"data": {"text": "The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.", "entity1": "amlodipine", "entity2": "hypertension", "span1": [57, 67], "span2": [105, 117]}, "bert_text": "The data show that valsartan is at least as effective as <e1> amlodipine </e1> in the treatment of mild to moderate <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"412": {"data": {"text": "It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.", "entity1": "morphine", "entity2": "catalepsy", "span1": [22, 30], "span2": [31, 40]}, "bert_text": "It was concluded that <e1> morphine </e1> <e2> catalepsy </e2> can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"413": {"data": {"text": "It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.", "entity1": "morphine", "entity2": "catalepsy", "span1": [118, 126], "span2": [31, 40]}, "bert_text": "It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of <e1> morphine </e1> <e2> catalepsy </e2> can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"414": {"data": {"text": "It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.", "entity1": "nicotine", "entity2": "catalepsy", "span1": [138, 146], "span2": [31, 40]}, "bert_text": "It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by <e1> nicotine </e1> <e2> catalepsy </e2> can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"415": {"data": {"text": "These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.", "entity1": "D-penicillamine", "entity2": "localized scleroderma", "span1": [24, 39], "span2": [76, 97]}, "bert_text": "These data suggest that <e1> D-penicillamine </e1> may be effective in severe cases of <e2> localized scleroderma </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"416": {"data": {"text": "Why may epsilon-aminocaproic acid (EACA) induce myopathy in man?", "entity1": "epsilon-aminocaproic acid", "entity2": "myopathy", "span1": [8, 33], "span2": [48, 56]}, "bert_text": "Why may <e1> epsilon-aminocaproic acid </e1> (EACA) induce <e2> myopathy </e2> in man?", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"417": {"data": {"text": "Why may epsilon-aminocaproic acid (EACA) induce myopathy in man?", "entity1": "EACA", "entity2": "myopathy", "span1": [35, 39], "span2": [48, 56]}, "bert_text": "Why may epsilon-aminocaproic acid (<e1> EACA </e1>) induce <e2> myopathy </e2> in man?", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"418": {"data": {"text": "Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.\n", "entity1": "nicotine", "entity2": "locomotor hyperactivity", "span1": [23, 31], "span2": [40, 63]}, "bert_text": "Receptor mechanisms of <e1> nicotine </e1>-induced <e2> locomotor hyperactivity </e2> in chronic nicotine-treated rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"419": {"data": {"text": "Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.\n", "entity1": "nicotine", "entity2": "locomotor hyperactivity", "span1": [75, 83], "span2": [40, 63]}, "bert_text": "Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic <e1> nicotine </e1> <e2> locomotor hyperactivity </e2> in chronic nicotine-treated rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"420": {"data": {"text": "The DLT included hypercalcemia, and may be predicted by serum cis-RA levels.", "entity1": "cis-RA", "entity2": "hypercalcemia", "span1": [62, 68], "span2": [17, 30]}, "bert_text": "The DLT included hypercalcemia, and may be predicted by serum <e1> cis-RA </e1> <e2> hypercalcemia </e2>, and may be predicted by serum cis-RA levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
	"421": {"data": {"text": "It should be considered early in cases of cardiac arrest after diltiazem overdose.", "entity1": "diltiazem", "entity2": "cardiac arrest", "span1": [63, 72], "span2": [42, 56]}, "bert_text": "It should be considered early in cases of cardiac arrest after <e1> diltiazem </e1> <e2> cardiac arrest </e2> after diltiazem overdose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"422": {"data": {"text": "It should be considered early in cases of cardiac arrest after diltiazem overdose.", "entity1": "diltiazem", "entity2": "overdose", "span1": [63, 72], "span2": [73, 81]}, "bert_text": "It should be considered early in cases of cardiac arrest after <e1> diltiazem </e1> <e2> overdose </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"423": {"data": {"text": "Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.", "entity1": "acetylcholine", "entity2": "spasm", "span1": [57, 70], "span2": [9, 14]}, "bert_text": "Coronary spasm was induced by intracoronary injection of <e1> acetylcholine </e1> <e2> spasm </e2> was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"424": {"data": {"text": "Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.", "entity1": "acetylcholine", "entity2": "coronary artery stenosis", "span1": [57, 70], "span2": [85, 109]}, "bert_text": "Coronary spasm was induced by intracoronary injection of <e1> acetylcholine </e1>, and no fixed <e2> coronary artery stenosis </e2> was documented on angiograms in all patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
	"425": {"data": {"text": "Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.", "entity1": "dexrazoxane", "entity2": "brain metastases", "span1": [60, 71], "span2": [33, 49]}, "bert_text": "Clinical trials in patients with brain metastases combining <e1> dexrazoxane </e1> <e2> brain metastases </e2> combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"426": {"data": {"text": "Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.", "entity1": "dexrazoxane", "entity2": "hematologic toxicity", "span1": [60, 71], "span2": [166, 186]}, "bert_text": "Clinical trials in patients with brain metastases combining <e1> dexrazoxane </e1> and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating <e2> hematologic toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
	"427": {"data": {"text": "Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.", "entity1": "etoposide", "entity2": "brain metastases", "span1": [90, 99], "span2": [33, 49]}, "bert_text": "Clinical trials in patients with brain metastases combining dexrazoxane and high doses of <e1> etoposide </e1> <e2> brain metastases </e2> combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"428": {"data": {"text": "Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.", "entity1": "etoposide", "entity2": "hematologic toxicity", "span1": [90, 99], "span2": [166, 186]}, "bert_text": "Clinical trials in patients with brain metastases combining dexrazoxane and high doses of <e1> etoposide </e1> is ongoing with the aim of improving efficacy without aggravating <e2> hematologic toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 1},
	"429": {"data": {"text": "In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.", "entity1": "OCT", "entity2": "fibrosis", "span1": [12, 15], "span2": [76, 84]}, "bert_text": "In Nx dogs, <e1> OCT </e1> reversed abnormal bone formation, such as woven osteoid and <e2> fibrosis </e2>, but did not significantly alter the level of bone turnover.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"430": {"data": {"text": "Tiapride had no effect on levodopa-induced early morning of \"off-period\" segmental dystonia.", "entity1": "Tiapride", "entity2": "dystonia", "span1": [0, 8], "span2": [83, 91]}, "bert_text": "<e1> Tiapride </e1> had no effect on levodopa-induced early morning of \"off-period\" segmental <e2> dystonia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"431": {"data": {"text": "Tiapride had no effect on levodopa-induced early morning of \"off-period\" segmental dystonia.", "entity1": "levodopa", "entity2": "dystonia", "span1": [26, 34], "span2": [83, 91]}, "bert_text": "Tiapride had no effect on <e1> levodopa </e1>-induced early morning of \"off-period\" segmental <e2> dystonia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"432": {"data": {"text": "nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.", "entity1": "nitroprusside", "entity2": "ischemia", "span1": [0, 13], "span2": [73, 81]}, "bert_text": "<e1> nitroprusside </e1> at a flow rate of 103 microliters/min intravenously during <e2> ischemia </e2>, although in this latter group malondialdehyde was significantly higher.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"433": {"data": {"text": "nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.", "entity1": "malondialdehyde", "entity2": "ischemia", "span1": [113, 128], "span2": [73, 81]}, "bert_text": "nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group <e1> malondialdehyde </e1> <e2> ischemia </e2>, although in this latter group malondialdehyde was significantly higher.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"434": {"data": {"text": "Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.\n", "entity1": "sulphasalazine", "entity2": "glomerulonephritis", "span1": [117, 131], "span2": [81, 99]}, "bert_text": "Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting <e1> sulphasalazine </e1> <e2> glomerulonephritis </e2> after restarting sulphasalazine treatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"435": {"data": {"text": "Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.", "entity1": "MK-801", "entity2": "spastic paraparesis", "span1": [41, 47], "span2": [130, 149]}, "bert_text": "Second, we investigated the effect of IT <e1> MK-801 </e1> (30 mug) on the histopathologic changes in the spinal cord after morphine-induced <e2> spastic paraparesis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"436": {"data": {"text": "Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.", "entity1": "morphine", "entity2": "spastic paraparesis", "span1": [113, 121], "span2": [130, 149]}, "bert_text": "Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after <e1> morphine </e1>-induced <e2> spastic paraparesis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"437": {"data": {"text": "Also, reflex bradycardia was produced in rats by intravenous infusion of adrenaline (1.25-2.5 micrograms kg-1).", "entity1": "adrenaline", "entity2": "bradycardia", "span1": [73, 83], "span2": [13, 24]}, "bert_text": "Also, reflex bradycardia was produced in rats by intravenous infusion of <e1> adrenaline </e1> <e2> bradycardia </e2> was produced in rats by intravenous infusion of adrenaline (1.25-2.5 micrograms kg-1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"438": {"data": {"text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "entity1": "erythromycin", "entity2": "Prolongation of QT interval", "span1": [132, 144], "span2": [0, 27]}, "bert_text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with <e1> erythromycin </e1> <e2> Prolongation of QT interval </e2>, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"439": {"data": {"text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "entity1": "erythromycin", "entity2": "torsades de pointes", "span1": [132, 144], "span2": [29, 48]}, "bert_text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with <e1> erythromycin </e1> <e2> torsades de pointes </e2>, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"440": {"data": {"text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "entity1": "erythromycin", "entity2": "sudden cardiac death", "span1": [132, 144], "span2": [54, 74]}, "bert_text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with <e1> erythromycin </e1> <e2> sudden cardiac death </e2> have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"441": {"data": {"text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "entity1": "azole", "entity2": "Prolongation of QT interval", "span1": [148, 153], "span2": [0, 27]}, "bert_text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or <e1> azole </e1> <e2> Prolongation of QT interval </e2>, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"442": {"data": {"text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "entity1": "azole", "entity2": "torsades de pointes", "span1": [148, 153], "span2": [29, 48]}, "bert_text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or <e1> azole </e1> <e2> torsades de pointes </e2>, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"443": {"data": {"text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "entity1": "azole", "entity2": "sudden cardiac death", "span1": [148, 153], "span2": [54, 74]}, "bert_text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or <e1> azole </e1> <e2> sudden cardiac death </e2> have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"444": {"data": {"text": "These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).", "entity1": "lithium", "entity2": "thyroid disease", "span1": [53, 60], "span2": [160, 175]}, "bert_text": "These were evaluated with respect to the duration of <e1> lithium </e1> therapy, age, sex, and family history (whether or not the patient had a first-degree relative with <e2> thyroid disease </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"445": {"data": {"text": "Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema was suspected, and anti-hypertensive medications were discontinued.", "entity1": "ACEI)-induced", "entity2": "angioedema", "span1": [41, 54], "span2": [55, 65]}, "bert_text": "Angiotensin-converting enzyme inhibitor (<e1> ACEI)-induced </e1> <e2> angioedema </e2> was suspected, and anti-hypertensive medications were discontinued.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"446": {"data": {"text": "Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema was suspected, and anti-hypertensive medications were discontinued.", "entity1": "ACEI)-induced", "entity2": "hypertensive", "span1": [41, 54], "span2": [90, 102]}, "bert_text": "Angiotensin-converting enzyme inhibitor (<e1> ACEI)-induced </e1> angioedema was suspected, and anti-<e2> hypertensive </e2> medications were discontinued.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"447": {"data": {"text": "However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.", "entity1": "MK-801", "entity2": "tremor", "span1": [9, 15], "span2": [61, 67]}, "bert_text": "However, <e1> MK-801 </e1> injection produced a significant increase of <e2> tremor </e2> in reserpine-treated mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"448": {"data": {"text": "However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.", "entity1": "reserpine", "entity2": "tremor", "span1": [71, 80], "span2": [61, 67]}, "bert_text": "However, MK-801 injection produced a significant increase of tremor in <e1> reserpine </e1> <e2> tremor </e2> in reserpine-treated mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"449": {"data": {"text": "These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.", "entity1": "reserpine", "entity2": "parkinsonian", "span1": [24, 33], "span2": [150, 162]}, "bert_text": "These results show that <e1> reserpine </e1> produces different and abnormal movements, which are related to dose and schedule employed and can be considered as <e2> parkinsonian </e2>-like and tardive dsykinesia signs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"450": {"data": {"text": "These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.", "entity1": "reserpine", "entity2": "tardive dsykinesia", "span1": [24, 33], "span2": [172, 190]}, "bert_text": "These results show that <e1> reserpine </e1> produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and <e2> tardive dsykinesia </e2> signs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"451": {"data": {"text": "A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.", "entity1": "epsilon-aminocaproic acid", "entity2": "necrotizing myopathy", "span1": [46, 71], "span2": [10, 30]}, "bert_text": "A case of necrotizing myopathy due to a short <e1> epsilon-aminocaproic acid </e1> <e2> necrotizing myopathy </e2> due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"452": {"data": {"text": "A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.", "entity1": "epsilon-aminocaproic acid", "entity2": "subarachnoid haemorrhage", "span1": [46, 71], "span2": [119, 143]}, "bert_text": "A case of necrotizing myopathy due to a short <e1> epsilon-aminocaproic acid </e1> (EACA) treatment in a 72 year-old patient with <e2> subarachnoid haemorrhage </e2> (SAH) is described.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"453": {"data": {"text": "A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.", "entity1": "epsilon-aminocaproic acid", "entity2": "SAH", "span1": [46, 71], "span2": [145, 148]}, "bert_text": "A case of necrotizing myopathy due to a short <e1> epsilon-aminocaproic acid </e1> (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (<e2> SAH </e2>) is described.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"454": {"data": {"text": "A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.", "entity1": "EACA", "entity2": "necrotizing myopathy", "span1": [73, 77], "span2": [10, 30]}, "bert_text": "A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (<e1> EACA </e1> <e2> necrotizing myopathy </e2> due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"455": {"data": {"text": "A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.", "entity1": "EACA", "entity2": "subarachnoid haemorrhage", "span1": [73, 77], "span2": [119, 143]}, "bert_text": "A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (<e1> EACA </e1>) treatment in a 72 year-old patient with <e2> subarachnoid haemorrhage </e2> (SAH) is described.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"456": {"data": {"text": "A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.", "entity1": "EACA", "entity2": "SAH", "span1": [73, 77], "span2": [145, 148]}, "bert_text": "A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (<e1> EACA </e1>) treatment in a 72 year-old patient with subarachnoid haemorrhage (<e2> SAH </e2>) is described.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"457": {"data": {"text": "Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.", "entity1": "Lithium carbonate", "entity2": "congenital heart disease", "span1": [0, 17], "span2": [65, 89]}, "bert_text": "<e1> Lithium carbonate </e1> may be a factor in the increasing incidence of <e2> congenital heart disease </e2> when taken during early pregnancy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"458": {"data": {"text": "Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.", "entity1": "Reserpine", "entity2": "tremor", "span1": [0, 9], "span2": [24, 30]}, "bert_text": "<e1> Reserpine </e1> also produced <e2> tremor </e2> and catalepsy, which are signs suggestive of Parkinson's disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"459": {"data": {"text": "Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.", "entity1": "Reserpine", "entity2": "catalepsy", "span1": [0, 9], "span2": [35, 44]}, "bert_text": "<e1> Reserpine </e1> also produced tremor and <e2> catalepsy </e2>, which are signs suggestive of Parkinson's disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"460": {"data": {"text": "Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.", "entity1": "Reserpine", "entity2": "Parkinson's disease", "span1": [0, 9], "span2": [76, 95]}, "bert_text": "<e1> Reserpine </e1> also produced tremor and catalepsy, which are signs suggestive of <e2> Parkinson's disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"461": {"data": {"text": "Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.\n", "entity1": "cefotetan", "entity2": "hemolytic anemia", "span1": [67, 76], "span2": [14, 30]}, "bert_text": "Severe immune hemolytic anemia associated with prophylactic use of <e1> cefotetan </e1> <e2> hemolytic anemia </e2> associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"462": {"data": {"text": "Amelioration of bendrofluazide-induced hypokalemia by timolol.\n", "entity1": "bendrofluazide", "entity2": "hypokalemia", "span1": [16, 30], "span2": [39, 50]}, "bert_text": "Amelioration of <e1> bendrofluazide </e1>-induced <e2> hypokalemia </e2> by timolol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"463": {"data": {"text": "Amelioration of bendrofluazide-induced hypokalemia by timolol.\n", "entity1": "timolol", "entity2": "hypokalemia", "span1": [54, 61], "span2": [39, 50]}, "bert_text": "Amelioration of bendrofluazide-induced hypokalemia by <e1> timolol </e1> <e2> hypokalemia </e2> by timolol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"464": {"data": {"text": "SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01). CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.", "entity1": "propofol", "entity2": "delirium", "span1": [195, 203], "span2": [21, 29]}, "bert_text": "SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01). CONCLUSION: The use of light <e1> propofol </e1> <e2> delirium </e2> during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01). CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"465": {"data": {"text": "SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01). CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.", "entity1": "propofol", "entity2": "postoperative delirium", "span1": [195, 203], "span2": [241, 263]}, "bert_text": "SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01). CONCLUSION: The use of light <e1> propofol </e1> sedation decreased the prevalence of <e2> postoperative delirium </e2> by 50% compared with deep sedation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"466": {"data": {"text": "These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.", "entity1": "morphine", "entity2": "spastic paraparesis", "span1": [28, 36], "span2": [45, 64]}, "bert_text": "These data indicate that IT <e1> morphine </e1> induces <e2> spastic paraparesis </e2> with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"467": {"data": {"text": "Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.\n", "entity1": "nimesulide", "entity2": "urticaria", "span1": [16, 26], "span2": [74, 83]}, "bert_text": "Tolerability of <e1> nimesulide </e1> and paracetamol in patients with NSAID-induced <e2> urticaria </e2>/angioedema.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"468": {"data": {"text": "Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.\n", "entity1": "nimesulide", "entity2": "angioedema", "span1": [16, 26], "span2": [84, 94]}, "bert_text": "Tolerability of <e1> nimesulide </e1> and paracetamol in patients with NSAID-induced urticaria/<e2> angioedema </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"469": {"data": {"text": "Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.\n", "entity1": "paracetamol", "entity2": "urticaria", "span1": [31, 42], "span2": [74, 83]}, "bert_text": "Tolerability of nimesulide and <e1> paracetamol </e1> in patients with NSAID-induced <e2> urticaria </e2>/angioedema.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"470": {"data": {"text": "Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.\n", "entity1": "paracetamol", "entity2": "angioedema", "span1": [31, 42], "span2": [84, 94]}, "bert_text": "Tolerability of nimesulide and <e1> paracetamol </e1> in patients with NSAID-induced urticaria/<e2> angioedema </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"471": {"data": {"text": "Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.\n", "entity1": "NSAID", "entity2": "urticaria", "span1": [60, 65], "span2": [74, 83]}, "bert_text": "Tolerability of nimesulide and paracetamol in patients with <e1> NSAID </e1>-induced <e2> urticaria </e2>/angioedema.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"472": {"data": {"text": "Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.\n", "entity1": "NSAID", "entity2": "angioedema", "span1": [60, 65], "span2": [84, 94]}, "bert_text": "Tolerability of nimesulide and paracetamol in patients with <e1> NSAID </e1>-induced urticaria/<e2> angioedema </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"473": {"data": {"text": "We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.", "entity1": "quinidine", "entity2": "hepatotoxicity", "span1": [35, 44], "span2": [45, 59]}, "bert_text": "We concluded that this patient had <e1> quinidine </e1> <e2> hepatotoxicity </e2> and believe that this is the first case reported with liver biopsy documentation.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"474": {"data": {"text": "This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.", "entity1": "paroxetine", "entity2": "chronic pain", "span1": [44, 54], "span2": [115, 127]}, "bert_text": "This drug was initiated in association with <e1> paroxetine </e1> and dosulepine hydrochloride in a tetraparetic patient with <e2> chronic pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"475": {"data": {"text": "This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.", "entity1": "dosulepine hydrochloride", "entity2": "chronic pain", "span1": [59, 83], "span2": [115, 127]}, "bert_text": "This drug was initiated in association with paroxetine and <e1> dosulepine hydrochloride </e1> in a tetraparetic patient with <e2> chronic pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"476": {"data": {"text": "Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.", "entity1": "cyclooxygenase inhibitors", "entity2": "myocardial infarction", "span1": [169, 194], "span2": [85, 106]}, "bert_text": "Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with <e1> cyclooxygenase inhibitors </e1> <e2> myocardial infarction </e2>, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
	"477": {"data": {"text": "Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.", "entity1": "cyclooxygenase inhibitors", "entity2": "stroke", "span1": [169, 194], "span2": [108, 114]}, "bert_text": "Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with <e1> cyclooxygenase inhibitors </e1> <e2> stroke </e2>, hypertension and heart failure during treatment with cyclooxygenase inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"478": {"data": {"text": "Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.", "entity1": "cyclooxygenase inhibitors", "entity2": "hypertension", "span1": [169, 194], "span2": [116, 128]}, "bert_text": "Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with <e1> cyclooxygenase inhibitors </e1> <e2> hypertension </e2> and heart failure during treatment with cyclooxygenase inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"479": {"data": {"text": "Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.", "entity1": "cyclooxygenase inhibitors", "entity2": "heart failure", "span1": [169, 194], "span2": [133, 146]}, "bert_text": "Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with <e1> cyclooxygenase inhibitors </e1> <e2> heart failure </e2> during treatment with cyclooxygenase inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"480": {"data": {"text": "Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.\n", "entity1": "sulindac", "entity2": "colorectal adenomas", "span1": [114, 122], "span2": [150, 169]}, "bert_text": "Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and <e1> sulindac </e1> for prevention of sporadic <e2> colorectal adenomas </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"481": {"data": {"text": "We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.", "entity1": "morphine", "entity2": "aortic occlusion", "span1": [154, 162], "span2": [200, 216]}, "bert_text": "We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial <e1> morphine </e1> following a noninjurious interval of <e2> aortic occlusion </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"482": {"data": {"text": "Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).", "entity1": "cisapride", "entity2": "irritable bowel syndrome", "span1": [82, 91], "span2": [146, 170]}, "bert_text": "Our aim was to assess the effects of long-term treatment with a prokinetic agent, <e1> cisapride </e1>, on postprandial jejunal motility and symptoms in the <e2> irritable bowel syndrome </e2> (IBS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"483": {"data": {"text": "Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).", "entity1": "cisapride", "entity2": "IBS", "span1": [82, 91], "span2": [172, 175]}, "bert_text": "Our aim was to assess the effects of long-term treatment with a prokinetic agent, <e1> cisapride </e1>, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (<e2> IBS </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"484": {"data": {"text": "Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.", "entity1": "PB", "entity2": "liver damage", "span1": [29, 31], "span2": [63, 75]}, "bert_text": "Our findings illustrate that <e1> PB </e1> may be associated with chronic <e2> liver damage </e2>, which may lead to more serious and deleterious consequences.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"485": {"data": {"text": "These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.", "entity1": "DX", "entity2": "renal toxicity", "span1": [101, 103], "span2": [128, 142]}, "bert_text": "These results demonstrate that, in these experimental conditions, DXNP killed less animals than free <e1> DX </e1>, despite of an enhanced <e2> renal toxicity </e2> of the former.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"486": {"data": {"text": "Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.\n", "entity1": "Cyclophosphamide", "entity2": "bladder cancer--", "span1": [0, 16], "span2": [28, 44]}, "bert_text": "<e1> Cyclophosphamide </e1> associated <e2> bladder cancer-- </e2>a highly aggressive disease: analysis of 12 cases.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"487": {"data": {"text": "Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.\n", "entity1": "Cyclophosphamide", "entity2": "aggressive disease", "span1": [0, 16], "span2": [53, 71]}, "bert_text": "<e1> Cyclophosphamide </e1> associated bladder cancer--a highly <e2> aggressive disease </e2>: analysis of 12 cases.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"488": {"data": {"text": "In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.", "entity1": "nimesulide", "entity2": "urticaria", "span1": [62, 72], "span2": [183, 192]}, "bert_text": "In this study we investigated tolerability and reliability of <e1> nimesulide </e1> and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced <e2> urticaria </e2>/angioedema.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"489": {"data": {"text": "In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.", "entity1": "nimesulide", "entity2": "angioedema", "span1": [62, 72], "span2": [193, 203]}, "bert_text": "In this study we investigated tolerability and reliability of <e1> nimesulide </e1> and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/<e2> angioedema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"490": {"data": {"text": "In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.", "entity1": "paracetamol", "entity2": "urticaria", "span1": [77, 88], "span2": [183, 192]}, "bert_text": "In this study we investigated tolerability and reliability of nimesulide and <e1> paracetamol </e1> in a very large number of patients with an exclusive well-documented history of NSAID-induced <e2> urticaria </e2>/angioedema.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"491": {"data": {"text": "In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.", "entity1": "paracetamol", "entity2": "angioedema", "span1": [77, 88], "span2": [193, 203]}, "bert_text": "In this study we investigated tolerability and reliability of nimesulide and <e1> paracetamol </e1> in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/<e2> angioedema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"492": {"data": {"text": "In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.", "entity1": "NSAID", "entity2": "urticaria", "span1": [169, 174], "span2": [183, 192]}, "bert_text": "In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of <e1> NSAID </e1>-induced <e2> urticaria </e2>/angioedema.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"493": {"data": {"text": "In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.", "entity1": "NSAID", "entity2": "angioedema", "span1": [169, 174], "span2": [193, 203]}, "bert_text": "In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of <e1> NSAID </e1>-induced urticaria/<e2> angioedema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"494": {"data": {"text": "PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.\n", "entity1": "PTU", "entity2": "vasculitis", "span1": [0, 3], "span2": [15, 25]}, "bert_text": "<e1> PTU </e1>-associated <e2> vasculitis </e2> in a girl with Turner Syndrome and Graves' disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"495": {"data": {"text": "PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.\n", "entity1": "PTU", "entity2": "Turner Syndrome", "span1": [0, 3], "span2": [41, 56]}, "bert_text": "<e1> PTU </e1>-associated vasculitis in a girl with <e2> Turner Syndrome </e2> and Graves' disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"496": {"data": {"text": "PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.\n", "entity1": "PTU", "entity2": "Graves' disease", "span1": [0, 3], "span2": [61, 76]}, "bert_text": "<e1> PTU </e1>-associated vasculitis in a girl with Turner Syndrome and <e2> Graves' disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"497": {"data": {"text": "Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.\n", "entity1": "methadone", "entity2": "Syncope", "span1": [56, 65], "span2": [0, 7]}, "bert_text": "Syncope and QT prolongation among patients treated with <e1> methadone </e1> <e2> Syncope </e2> and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"498": {"data": {"text": "Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.\n", "entity1": "methadone", "entity2": "QT prolongation", "span1": [56, 65], "span2": [12, 27]}, "bert_text": "Syncope and QT prolongation among patients treated with <e1> methadone </e1> <e2> QT prolongation </e2> among patients treated with methadone for heroin dependence in the city of Copenhagen.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"499": {"data": {"text": "Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.\n", "entity1": "heroin", "entity2": "Syncope", "span1": [70, 76], "span2": [0, 7]}, "bert_text": "Syncope and QT prolongation among patients treated with methadone for <e1> heroin </e1> <e2> Syncope </e2> and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"500": {"data": {"text": "Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.\n", "entity1": "heroin", "entity2": "QT prolongation", "span1": [70, 76], "span2": [12, 27]}, "bert_text": "Syncope and QT prolongation among patients treated with methadone for <e1> heroin </e1> <e2> QT prolongation </e2> among patients treated with methadone for heroin dependence in the city of Copenhagen.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"501": {"data": {"text": "Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.\n", "entity1": "phenobarbital", "entity2": "Hepatonecrosis and cholangitis", "span1": [52, 65], "span2": [0, 30]}, "bert_text": "Hepatonecrosis and cholangitis related to long-term <e1> phenobarbital </e1> <e2> Hepatonecrosis and cholangitis </e2> related to long-term phenobarbital therapy: an autopsy report of two patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"502": {"data": {"text": "PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.", "entity1": "cyclophosphamide", "entity2": "urothelial cancer", "span1": [74, 90], "span2": [102, 119]}, "bert_text": "PURPOSE: We gained knowledge of the etiology, treatment and prevention of <e1> cyclophosphamide </e1> associated <e2> urothelial cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"503": {"data": {"text": "These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.", "entity1": "pilocarpine", "entity2": "arrhythmic", "span1": [24, 35], "span2": [71, 81]}, "bert_text": "These data suggest that <e1> pilocarpine </e1> produced antiarrhythmic actions on <e2> arrhythmic </e2> rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"504": {"data": {"text": "These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.", "entity1": "aconitine", "entity2": "arrhythmic", "span1": [119, 128], "span2": [71, 81]}, "bert_text": "These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by <e1> aconitine </e1> <e2> arrhythmic </e2> rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"505": {"data": {"text": "These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.", "entity1": "ouabain", "entity2": "arrhythmic", "span1": [132, 139], "span2": [71, 81]}, "bert_text": "These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or <e1> ouabain </e1> <e2> arrhythmic </e2> rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"506": {"data": {"text": "These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.", "entity1": "Ca(2", "entity2": "arrhythmic", "span1": [231, 235], "span2": [71, 81]}, "bert_text": "These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of <e1> Ca(2 </e1> <e2> arrhythmic </e2> rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"507": {"data": {"text": "CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.", "entity1": "trihexyphenidyl", "entity2": "mental slowing", "span1": [113, 128], "span2": [92, 106]}, "bert_text": "CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after <e1> trihexyphenidyl </e1> <e2> mental slowing </e2> after trihexyphenidyl anticholinergic challenge.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"508": {"data": {"text": "Diazepam facilitates reflex bradycardia in conscious rats.\n", "entity1": "Diazepam", "entity2": "bradycardia", "span1": [0, 8], "span2": [28, 39]}, "bert_text": "<e1> Diazepam </e1> facilitates reflex <e2> bradycardia </e2> in conscious rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"509": {"data": {"text": "T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.", "entity1": "T", "entity2": "irritability", "span1": [0, 1], "span2": [37, 49]}, "bert_text": "<e1> T </e1> alone had no effect on locomotion, <e2> irritability </e2>, or sexual behavior but increased partner preference and aggression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
	"510": {"data": {"text": "T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.", "entity1": "T", "entity2": "aggression", "span1": [0, 1], "span2": [107, 117]}, "bert_text": "<e1> T </e1> alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and <e2> aggression </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"511": {"data": {"text": "L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.", "entity1": "diazepam", "entity2": "convulsions", "span1": [29, 37], "span2": [118, 129]}, "bert_text": "L-NAME (100 mg/kg, i.p.) and <e1> diazepam </e1> (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"512": {"data": {"text": "L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.", "entity1": "lidocaine", "entity2": "convulsions", "span1": [89, 98], "span2": [118, 129]}, "bert_text": "L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of <e1> lidocaine </e1> (50 mg/kg)-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"513": {"data": {"text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "entity1": "sulphasalazine", "entity2": "fever", "span1": [22, 36], "span2": [75, 80]}, "bert_text": "Although cessation of <e1> sulphasalazine </e1> treatment resulted in improvements in <e2> fever </e2>, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"514": {"data": {"text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "entity1": "sulphasalazine", "entity2": "chest pain", "span1": [22, 36], "span2": [92, 102]}, "bert_text": "Although cessation of <e1> sulphasalazine </e1> treatment resulted in improvements in fever, red eyes, <e2> chest pain </e2>, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"515": {"data": {"text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "entity1": "sulphasalazine", "entity2": "pleural effusions", "span1": [22, 36], "span2": [150, 167]}, "bert_text": "Although cessation of <e1> sulphasalazine </e1> treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the <e2> pleural effusions </e2>, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"516": {"data": {"text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "entity1": "sulphasalazine", "entity2": "pleural effusion", "span1": [22, 36], "span2": [296, 312]}, "bert_text": "Although cessation of <e1> sulphasalazine </e1> treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the <e2> pleural effusion </e2> remained.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"517": {"data": {"text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "entity1": "steroid", "entity2": "fever", "span1": [182, 189], "span2": [75, 80]}, "bert_text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated <e1> steroid </e1> <e2> fever </e2>, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
	"518": {"data": {"text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "entity1": "steroid", "entity2": "chest pain", "span1": [182, 189], "span2": [92, 102]}, "bert_text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated <e1> steroid </e1> <e2> chest pain </e2>, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
	"519": {"data": {"text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "entity1": "steroid", "entity2": "pleural effusions", "span1": [182, 189], "span2": [150, 167]}, "bert_text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated <e1> steroid </e1> <e2> pleural effusions </e2>, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"520": {"data": {"text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "entity1": "steroid", "entity2": "pleural effusion", "span1": [182, 189], "span2": [296, 312]}, "bert_text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated <e1> steroid </e1> therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the <e2> pleural effusion </e2> remained.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"521": {"data": {"text": "Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.\n", "entity1": "Vasopressin", "entity2": "hypotension", "span1": [0, 11], "span2": [50, 61]}, "bert_text": "<e1> Vasopressin </e1> in the treatment of milrinone-induced <e2> hypotension </e2> in severe heart failure.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"522": {"data": {"text": "Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.\n", "entity1": "Vasopressin", "entity2": "heart failure", "span1": [0, 11], "span2": [72, 85]}, "bert_text": "<e1> Vasopressin </e1> in the treatment of milrinone-induced hypotension in severe <e2> heart failure </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"523": {"data": {"text": "Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.\n", "entity1": "milrinone", "entity2": "hypotension", "span1": [32, 41], "span2": [50, 61]}, "bert_text": "Vasopressin in the treatment of <e1> milrinone </e1>-induced <e2> hypotension </e2> in severe heart failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"524": {"data": {"text": "Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.\n", "entity1": "milrinone", "entity2": "heart failure", "span1": [32, 41], "span2": [72, 85]}, "bert_text": "Vasopressin in the treatment of <e1> milrinone </e1>-induced hypotension in severe <e2> heart failure </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"525": {"data": {"text": "The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.", "entity1": "N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride", "entity2": "PD", "span1": [15, 66], "span2": [185, 187]}, "bert_text": "The effects of <e1> N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride </e1> (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of <e2> PD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"526": {"data": {"text": "The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.", "entity1": "AMN082", "entity2": "PD", "span1": [68, 74], "span2": [185, 187]}, "bert_text": "The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (<e1> AMN082 </e1>), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of <e2> PD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"527": {"data": {"text": "Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.\n", "entity1": "puromycin aminonucleoside", "entity2": "nephrosis", "span1": [38, 63], "span2": [64, 73]}, "bert_text": "Protective effects of antithrombin on <e1> puromycin aminonucleoside </e1> <e2> nephrosis </e2> in rats.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"528": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "3-methylcholanthrene", "entity2": "convulsions", "span1": [64, 84], "span2": [193, 204]}, "bert_text": "Induction studies have further shown that while pretreatment of <e1> 3-methylcholanthrene </e1> (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced <e2> convulsions </e2>, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"529": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "3-methylcholanthrene", "entity2": "convulsions", "span1": [64, 84], "span2": [384, 395]}, "bert_text": "Induction studies have further shown that while pretreatment of <e1> 3-methylcholanthrene </e1> (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"530": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "MC", "entity2": "convulsions", "span1": [86, 88], "span2": [193, 204]}, "bert_text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (<e1> MC </e1>), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced <e2> convulsions </e2>, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"531": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "MC", "entity2": "convulsions", "span1": [86, 88], "span2": [384, 395]}, "bert_text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (<e1> MC </e1>), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"532": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "lindane", "entity2": "convulsions", "span1": [177, 184], "span2": [193, 204]}, "bert_text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of <e1> lindane </e1> induced <e2> convulsions </e2>, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"533": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "lindane", "entity2": "convulsions", "span1": [177, 184], "span2": [384, 395]}, "bert_text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of <e1> lindane </e1> induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"534": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "lindane", "entity2": "convulsions", "span1": [368, 375], "span2": [193, 204]}, "bert_text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of <e1> lindane </e1> <e2> convulsions </e2>, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"535": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "lindane", "entity2": "convulsions", "span1": [368, 375], "span2": [384, 395]}, "bert_text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of <e1> lindane </e1> induced <e2> convulsions </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"536": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "phenobarbital", "entity2": "convulsions", "span1": [224, 237], "span2": [193, 204]}, "bert_text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with <e1> phenobarbital </e1> <e2> convulsions </e2>, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"537": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "phenobarbital", "entity2": "convulsions", "span1": [224, 237], "span2": [384, 395]}, "bert_text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with <e1> phenobarbital </e1> (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"538": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "PB", "entity2": "convulsions", "span1": [239, 241], "span2": [193, 204]}, "bert_text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (<e1> PB </e1> <e2> convulsions </e2>, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"539": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "PB", "entity2": "convulsions", "span1": [239, 241], "span2": [384, 395]}, "bert_text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (<e1> PB </e1>), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"540": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "ethanol", "entity2": "convulsions", "span1": [274, 281], "span2": [193, 204]}, "bert_text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or <e1> ethanol </e1> <e2> convulsions </e2>, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"541": {"data": {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity1": "ethanol", "entity2": "convulsions", "span1": [274, 281], "span2": [384, 395]}, "bert_text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or <e1> ethanol </e1>, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"542": {"data": {"text": "Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.", "entity1": "methadone", "entity2": "torsade de pointes", "span1": [106, 115], "span2": [60, 78]}, "bert_text": "Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in <e1> methadone </e1> <e2> torsade de pointes </e2> (TdP) has been reported in methadone users.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"543": {"data": {"text": "Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.", "entity1": "methadone", "entity2": "TdP", "span1": [106, 115], "span2": [80, 83]}, "bert_text": "Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in <e1> methadone </e1> <e2> TdP </e2>) has been reported in methadone users.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"544": {"data": {"text": "These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.", "entity1": "dobutamine", "entity2": "coronary spasm", "span1": [29, 39], "span2": [52, 66]}, "bert_text": "These findings indicate that <e1> dobutamine </e1> can provoke <e2> coronary spasm </e2> in some patients with coronary spastic angina.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"545": {"data": {"text": "These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.", "entity1": "dobutamine", "entity2": "coronary spastic angina", "span1": [29, 39], "span2": [89, 112]}, "bert_text": "These findings indicate that <e1> dobutamine </e1> can provoke coronary spasm in some patients with <e2> coronary spastic angina </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"546": {"data": {"text": "We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.", "entity1": "warfarin", "entity2": "haemorrhage", "span1": [151, 159], "span2": [35, 46]}, "bert_text": "We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of <e1> warfarin </e1> <e2> haemorrhage </e2> in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"547": {"data": {"text": "A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.", "entity1": "cisapride", "entity2": "gastroesophageal reflux disorder", "span1": [75, 84], "span2": [89, 121]}, "bert_text": "A possible drug interaction occurred in a 45-year-old woman who was taking <e1> cisapride </e1> for <e2> gastroesophageal reflux disorder </e2> and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"548": {"data": {"text": "A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.", "entity1": "cisapride", "entity2": "hypertension", "span1": [75, 84], "span2": [188, 200]}, "bert_text": "A possible drug interaction occurred in a 45-year-old woman who was taking <e1> cisapride </e1> for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"549": {"data": {"text": "A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.", "entity1": "diltiazem", "entity2": "gastroesophageal reflux disorder", "span1": [126, 135], "span2": [89, 121]}, "bert_text": "A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and <e1> diltiazem </e1> <e2> gastroesophageal reflux disorder </e2> and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"550": {"data": {"text": "A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.", "entity1": "diltiazem", "entity2": "hypertension", "span1": [126, 135], "span2": [188, 200]}, "bert_text": "A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and <e1> diltiazem </e1>, an agent that has inhibitory effect on CYP3A4, for <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"551": {"data": {"text": "Amphetamine-induced locomotor hyperactivity was similar in all groups.", "entity1": "Amphetamine", "entity2": "locomotor hyperactivity", "span1": [0, 11], "span2": [20, 43]}, "bert_text": "<e1> Amphetamine </e1>-induced <e2> locomotor hyperactivity </e2> was similar in all groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"552": {"data": {"text": "IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.", "entity1": "MK-801", "entity2": "spastic paraparesis", "span1": [3, 9], "span2": [100, 119]}, "bert_text": "IT <e1> MK-801 </e1> significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced <e2> spastic paraparesis </e2> compared with the saline group.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"553": {"data": {"text": "IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.", "entity1": "morphine", "entity2": "spastic paraparesis", "span1": [83, 91], "span2": [100, 119]}, "bert_text": "IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after <e1> morphine </e1>-induced <e2> spastic paraparesis </e2> compared with the saline group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"554": {"data": {"text": "Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.", "entity1": "carbamazepine", "entity2": "psychiatric", "span1": [8, 21], "span2": [77, 88]}, "bert_text": "Because <e1> carbamazepine </e1> is widely used in the treatment of many neurologic and <e2> psychiatric </e2> conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"555": {"data": {"text": "Nicotine potentiation of morphine-induced catalepsy in mice.\n", "entity1": "Nicotine", "entity2": "catalepsy", "span1": [0, 8], "span2": [42, 51]}, "bert_text": "<e1> Nicotine </e1> potentiation of morphine-induced <e2> catalepsy </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"556": {"data": {"text": "Nicotine potentiation of morphine-induced catalepsy in mice.\n", "entity1": "morphine", "entity2": "catalepsy", "span1": [25, 33], "span2": [42, 51]}, "bert_text": "Nicotine potentiation of <e1> morphine </e1>-induced <e2> catalepsy </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"557": {"data": {"text": "Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.", "entity1": "RA", "entity2": "Tumors", "span1": [64, 66], "span2": [0, 6]}, "bert_text": "Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% <e1> RA </e1> <e2> Tumors </e2>, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"558": {"data": {"text": "Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.", "entity1": "RA", "entity2": "papillomas", "span1": [64, 66], "span2": [12, 22]}, "bert_text": "Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% <e1> RA </e1> <e2> papillomas </e2>, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"559": {"data": {"text": "Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.", "entity1": "RA", "entity2": "Tumors", "span1": [99, 101], "span2": [0, 6]}, "bert_text": "Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% <e1> RA </e1> <e2> Tumors </e2>, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"560": {"data": {"text": "Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.", "entity1": "RA", "entity2": "papillomas", "span1": [99, 101], "span2": [12, 22]}, "bert_text": "Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% <e1> RA </e1> <e2> papillomas </e2>, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"561": {"data": {"text": "Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.", "entity1": "Oxacillin", "entity2": "leucocytoclastic vasculitis", "span1": [0, 9], "span2": [60, 87]}, "bert_text": "<e1> Oxacillin </e1> should be included among the drugs that can cause <e2> leucocytoclastic vasculitis </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"562": {"data": {"text": "CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.", "entity1": "thalidomide", "entity2": "renal cell carcinoma", "span1": [73, 84], "span2": [88, 108]}, "bert_text": "CONCLUSION: These results are consistent with a low level of activity of <e1> thalidomide </e1> in <e2> renal cell carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"563": {"data": {"text": "Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.\n", "entity1": "metoprolol", "entity2": "myocardial ischemia", "span1": [22, 32], "span2": [95, 114]}, "bert_text": "Effect of intravenous <e1> metoprolol </e1> or intravenous metoprolol plus glucagon on dobutamine-induced <e2> myocardial ischemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"564": {"data": {"text": "Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.\n", "entity1": "metoprolol", "entity2": "myocardial ischemia", "span1": [48, 58], "span2": [95, 114]}, "bert_text": "Effect of intravenous metoprolol or intravenous <e1> metoprolol </e1> plus glucagon on dobutamine-induced <e2> myocardial ischemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"565": {"data": {"text": "Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.\n", "entity1": "dobutamine", "entity2": "myocardial ischemia", "span1": [76, 86], "span2": [95, 114]}, "bert_text": "Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on <e1> dobutamine </e1>-induced <e2> myocardial ischemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"566": {"data": {"text": "The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.", "entity1": "dobutamine", "entity2": "myocardial ischemia", "span1": [107, 117], "span2": [51, 70]}, "bert_text": "The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by <e1> dobutamine </e1> <e2> myocardial ischemia </e2> due to coronary spasm is induced by dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"567": {"data": {"text": "The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.", "entity1": "dobutamine", "entity2": "coronary spasm", "span1": [107, 117], "span2": [78, 92]}, "bert_text": "The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by <e1> dobutamine </e1> <e2> coronary spasm </e2> is induced by dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"568": {"data": {"text": "The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.", "entity1": "GTN", "entity2": "headache", "span1": [66, 69], "span2": [100, 108]}, "bert_text": "The subjects were randomly allocated to receive 0.5 microg/kg/min <e1> GTN </e1> or placebo over 20 min on two <e2> headache </e2>-free days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"569": {"data": {"text": "PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.", "entity1": "propofol", "entity2": "delirium", "span1": [256, 264], "span2": [165, 173]}, "bert_text": "PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with <e1> propofol </e1> <e2> delirium </e2> or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"570": {"data": {"text": "PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.", "entity1": "propofol", "entity2": "dementia", "span1": [256, 264], "span2": [184, 192]}, "bert_text": "PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with <e1> propofol </e1> <e2> dementia </e2> who underwent hip fracture repair under spinal anesthesia with propofol sedation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"571": {"data": {"text": "PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.", "entity1": "propofol", "entity2": "hip fracture", "span1": [256, 264], "span2": [207, 219]}, "bert_text": "PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with <e1> propofol </e1> <e2> hip fracture </e2> repair under spinal anesthesia with propofol sedation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"572": {"data": {"text": "Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids.", "entity1": "corticosteroids", "entity2": "myopathy", "span1": [107, 122], "span2": [46, 54]}, "bert_text": "Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of <e1> corticosteroids </e1> <e2> myopathy </e2> may occur in patients treated with massive doses of corticosteroids.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"573": {"data": {"text": "In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.", "entity1": "AMN082", "entity2": "akinetic", "span1": [97, 103], "span2": [55, 63]}, "bert_text": "In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg <e1> AMN082 </e1> <e2> akinetic </e2> symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"574": {"data": {"text": "In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.", "entity1": "AMN082", "entity2": "PD", "span1": [97, 103], "span2": [76, 78]}, "bert_text": "In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg <e1> AMN082 </e1> <e2> PD </e2> patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"575": {"data": {"text": "In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.", "entity1": "6-OHDA", "entity2": "akinetic", "span1": [174, 180], "span2": [55, 63]}, "bert_text": "In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral <e1> 6-OHDA </e1> <e2> akinetic </e2> symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"576": {"data": {"text": "In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.", "entity1": "6-OHDA", "entity2": "PD", "span1": [174, 180], "span2": [76, 78]}, "bert_text": "In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral <e1> 6-OHDA </e1> <e2> PD </e2> patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"577": {"data": {"text": "Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.\n", "entity1": "creatine", "entity2": "systemic lupus erythematosus", "span1": [37, 45], "span2": [63, 91]}, "bert_text": "Differential diagnosis of high serum <e1> creatine </e1> kinase levels in <e2> systemic lupus erythematosus </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
	"578": {"data": {"text": "The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.", "entity1": "amiodarone", "entity2": "pulmonary toxicity", "span1": [42, 52], "span2": [61, 79]}, "bert_text": "The clinical and radiographic features of <e1> amiodarone </e1>-induced <e2> pulmonary toxicity </e2> are characteristic but nonspecific.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"579": {"data": {"text": "Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.\n", "entity1": "lithium carbonate", "entity2": "Tricuspid valve regurgitation", "span1": [34, 51], "span2": [0, 29]}, "bert_text": "Tricuspid valve regurgitation and <e1> lithium carbonate </e1> <e2> Tricuspid valve regurgitation </e2> and lithium carbonate toxicity in a newborn infant.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"580": {"data": {"text": "Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.\n", "entity1": "lithium carbonate", "entity2": "toxicity", "span1": [34, 51], "span2": [52, 60]}, "bert_text": "Tricuspid valve regurgitation and <e1> lithium carbonate </e1> <e2> toxicity </e2> in a newborn infant.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"581": {"data": {"text": "The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.", "entity1": "estrogen", "entity2": "tumor", "span1": [64, 72], "span2": [27, 32]}, "bert_text": "The mechanistic details of tumor angiogenesis induction, during <e1> estrogen </e1> <e2> tumor </e2> angiogenesis induction, during estrogen carcinogenesis, are still unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"582": {"data": {"text": "The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.", "entity1": "estrogen", "entity2": "carcinogenesis", "span1": [64, 72], "span2": [73, 87]}, "bert_text": "The mechanistic details of tumor angiogenesis induction, during <e1> estrogen </e1> <e2> carcinogenesis </e2>, are still unknown.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"583": {"data": {"text": "Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.", "entity1": "atropine", "entity2": "catalepsy", "span1": [37, 45], "span2": [90, 99]}, "bert_text": "Intracerebroventricular injection of <e1> atropine </e1>, hexamethonium, and naloxone also decreased <e2> catalepsy </e2> induced by morphine plus nicotine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"584": {"data": {"text": "Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.", "entity1": "hexamethonium", "entity2": "catalepsy", "span1": [47, 60], "span2": [90, 99]}, "bert_text": "Intracerebroventricular injection of atropine, <e1> hexamethonium </e1>, and naloxone also decreased <e2> catalepsy </e2> induced by morphine plus nicotine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"585": {"data": {"text": "Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.", "entity1": "naloxone", "entity2": "catalepsy", "span1": [66, 74], "span2": [90, 99]}, "bert_text": "Intracerebroventricular injection of atropine, hexamethonium, and <e1> naloxone </e1> also decreased <e2> catalepsy </e2> induced by morphine plus nicotine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"586": {"data": {"text": "Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.", "entity1": "morphine", "entity2": "catalepsy", "span1": [111, 119], "span2": [90, 99]}, "bert_text": "Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by <e1> morphine </e1> <e2> catalepsy </e2> induced by morphine plus nicotine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"587": {"data": {"text": "Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.", "entity1": "nicotine", "entity2": "catalepsy", "span1": [125, 133], "span2": [90, 99]}, "bert_text": "Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus <e1> nicotine </e1> <e2> catalepsy </e2> induced by morphine plus nicotine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"588": {"data": {"text": "Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.\n", "entity1": "oral contraceptives", "entity2": "liver tumors", "span1": [70, 89], "span2": [41, 53]}, "bert_text": "Etiologic factors in the pathogenesis of liver tumors associated with <e1> oral contraceptives </e1> <e2> liver tumors </e2> associated with oral contraceptives.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"589": {"data": {"text": "The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.", "entity1": "angiotensin", "entity2": "intestinal angioedema", "span1": [19, 30], "span2": [94, 115]}, "bert_text": "The recognition of <e1> angiotensin </e1>-converting enzyme (ACE) and angiotensin receptor blocker (ARB) <e2> intestinal angioedema </e2> constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"590": {"data": {"text": "The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.", "entity1": "angiotensin", "entity2": "intestinal angioedema", "span1": [59, 70], "span2": [94, 115]}, "bert_text": "The recognition of angiotensin-converting enzyme (ACE) and <e1> angiotensin </e1> receptor blocker (ARB) <e2> intestinal angioedema </e2> constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"591": {"data": {"text": "The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.", "entity1": "ARB", "entity2": "intestinal angioedema", "span1": [89, 92], "span2": [94, 115]}, "bert_text": "The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (<e1> ARB </e1>) <e2> intestinal angioedema </e2> constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"592": {"data": {"text": "This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.", "entity1": "SM-5887", "entity2": "cardiotoxic", "span1": [76, 83], "span2": [51, 62]}, "bert_text": "This study was designed to investigate the chronic cardiotoxic potential of <e1> SM-5887 </e1> <e2> cardiotoxic </e2> potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"593": {"data": {"text": "This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.", "entity1": "SM-5887", "entity2": "cardiotoxicity", "span1": [76, 83], "span2": [144, 158]}, "bert_text": "This study was designed to investigate the chronic cardiotoxic potential of <e1> SM-5887 </e1> and a possible deteriorating effect of SM-5887 on low-grade <e2> cardiotoxicity </e2> pre-induced by doxorubicin in beagle dogs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"594": {"data": {"text": "This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.", "entity1": "SM-5887", "entity2": "cardiotoxic", "span1": [123, 130], "span2": [51, 62]}, "bert_text": "This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of <e1> SM-5887 </e1> <e2> cardiotoxic </e2> potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"595": {"data": {"text": "This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.", "entity1": "SM-5887", "entity2": "cardiotoxicity", "span1": [123, 130], "span2": [144, 158]}, "bert_text": "This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of <e1> SM-5887 </e1> on low-grade <e2> cardiotoxicity </e2> pre-induced by doxorubicin in beagle dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
	"596": {"data": {"text": "This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.", "entity1": "doxorubicin", "entity2": "cardiotoxic", "span1": [174, 185], "span2": [51, 62]}, "bert_text": "This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by <e1> doxorubicin </e1> <e2> cardiotoxic </e2> potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"597": {"data": {"text": "This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [174, 185], "span2": [144, 158]}, "bert_text": "This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> pre-induced by doxorubicin in beagle dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"598": {"data": {"text": "The present study indicates that NO-induced immediate headache is not associated with release of CGRP.", "entity1": "NO", "entity2": "headache", "span1": [33, 35], "span2": [54, 62]}, "bert_text": "The present study indicates that <e1> NO </e1>-induced immediate <e2> headache </e2> is not associated with release of CGRP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"599": {"data": {"text": "The present study indicates that NO-induced immediate headache is not associated with release of CGRP.", "entity1": "CGRP", "entity2": "headache", "span1": [97, 101], "span2": [54, 62]}, "bert_text": "The present study indicates that NO-induced immediate headache is not associated with release of <e1> CGRP </e1> <e2> headache </e2> is not associated with release of CGRP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"600": {"data": {"text": "CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.", "entity1": "quetiapine", "entity2": "bipolar mania", "span1": [79, 89], "span2": [16, 29]}, "bert_text": "CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with <e1> quetiapine </e1> <e2> bipolar mania </e2>, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"601": {"data": {"text": "CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.", "entity1": "quetiapine", "entity2": "EPS", "span1": [79, 89], "span2": [48, 51]}, "bert_text": "CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with <e1> quetiapine </e1> <e2> EPS </e2>, including akathisia, with quetiapine therapy is similar to that with placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"602": {"data": {"text": "CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.", "entity1": "quetiapine", "entity2": "akathisia", "span1": [79, 89], "span2": [63, 72]}, "bert_text": "CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with <e1> quetiapine </e1> <e2> akathisia </e2>, with quetiapine therapy is similar to that with placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"603": {"data": {"text": "Carbamazepine-induced cardiac dysfunction.", "entity1": "Carbamazepine", "entity2": "cardiac dysfunction", "span1": [0, 13], "span2": [22, 41]}, "bert_text": "<e1> Carbamazepine </e1>-induced <e2> cardiac dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"604": {"data": {"text": "A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.", "entity1": "nimesulide", "entity2": "urticaria", "span1": [58, 68], "span2": [144, 153]}, "bert_text": "A single-placebo-controlled oral challenge procedure with <e1> nimesulide </e1> or paracetamol was applied to 829 patients with a history of NSAID-induced <e2> urticaria </e2>/angioedema.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"605": {"data": {"text": "A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.", "entity1": "nimesulide", "entity2": "angioedema", "span1": [58, 68], "span2": [154, 164]}, "bert_text": "A single-placebo-controlled oral challenge procedure with <e1> nimesulide </e1> or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/<e2> angioedema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"606": {"data": {"text": "A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.", "entity1": "paracetamol", "entity2": "urticaria", "span1": [72, 83], "span2": [144, 153]}, "bert_text": "A single-placebo-controlled oral challenge procedure with nimesulide or <e1> paracetamol </e1> was applied to 829 patients with a history of NSAID-induced <e2> urticaria </e2>/angioedema.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"607": {"data": {"text": "A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.", "entity1": "paracetamol", "entity2": "angioedema", "span1": [72, 83], "span2": [154, 164]}, "bert_text": "A single-placebo-controlled oral challenge procedure with nimesulide or <e1> paracetamol </e1> was applied to 829 patients with a history of NSAID-induced urticaria/<e2> angioedema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"608": {"data": {"text": "A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.", "entity1": "NSAID", "entity2": "urticaria", "span1": [130, 135], "span2": [144, 153]}, "bert_text": "A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of <e1> NSAID </e1>-induced <e2> urticaria </e2>/angioedema.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"609": {"data": {"text": "A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.", "entity1": "NSAID", "entity2": "angioedema", "span1": [130, 135], "span2": [154, 164]}, "bert_text": "A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of <e1> NSAID </e1>-induced urticaria/<e2> angioedema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"610": {"data": {"text": "The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.", "entity1": "Oral Contraceptives", "entity2": "Liver Tumors", "span1": [46, 65], "span2": [17, 29]}, "bert_text": "The Registry for Liver Tumors Associated with <e1> Oral Contraceptives </e1> <e2> Liver Tumors </e2> Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"611": {"data": {"text": "Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.", "entity1": "T", "entity2": "muscle atrophy", "span1": [57, 58], "span2": [81, 95]}, "bert_text": "Finally, a pair-fed (PF) study, performed in 18 rats (C, <e1> T </e1>, and PF), showed that <e2> muscle atrophy </e2> was considerably less pronounced in PF animals than in T-treated animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"612": {"data": {"text": "Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.", "entity1": "T", "entity2": "muscle atrophy", "span1": [151, 152], "span2": [81, 95]}, "bert_text": "Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in <e1> T </e1> <e2> muscle atrophy </e2> was considerably less pronounced in PF animals than in T-treated animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"613": {"data": {"text": "Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.", "entity1": "Tacrine", "entity2": "seizures", "span1": [0, 7], "span2": [78, 86]}, "bert_text": "<e1> Tacrine </e1>, administered in LiCl pre-treated rats, induces electrocorticographic <e2> seizures </e2> and delayed hippocampal damage.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"614": {"data": {"text": "Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.", "entity1": "LiCl", "entity2": "seizures", "span1": [25, 29], "span2": [78, 86]}, "bert_text": "Tacrine, administered in <e1> LiCl </e1> pre-treated rats, induces electrocorticographic <e2> seizures </e2> and delayed hippocampal damage.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"615": {"data": {"text": "Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.\n", "entity1": "estrogen", "entity2": "pituitary tumors", "span1": [97, 105], "span2": [118, 134]}, "bert_text": "Over expression of vascular endothelial growth factor and its receptor during the development of <e1> estrogen </e1>-induced rat <e2> pituitary tumors </e2> may mediate estrogen-initiated tumor angiogenesis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"616": {"data": {"text": "Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.\n", "entity1": "estrogen", "entity2": "tumor", "span1": [97, 105], "span2": [166, 171]}, "bert_text": "Over expression of vascular endothelial growth factor and its receptor during the development of <e1> estrogen </e1>-induced rat pituitary tumors may mediate estrogen-initiated <e2> tumor </e2> angiogenesis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"617": {"data": {"text": "Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.\n", "entity1": "estrogen", "entity2": "pituitary tumors", "span1": [147, 155], "span2": [118, 134]}, "bert_text": "Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate <e1> estrogen </e1> <e2> pituitary tumors </e2> may mediate estrogen-initiated tumor angiogenesis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"618": {"data": {"text": "Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.\n", "entity1": "estrogen", "entity2": "tumor", "span1": [147, 155], "span2": [166, 171]}, "bert_text": "Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate <e1> estrogen </e1>-initiated <e2> tumor </e2> angiogenesis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"619": {"data": {"text": "Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.", "entity1": "Cisapride", "entity2": "gastrointestinal motility disorders", "span1": [0, 9], "span2": [95, 130]}, "bert_text": "<e1> Cisapride </e1>, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of <e2> gastrointestinal motility disorders </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"620": {"data": {"text": "In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups.", "entity1": "cisapride", "entity2": "diarrhoea", "span1": [115, 124], "span2": [3, 12]}, "bert_text": "In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the <e1> cisapride </e1> <e2> diarrhoea </e2>-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"621": {"data": {"text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "entity1": "CGRP", "entity2": "headache", "span1": [62, 66], "span2": [74, 82]}, "bert_text": "In the present study we aimed to investigate plasma levels of <e1> CGRP </e1> during <e2> headache </e2> induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"622": {"data": {"text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "entity1": "CGRP", "entity2": "tension-type headache", "span1": [62, 66], "span2": [161, 182]}, "bert_text": "In the present study we aimed to investigate plasma levels of <e1> CGRP </e1> during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic <e2> tension-type headache </e2> and 16 healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"623": {"data": {"text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "entity1": "NO", "entity2": "headache", "span1": [98, 100], "span2": [74, 82]}, "bert_text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the <e1> NO </e1> <e2> headache </e2> induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"624": {"data": {"text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "entity1": "NO", "entity2": "tension-type headache", "span1": [98, 100], "span2": [161, 182]}, "bert_text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the <e1> NO </e1> donor glyceryl trinitrate (GTN) in 16 patients with chronic <e2> tension-type headache </e2> and 16 healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"625": {"data": {"text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "entity1": "glyceryl trinitrate", "entity2": "headache", "span1": [107, 126], "span2": [74, 82]}, "bert_text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor <e1> glyceryl trinitrate </e1> <e2> headache </e2> induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"626": {"data": {"text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "entity1": "glyceryl trinitrate", "entity2": "tension-type headache", "span1": [107, 126], "span2": [161, 182]}, "bert_text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor <e1> glyceryl trinitrate </e1> (GTN) in 16 patients with chronic <e2> tension-type headache </e2> and 16 healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"627": {"data": {"text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "entity1": "GTN", "entity2": "headache", "span1": [128, 131], "span2": [74, 82]}, "bert_text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (<e1> GTN </e1> <e2> headache </e2> induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"628": {"data": {"text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "entity1": "GTN", "entity2": "tension-type headache", "span1": [128, 131], "span2": [161, 182]}, "bert_text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (<e1> GTN </e1>) in 16 patients with chronic <e2> tension-type headache </e2> and 16 healthy controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"629": {"data": {"text": "Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.", "entity1": "atropine", "entity2": "catalepsy", "span1": [34, 42], "span2": [102, 111]}, "bert_text": "Intraperitoneal administration of <e1> atropine </e1>, naloxone, mecamylamine, and hexamethonium to mice reduced <e2> catalepsy </e2> induced by a combination of morphine with nicotine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"630": {"data": {"text": "Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.", "entity1": "naloxone", "entity2": "catalepsy", "span1": [44, 52], "span2": [102, 111]}, "bert_text": "Intraperitoneal administration of atropine, <e1> naloxone </e1>, mecamylamine, and hexamethonium to mice reduced <e2> catalepsy </e2> induced by a combination of morphine with nicotine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"631": {"data": {"text": "Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.", "entity1": "mecamylamine", "entity2": "catalepsy", "span1": [54, 66], "span2": [102, 111]}, "bert_text": "Intraperitoneal administration of atropine, naloxone, <e1> mecamylamine </e1>, and hexamethonium to mice reduced <e2> catalepsy </e2> induced by a combination of morphine with nicotine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"632": {"data": {"text": "Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.", "entity1": "hexamethonium", "entity2": "catalepsy", "span1": [72, 85], "span2": [102, 111]}, "bert_text": "Intraperitoneal administration of atropine, naloxone, mecamylamine, and <e1> hexamethonium </e1> to mice reduced <e2> catalepsy </e2> induced by a combination of morphine with nicotine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"633": {"data": {"text": "Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.", "entity1": "morphine", "entity2": "catalepsy", "span1": [140, 148], "span2": [102, 111]}, "bert_text": "Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of <e1> morphine </e1> <e2> catalepsy </e2> induced by a combination of morphine with nicotine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"634": {"data": {"text": "Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.", "entity1": "nicotine", "entity2": "catalepsy", "span1": [154, 162], "span2": [102, 111]}, "bert_text": "Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with <e1> nicotine </e1> <e2> catalepsy </e2> induced by a combination of morphine with nicotine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"635": {"data": {"text": "Post-operative rigidity after fentanyl administration.\n", "entity1": "fentanyl", "entity2": "rigidity", "span1": [30, 38], "span2": [15, 23]}, "bert_text": "Post-operative rigidity after <e1> fentanyl </e1> <e2> rigidity </e2> after fentanyl administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"636": {"data": {"text": "Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.", "entity1": "Tiapride", "entity2": "involuntary movements", "span1": [0, 8], "span2": [115, 136]}, "bert_text": "<e1> Tiapride </e1>, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose <e2> involuntary movements </e2> in 16 patients with idiopathic Parkinson's disease.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"637": {"data": {"text": "Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.", "entity1": "Tiapride", "entity2": "idiopathic Parkinson's disease", "span1": [0, 8], "span2": [157, 187]}, "bert_text": "<e1> Tiapride </e1>, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with <e2> idiopathic Parkinson's disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"638": {"data": {"text": "Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.", "entity1": "benzamide", "entity2": "involuntary movements", "span1": [24, 33], "span2": [115, 136]}, "bert_text": "Tiapride, a substituted <e1> benzamide </e1> derivative closely related to metoclopramide, reduced levodopa-induced peak dose <e2> involuntary movements </e2> in 16 patients with idiopathic Parkinson's disease.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"639": {"data": {"text": "Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.", "entity1": "benzamide", "entity2": "idiopathic Parkinson's disease", "span1": [24, 33], "span2": [157, 187]}, "bert_text": "Tiapride, a substituted <e1> benzamide </e1> derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with <e2> idiopathic Parkinson's disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"640": {"data": {"text": "Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.", "entity1": "metoclopramide", "entity2": "involuntary movements", "span1": [64, 78], "span2": [115, 136]}, "bert_text": "Tiapride, a substituted benzamide derivative closely related to <e1> metoclopramide </e1>, reduced levodopa-induced peak dose <e2> involuntary movements </e2> in 16 patients with idiopathic Parkinson's disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"641": {"data": {"text": "Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.", "entity1": "metoclopramide", "entity2": "idiopathic Parkinson's disease", "span1": [64, 78], "span2": [157, 187]}, "bert_text": "Tiapride, a substituted benzamide derivative closely related to <e1> metoclopramide </e1>, reduced levodopa-induced peak dose involuntary movements in 16 patients with <e2> idiopathic Parkinson's disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"642": {"data": {"text": "Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.", "entity1": "levodopa", "entity2": "involuntary movements", "span1": [88, 96], "span2": [115, 136]}, "bert_text": "Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced <e1> levodopa </e1>-induced peak dose <e2> involuntary movements </e2> in 16 patients with idiopathic Parkinson's disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"643": {"data": {"text": "Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.", "entity1": "levodopa", "entity2": "idiopathic Parkinson's disease", "span1": [88, 96], "span2": [157, 187]}, "bert_text": "Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced <e1> levodopa </e1>-induced peak dose involuntary movements in 16 patients with <e2> idiopathic Parkinson's disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"644": {"data": {"text": "A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity.", "entity1": "fluvoxamine", "entity2": "hyperactivity", "span1": [26, 37], "span2": [129, 142]}, "bert_text": "A repeated treatment with <e1> fluvoxamine </e1> (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"645": {"data": {"text": "A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity.", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [109, 120], "span2": [129, 142]}, "bert_text": "A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the <e1> amphetamine </e1>-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"646": {"data": {"text": "Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [43, 54], "span2": [165, 179]}, "bert_text": "Animals which received over six courses of <e1> doxorubicin </e1> demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological <e2> cardiomyopathy </e2>, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"647": {"data": {"text": "Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.", "entity1": "SM-5887", "entity2": "cardiomyopathy", "span1": [238, 245], "span2": [165, 179]}, "bert_text": "Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the <e1> SM-5887 </e1> <e2> cardiomyopathy </e2>, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"648": {"data": {"text": "We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.", "entity1": "puromycin aminonucleoside", "entity2": "nephrosis", "span1": [101, 126], "span2": [135, 144]}, "bert_text": "We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with <e1> puromycin aminonucleoside </e1>-induced <e2> nephrosis </e2>, which is an experimental model of human nephrotic syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"649": {"data": {"text": "We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.", "entity1": "puromycin aminonucleoside", "entity2": "nephrotic syndrome", "span1": [101, 126], "span2": [186, 204]}, "bert_text": "We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with <e1> puromycin aminonucleoside </e1>-induced nephrosis, which is an experimental model of human <e2> nephrotic syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"650": {"data": {"text": "Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.", "entity1": "Reserpine", "entity2": "dyskinesia", "span1": [0, 9], "span2": [99, 109]}, "bert_text": "<e1> Reserpine </e1> (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial <e2> dyskinesia </e2>, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"651": {"data": {"text": "Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.", "entity1": "Reserpine", "entity2": "tardive dyskinesia", "span1": [0, 9], "span2": [188, 206]}, "bert_text": "<e1> Reserpine </e1> (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of <e2> tardive dyskinesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"652": {"data": {"text": "Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis.", "entity1": "phenytoin", "entity2": "seizure", "span1": [12, 21], "span2": [80, 87]}, "bert_text": "Intravenous <e1> phenytoin </e1> was administered during the later part of the surgery for <e2> seizure </e2> prophylaxis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"653": {"data": {"text": "The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "entity1": "amlodipine", "entity2": "edema", "span1": [73, 83], "span2": [40, 45]}, "bert_text": "The incidence of drug-related dependent edema was somewhat higher in the <e1> amlodipine </e1> <e2> edema </e2> was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"654": {"data": {"text": "The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "entity1": "amlodipine", "entity2": "edema", "span1": [172, 182], "span2": [40, 45]}, "bert_text": "The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg <e1> amlodipine </e1> <e2> edema </e2> was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"655": {"data": {"text": "The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "entity1": "amlodipine", "entity2": "edema", "span1": [211, 221], "span2": [40, 45]}, "bert_text": "The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg <e1> amlodipine </e1> <e2> edema </e2> was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"656": {"data": {"text": "The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "entity1": "amlodipine", "entity2": "edema", "span1": [239, 249], "span2": [40, 45]}, "bert_text": "The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg <e1> amlodipine </e1> <e2> edema </e2> was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"657": {"data": {"text": "The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "entity1": "valsartan", "entity2": "edema", "span1": [147, 156], "span2": [40, 45]}, "bert_text": "The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg <e1> valsartan </e1> <e2> edema </e2> was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"658": {"data": {"text": "The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "entity1": "valsartan", "entity2": "edema", "span1": [191, 200], "span2": [40, 45]}, "bert_text": "The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for <e1> valsartan </e1> <e2> edema </e2> was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"659": {"data": {"text": "Acute renal failure subsequent to the administration of rifampicin.", "entity1": "rifampicin", "entity2": "Acute renal failure", "span1": [56, 66], "span2": [0, 19]}, "bert_text": "Acute renal failure subsequent to the administration of <e1> rifampicin </e1> <e2> Acute renal failure </e2> subsequent to the administration of rifampicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"660": {"data": {"text": "The role of nitrergic system in lidocaine-induced convulsion in the mouse.\n", "entity1": "lidocaine", "entity2": "convulsion", "span1": [32, 41], "span2": [50, 60]}, "bert_text": "The role of nitrergic system in <e1> lidocaine </e1>-induced <e2> convulsion </e2> in the mouse.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"661": {"data": {"text": "In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.", "entity1": "BHA", "entity2": "epithelial hyperplasia", "span1": [17, 20], "span2": [157, 179]}, "bert_text": "In rats given 1% <e1> BHA </e1>, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced <e2> epithelial hyperplasia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"662": {"data": {"text": "In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.", "entity1": "BHA", "entity2": "epithelial hyperplasia", "span1": [145, 148], "span2": [157, 179]}, "bert_text": "In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the <e1> BHA </e1>-induced <e2> epithelial hyperplasia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"663": {"data": {"text": "In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.", "entity1": "RA", "entity2": "epithelial hyperplasia", "span1": [22, 24], "span2": [157, 179]}, "bert_text": "In rats given 1% BHA, <e1> RA </e1> co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced <e2> epithelial hyperplasia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"664": {"data": {"text": "MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.", "entity1": "MK-801", "entity2": "catalepsy", "span1": [0, 6], "span2": [133, 142]}, "bert_text": "<e1> MK-801 </e1> (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and <e2> catalepsy </e2> induced by reserpine.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"665": {"data": {"text": "MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.", "entity1": "reserpine", "entity2": "catalepsy", "span1": [154, 163], "span2": [133, 142]}, "bert_text": "MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by <e1> reserpine </e1> <e2> catalepsy </e2> induced by reserpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"666": {"data": {"text": "This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.", "entity1": "lithium", "entity2": "tricuspid regurgitation", "span1": [169, 176], "span2": [48, 71]}, "bert_text": "This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to <e1> lithium </e1> <e2> tricuspid regurgitation </e2> and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"667": {"data": {"text": "This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.", "entity1": "lithium", "entity2": "atrial flutter", "span1": [169, 176], "span2": [76, 90]}, "bert_text": "This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to <e1> lithium </e1> <e2> atrial flutter </e2>, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"668": {"data": {"text": "This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.", "entity1": "lithium", "entity2": "cardiac disease", "span1": [169, 176], "span2": [128, 143]}, "bert_text": "This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to <e1> lithium </e1> <e2> cardiac disease </e2> among infants exposed to lithium compounds in the first trimester of pregnancy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"669": {"data": {"text": "Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.", "entity1": "Amiodarone", "entity2": "pneumonitis", "span1": [0, 10], "span2": [122, 133]}, "bert_text": "<e1> Amiodarone </e1> is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being <e2> pneumonitis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"670": {"data": {"text": "The effect of isoflurane-induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects.", "entity1": "isoflurane", "entity2": "hypotension", "span1": [14, 24], "span2": [33, 44]}, "bert_text": "The effect of <e1> isoflurane </e1>-induced <e2> hypotension </e2> on glomerular function and renal blood flow was investigated in 20 human subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"671": {"data": {"text": "OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.", "entity1": "angiotensin II", "entity2": "hypertension", "span1": [61, 75], "span2": [210, 222]}, "bert_text": "OBJECTIVE: To compare the antihypertensive efficacy of a new <e1> angiotensin II </e1> antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild to moderate <e2> hypertension </e2> were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"672": {"data": {"text": "OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.", "entity1": "valsartan", "entity2": "hypertension", "span1": [88, 97], "span2": [210, 222]}, "bert_text": "OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, <e1> valsartan </e1>, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild to moderate <e2> hypertension </e2> were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"673": {"data": {"text": "OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.", "entity1": "valsartan", "entity2": "hypertension", "span1": [305, 314], "span2": [210, 222]}, "bert_text": "OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg <e1> valsartan </e1> <e2> hypertension </e2> were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"674": {"data": {"text": "OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.", "entity1": "amlodipine", "entity2": "hypertension", "span1": [125, 135], "span2": [210, 222]}, "bert_text": "OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, <e1> amlodipine </e1>. METHODS: One hundred sixty-eight adult outpatients with mild to moderate <e2> hypertension </e2> were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"675": {"data": {"text": "OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.", "entity1": "amlodipine", "entity2": "hypertension", "span1": [323, 333], "span2": [210, 222]}, "bert_text": "OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg <e1> amlodipine </e1> <e2> hypertension </e2> were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"676": {"data": {"text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "entity1": "diazepam", "entity2": "bradycardia", "span1": [13, 21], "span2": [63, 74]}, "bert_text": "However, the <e1> diazepam </e1> enhancement of adrenaline-induced reflex <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"677": {"data": {"text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "entity1": "adrenaline", "entity2": "bradycardia", "span1": [37, 47], "span2": [63, 74]}, "bert_text": "However, the diazepam enhancement of <e1> adrenaline </e1>-induced reflex <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"678": {"data": {"text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "entity1": "picrotoxin", "entity2": "bradycardia", "span1": [143, 153], "span2": [63, 74]}, "bert_text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of <e1> picrotoxin </e1> <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"679": {"data": {"text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "entity1": "chloride", "entity2": "bradycardia", "span1": [171, 179], "span2": [63, 74]}, "bert_text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks <e1> chloride </e1> <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"680": {"data": {"text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "entity1": "chloride", "entity2": "bradycardia", "span1": [249, 257], "span2": [63, 74]}, "bert_text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-<e1> chloride </e1> <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"681": {"data": {"text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "entity1": "benzodiazepine", "entity2": "bradycardia", "span1": [229, 243], "span2": [63, 74]}, "bert_text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the <e1> benzodiazepine </e1> <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"682": {"data": {"text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "entity1": "GABA", "entity2": "bradycardia", "span1": [244, 248], "span2": [63, 74]}, "bert_text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-<e1> GABA </e1> <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"683": {"data": {"text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "entity1": "Myocet", "entity2": "cardiotoxicity", "span1": [30, 36], "span2": [199, 213]}, "bert_text": "PURPOSE: To determine whether <e1> Myocet </e1> (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin <e2> cardiotoxicity </e2> while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"684": {"data": {"text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "entity1": "Myocet", "entity2": "breast cancer", "span1": [30, 36], "span2": [298, 311]}, "bert_text": "PURPOSE: To determine whether <e1> Myocet </e1> (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic <e2> breast cancer </e2> (MBC).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"685": {"data": {"text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "entity1": "Myocet", "entity2": "MBC", "span1": [30, 36], "span2": [313, 316]}, "bert_text": "PURPOSE: To determine whether <e1> Myocet </e1> (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (<e2> MBC </e2>).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"686": {"data": {"text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [60, 71], "span2": [199, 213]}, "bert_text": "PURPOSE: To determine whether Myocet (liposome-encapsulated <e1> doxorubicin </e1>; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin <e2> cardiotoxicity </e2> while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"687": {"data": {"text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "entity1": "doxorubicin", "entity2": "breast cancer", "span1": [60, 71], "span2": [298, 311]}, "bert_text": "PURPOSE: To determine whether Myocet (liposome-encapsulated <e1> doxorubicin </e1>; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic <e2> breast cancer </e2> (MBC).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"688": {"data": {"text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "entity1": "doxorubicin", "entity2": "MBC", "span1": [60, 71], "span2": [313, 316]}, "bert_text": "PURPOSE: To determine whether Myocet (liposome-encapsulated <e1> doxorubicin </e1>; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (<e2> MBC </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"689": {"data": {"text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [187, 198], "span2": [199, 213]}, "bert_text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"690": {"data": {"text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "entity1": "doxorubicin", "entity2": "breast cancer", "span1": [187, 198], "span2": [298, 311]}, "bert_text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces <e1> doxorubicin </e1> cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic <e2> breast cancer </e2> (MBC).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"691": {"data": {"text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "entity1": "doxorubicin", "entity2": "MBC", "span1": [187, 198], "span2": [313, 316]}, "bert_text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces <e1> doxorubicin </e1> cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (<e2> MBC </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, 0, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"692": {"data": {"text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "entity1": "cyclophosphamide", "entity2": "cardiotoxicity", "span1": [148, 164], "span2": [199, 213]}, "bert_text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with <e1> cyclophosphamide </e1> significantly reduces doxorubicin <e2> cardiotoxicity </e2> while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"693": {"data": {"text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "entity1": "cyclophosphamide", "entity2": "breast cancer", "span1": [148, 164], "span2": [298, 311]}, "bert_text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with <e1> cyclophosphamide </e1> significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic <e2> breast cancer </e2> (MBC).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"694": {"data": {"text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).", "entity1": "cyclophosphamide", "entity2": "MBC", "span1": [148, 164], "span2": [313, 316]}, "bert_text": "PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with <e1> cyclophosphamide </e1> significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (<e2> MBC </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"695": {"data": {"text": "This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.", "entity1": "pilocarpine", "entity2": "arrhythmia", "span1": [51, 62], "span2": [171, 181]}, "bert_text": "This study was designed to evaluate the effects of <e1> pilocarpine </e1> and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig <e2> arrhythmia </e2> models.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"696": {"data": {"text": "This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.", "entity1": "aconitine", "entity2": "arrhythmia", "span1": [118, 127], "span2": [171, 181]}, "bert_text": "This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both <e1> aconitine </e1>-induced rat and ouabain-induced guinea pig <e2> arrhythmia </e2> models.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"697": {"data": {"text": "This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.", "entity1": "ouabain", "entity2": "arrhythmia", "span1": [144, 151], "span2": [171, 181]}, "bert_text": "This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and <e1> ouabain </e1>-induced guinea pig <e2> arrhythmia </e2> models.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"698": {"data": {"text": "In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.", "entity1": "DX", "entity2": "glomerulonephritis", "span1": [68, 70], "span2": [33, 51]}, "bert_text": "In rats with immune experimental glomerulonephritis, 5/6 rats given <e1> DX </e1> <e2> glomerulonephritis </e2>, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"699": {"data": {"text": "In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.", "entity1": "OCT", "entity2": "secondary hyperparathyroidism", "span1": [48, 51], "span2": [17, 46]}, "bert_text": "In long-standing secondary hyperparathyroidism, <e1> OCT </e1> <e2> secondary hyperparathyroidism </e2>, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"700": {"data": {"text": "A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.", "entity1": "sulphasalazine", "entity2": "ulcerative colitis", "span1": [141, 155], "span2": [25, 43]}, "bert_text": "A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of <e1> sulphasalazine </e1> <e2> ulcerative colitis </e2> developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"701": {"data": {"text": "A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.", "entity1": "sulphasalazine", "entity2": "pleural effusion", "span1": [141, 155], "span2": [64, 80]}, "bert_text": "A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of <e1> sulphasalazine </e1> <e2> pleural effusion </e2>, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"702": {"data": {"text": "A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.", "entity1": "sulphasalazine", "entity2": "eosinophilia", "span1": [141, 155], "span2": [82, 94]}, "bert_text": "A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of <e1> sulphasalazine </e1> <e2> eosinophilia </e2> and urinary abnormalities after restarting of sulphasalazine treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"703": {"data": {"text": "In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.", "entity1": "SM-5887", "entity2": "cardiotoxicity", "span1": [15, 22], "span2": [62, 76]}, "bert_text": "In conclusion, <e1> SM-5887 </e1> does not have any potential of chronic <e2> cardiotoxicity </e2> and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"704": {"data": {"text": "In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.", "entity1": "SM-5887", "entity2": "cardiotoxicity", "span1": [15, 22], "span2": [125, 139]}, "bert_text": "In conclusion, <e1> SM-5887 </e1> does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced <e2> cardiotoxicity </e2> in dogs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"705": {"data": {"text": "In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [105, 116], "span2": [62, 76]}, "bert_text": "In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"706": {"data": {"text": "In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [105, 116], "span2": [125, 139]}, "bert_text": "In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on <e1> doxorubicin </e1>-induced <e2> cardiotoxicity </e2> in dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"707": {"data": {"text": "A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.", "entity1": "azathioprine", "entity2": "polymyositis", "span1": [192, 204], "span2": [36, 48]}, "bert_text": "A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of <e1> azathioprine </e1> <e2> polymyositis </e2> and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"708": {"data": {"text": "A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.", "entity1": "azathioprine", "entity2": "liver disease", "span1": [192, 204], "span2": [82, 95]}, "bert_text": "A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of <e1> azathioprine </e1> <e2> liver disease </e2>, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"709": {"data": {"text": "A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.", "entity1": "azathioprine", "entity2": "cholestasis", "span1": [192, 204], "span2": [151, 162]}, "bert_text": "A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of <e1> azathioprine </e1> <e2> cholestasis </e2> 3 months after initiation of azathioprine therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"710": {"data": {"text": "Postinfarction ventricular septal defect associated with long-term steroid therapy.\n", "entity1": "steroid", "entity2": "ventricular septal defect", "span1": [67, 74], "span2": [15, 40]}, "bert_text": "Postinfarction ventricular septal defect associated with long-term <e1> steroid </e1> <e2> ventricular septal defect </e2> associated with long-term steroid therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"711": {"data": {"text": "She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.", "entity1": "estrogens", "entity2": "ovarian failure", "span1": [113, 122], "span2": [8, 23]}, "bert_text": "She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous <e1> estrogens </e1> <e2> ovarian failure </e2> after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"712": {"data": {"text": "She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.", "entity1": "estrogens", "entity2": "Hodgkin disease", "span1": [113, 122], "span2": [73, 88]}, "bert_text": "She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous <e1> estrogens </e1> <e2> Hodgkin disease </e2>, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
	"713": {"data": {"text": "She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.", "entity1": "estrogens", "entity2": "endometrial cancer", "span1": [113, 122], "span2": [169, 187]}, "bert_text": "She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous <e1> estrogens </e1>, a treatment implicated in the development of <e2> endometrial cancer </e2> in menopausal women.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"714": {"data": {"text": "22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.\n", "entity1": "22-oxacalcitriol", "entity2": "hyperparathyroidism", "span1": [0, 16], "span2": [38, 57]}, "bert_text": "<e1> 22-oxacalcitriol </e1> suppresses secondary <e2> hyperparathyroidism </e2> without inducing low bone turnover in dogs with renal failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"715": {"data": {"text": "22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.\n", "entity1": "22-oxacalcitriol", "entity2": "low bone turnover", "span1": [0, 16], "span2": [75, 92]}, "bert_text": "<e1> 22-oxacalcitriol </e1> suppresses secondary hyperparathyroidism without inducing <e2> low bone turnover </e2> in dogs with renal failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"716": {"data": {"text": "22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.\n", "entity1": "22-oxacalcitriol", "entity2": "renal failure", "span1": [0, 16], "span2": [106, 119]}, "bert_text": "<e1> 22-oxacalcitriol </e1> suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with <e2> renal failure </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"717": {"data": {"text": "BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.", "entity1": "Calcitriol", "entity2": "renal failure", "span1": [12, 22], "span2": [101, 114]}, "bert_text": "BACKGROUND: <e1> Calcitriol </e1> therapy suppresses serum levels of parathyroid hormone (PTH) in patients with <e2> renal failure </e2> but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
	"718": {"data": {"text": "BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.", "entity1": "Calcitriol", "entity2": "hypercalcemia", "span1": [12, 22], "span2": [152, 165]}, "bert_text": "BACKGROUND: <e1> Calcitriol </e1> therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including <e2> hypercalcemia </e2> and/or marked suppression of bone turnover, which may lead to adynamic bone disease.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
	"719": {"data": {"text": "BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.", "entity1": "Calcitriol", "entity2": "bone disease", "span1": [12, 22], "span2": [237, 249]}, "bert_text": "BACKGROUND: <e1> Calcitriol </e1> therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic <e2> bone disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
	"720": {"data": {"text": "The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.", "entity1": "warfarin", "entity2": "LV Cutaneous lesions", "span1": [129, 137], "span2": [77, 97]}, "bert_text": "The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after <e1> warfarin </e1> <e2> LV Cutaneous lesions </e2> resolved in all patients after warfarin was discontinued.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"721": {"data": {"text": "OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.", "entity1": "trihexyphenidyl", "entity2": "confusion", "span1": [122, 137], "span2": [174, 183]}, "bert_text": "OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of <e1> trihexyphenidyl </e1> on measures reflecting sedation and <e2> confusion </e2> and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"722": {"data": {"text": "OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.", "entity1": "trihexyphenidyl", "entity2": "confusion", "span1": [228, 243], "span2": [174, 183]}, "bert_text": "OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between <e1> trihexyphenidyl </e1> <e2> confusion </e2> and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"723": {"data": {"text": "Naloxone reversal of hypotension due to captopril overdose.\n", "entity1": "Naloxone", "entity2": "hypotension", "span1": [0, 8], "span2": [21, 32]}, "bert_text": "<e1> Naloxone </e1> reversal of <e2> hypotension </e2> due to captopril overdose.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"724": {"data": {"text": "Naloxone reversal of hypotension due to captopril overdose.\n", "entity1": "Naloxone", "entity2": "overdose", "span1": [0, 8], "span2": [50, 58]}, "bert_text": "<e1> Naloxone </e1> reversal of hypotension due to captopril <e2> overdose </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"725": {"data": {"text": "In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-lithium model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.", "entity1": "tacrine", "entity2": "epilepsy", "span1": [122, 129], "span2": [147, 155]}, "bert_text": "In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the <e1> tacrine </e1>-lithium model of <e2> epilepsy </e2> in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"726": {"data": {"text": "In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-lithium model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.", "entity1": "lithium", "entity2": "epilepsy", "span1": [130, 137], "span2": [147, 155]}, "bert_text": "In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-<e1> lithium </e1> model of <e2> epilepsy </e2> in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"727": {"data": {"text": "Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.", "entity1": "apomorphine", "entity2": "Parkinson's disease", "span1": [379, 390], "span2": [21, 40]}, "bert_text": "Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of <e1> apomorphine </e1> <e2> Parkinson's disease </e2> with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"728": {"data": {"text": "Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.", "entity1": "apomorphine", "entity2": "dyskinesia", "span1": [379, 390], "span2": [56, 66]}, "bert_text": "Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of <e1> apomorphine </e1> <e2> dyskinesia </e2> were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"729": {"data": {"text": "Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.", "entity1": "apomorphine", "entity2": "dyskinesia", "span1": [379, 390], "span2": [312, 322]}, "bert_text": "Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of <e1> apomorphine </e1> <e2> dyskinesia </e2> following administration of an effective single dose of apomorphine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"730": {"data": {"text": "However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced angioedema.", "entity1": "NSAID", "entity2": "urticaria", "span1": [156, 161], "span2": [114, 123]}, "bert_text": "However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of <e1> NSAID </e1> <e2> urticaria </e2> and, above all, by a history of NSAID-induced angioedema.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"731": {"data": {"text": "However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced angioedema.", "entity1": "NSAID", "entity2": "angioedema", "span1": [156, 161], "span2": [170, 180]}, "bert_text": "However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of <e1> NSAID </e1>-induced <e2> angioedema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"732": {"data": {"text": "All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).", "entity1": "lithium", "entity2": "thyroid illness", "span1": [137, 144], "span2": [55, 70]}, "bert_text": "All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of <e1> lithium </e1> <e2> thyroid illness </e2> had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"733": {"data": {"text": "All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).", "entity1": "lithium", "entity2": "hypothyroidism", "span1": [137, 144], "span2": [96, 110]}, "bert_text": "All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of <e1> lithium </e1> <e2> hypothyroidism </e2> (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"734": {"data": {"text": "All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).", "entity1": "lithium", "entity2": "thyroid illness", "span1": [228, 235], "span2": [55, 70]}, "bert_text": "All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of <e1> lithium </e1> <e2> thyroid illness </e2> had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"735": {"data": {"text": "All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).", "entity1": "lithium", "entity2": "hypothyroidism", "span1": [228, 235], "span2": [96, 110]}, "bert_text": "All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of <e1> lithium </e1> <e2> hypothyroidism </e2> (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"736": {"data": {"text": "It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.", "entity1": "azathioprine", "entity2": "cholestasis", "span1": [66, 78], "span2": [87, 98]}, "bert_text": "It is believed that this is the first reported case of reversible <e1> azathioprine </e1>-induced <e2> cholestasis </e2> associated with histological evidence of bile duct injury.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"737": {"data": {"text": "It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.", "entity1": "azathioprine", "entity2": "bile duct injury", "span1": [66, 78], "span2": [140, 156]}, "bert_text": "It is believed that this is the first reported case of reversible <e1> azathioprine </e1>-induced cholestasis associated with histological evidence of <e2> bile duct injury </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"738": {"data": {"text": "It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.", "entity1": "dobutamine", "entity2": "hypersensitivity", "span1": [81, 91], "span2": [22, 38]}, "bert_text": "It is likely that the hypersensitivity (eosinophilic) myocarditis was related to <e1> dobutamine </e1> <e2> hypersensitivity </e2> (eosinophilic) myocarditis was related to dobutamine infusion therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"739": {"data": {"text": "It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.", "entity1": "dobutamine", "entity2": "myocarditis", "span1": [81, 91], "span2": [54, 65]}, "bert_text": "It is likely that the hypersensitivity (eosinophilic) myocarditis was related to <e1> dobutamine </e1> <e2> myocarditis </e2> was related to dobutamine infusion therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"740": {"data": {"text": "The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.", "entity1": "diazepam", "entity2": "bradycardia", "span1": [23, 31], "span2": [164, 175]}, "bert_text": "The data indicate that <e1> diazepam </e1> acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex <e2> bradycardia </e2> mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"741": {"data": {"text": "The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.", "entity1": "benzodiazepine", "entity2": "bradycardia", "span1": [49, 63], "span2": [164, 175]}, "bert_text": "The data indicate that diazepam acts through the <e1> benzodiazepine </e1>-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex <e2> bradycardia </e2> mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"742": {"data": {"text": "The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.", "entity1": "GABA", "entity2": "bradycardia", "span1": [64, 68], "span2": [164, 175]}, "bert_text": "The data indicate that diazepam acts through the benzodiazepine-<e1> GABA </e1>-chloride channel macromolecular complex within the central nervous system to facilitate reflex <e2> bradycardia </e2> mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"743": {"data": {"text": "The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.", "entity1": "chloride", "entity2": "bradycardia", "span1": [69, 77], "span2": [164, 175]}, "bert_text": "The data indicate that diazepam acts through the benzodiazepine-GABA-<e1> chloride </e1> channel macromolecular complex within the central nervous system to facilitate reflex <e2> bradycardia </e2> mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"744": {"data": {"text": "Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.", "entity1": "NSAID", "entity2": "urticaria", "span1": [109, 114], "span2": [58, 67]}, "bert_text": "Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of <e1> NSAID </e1> <e2> urticaria </e2> and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"745": {"data": {"text": "Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.", "entity1": "NSAID", "entity2": "urticaria", "span1": [109, 114], "span2": [123, 132]}, "bert_text": "Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of <e1> NSAID </e1>-induced <e2> urticaria </e2>/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"746": {"data": {"text": "Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.", "entity1": "NSAID", "entity2": "urticaria", "span1": [109, 114], "span2": [189, 198]}, "bert_text": "Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of <e1> NSAID </e1>-induced urticaria/angioedema or angioedema alone (with or without chronic <e2> urticaria </e2>) resulted to be intolerant to alternative drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"747": {"data": {"text": "Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.", "entity1": "NSAID", "entity2": "angioedema", "span1": [109, 114], "span2": [133, 143]}, "bert_text": "Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of <e1> NSAID </e1>-induced urticaria/<e2> angioedema </e2> or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"748": {"data": {"text": "Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.", "entity1": "NSAID", "entity2": "angioedema", "span1": [109, 114], "span2": [147, 157]}, "bert_text": "Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of <e1> NSAID </e1>-induced urticaria/angioedema or <e2> angioedema </e2> alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"749": {"data": {"text": "Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.", "entity1": "AMN082", "entity2": "catalepsy", "span1": [88, 94], "span2": [124, 133]}, "bert_text": "Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of <e1> AMN082 </e1> reverses haloperidol-induced <e2> catalepsy </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"750": {"data": {"text": "Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [104, 115], "span2": [124, 133]}, "bert_text": "Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses <e1> haloperidol </e1>-induced <e2> catalepsy </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"751": {"data": {"text": "Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.", "entity1": "levodopa", "entity2": "bradykinesia", "span1": [122, 130], "span2": [30, 42]}, "bert_text": "Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving <e1> levodopa </e1> <e2> bradykinesia </e2> and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"752": {"data": {"text": "Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.", "entity1": "levodopa", "entity2": "rigidity", "span1": [122, 130], "span2": [47, 55]}, "bert_text": "Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving <e1> levodopa </e1> <e2> rigidity </e2> to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"753": {"data": {"text": "Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [122, 130], "span2": [139, 150]}, "bert_text": "Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving <e1> levodopa </e1>-induced <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"754": {"data": {"text": "Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.", "entity1": "Tramadol", "entity2": "cancer", "span1": [0, 8], "span2": [110, 116]}, "bert_text": "<e1> Tramadol </e1> is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat <e2> cancer </e2> pain and chronic non malignant pain.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"755": {"data": {"text": "Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.", "entity1": "Tramadol", "entity2": "pain", "span1": [0, 8], "span2": [117, 121]}, "bert_text": "<e1> Tramadol </e1> is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer <e2> pain </e2> and chronic non malignant pain.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"756": {"data": {"text": "Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.", "entity1": "Tramadol", "entity2": "pain", "span1": [0, 8], "span2": [148, 152]}, "bert_text": "<e1> Tramadol </e1> is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant <e2> pain </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"757": {"data": {"text": "Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.\n", "entity1": "nitric oxide", "entity2": "headache", "span1": [46, 58], "span2": [67, 75]}, "bert_text": "Calcitonin gene-related peptide levels during <e1> nitric oxide </e1>-induced <e2> headache </e2> in patients with chronic tension-type headache.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"758": {"data": {"text": "Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.\n", "entity1": "nitric oxide", "entity2": "tension-type headache", "span1": [46, 58], "span2": [101, 122]}, "bert_text": "Calcitonin gene-related peptide levels during <e1> nitric oxide </e1>-induced headache in patients with chronic <e2> tension-type headache </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"759": {"data": {"text": "During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.", "entity1": "nucleosides", "entity2": "ischemia", "span1": [68, 79], "span2": [7, 15]}, "bert_text": "During ischemia, a time-dependent increase of plasma oxypurines and <e1> nucleosides </e1> <e2> ischemia </e2>, a time-dependent increase of plasma oxypurines and nucleosides was observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"760": {"data": {"text": "Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).", "entity1": "malondialdehyde", "entity2": "ischemia", "span1": [7, 22], "span2": [136, 144]}, "bert_text": "Plasma <e1> malondialdehyde </e1>, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of <e2> ischemia </e2>, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"761": {"data": {"text": "Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.", "entity1": "cephalosporins", "entity2": "hemolytic anemia", "span1": [29, 43], "span2": [131, 147]}, "bert_text": "Second- and third-generation <e1> cephalosporins </e1>, especially cefotetan, are increasingly associated with severe, sometimes fatal immune <e2> hemolytic anemia </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"762": {"data": {"text": "Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.", "entity1": "cefotetan", "entity2": "hemolytic anemia", "span1": [56, 65], "span2": [131, 147]}, "bert_text": "Second- and third-generation cephalosporins, especially <e1> cefotetan </e1>, are increasingly associated with severe, sometimes fatal immune <e2> hemolytic anemia </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"763": {"data": {"text": "METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].", "entity1": "cisapride", "entity2": "IBS", "span1": [188, 197], "span2": [36, 39]}, "bert_text": "METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [<e1> cisapride </e1> <e2> IBS </e2> (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"764": {"data": {"text": "METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].", "entity1": "cisapride", "entity2": "constipation", "span1": [188, 197], "span2": [41, 53]}, "bert_text": "METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [<e1> cisapride </e1> <e2> constipation </e2>-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"765": {"data": {"text": "METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].", "entity1": "cisapride", "entity2": "diarrhoea", "span1": [188, 197], "span2": [75, 84]}, "bert_text": "METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [<e1> cisapride </e1> <e2> diarrhoea </e2>-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"766": {"data": {"text": "Etoposide-related myocardial infarction.\n", "entity1": "Etoposide", "entity2": "myocardial infarction", "span1": [0, 9], "span2": [18, 39]}, "bert_text": "<e1> Etoposide </e1>-related <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"767": {"data": {"text": "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.", "entity1": "azathioprine", "entity2": "systemic lupus erythematosus", "span1": [138, 150], "span2": [40, 68]}, "bert_text": "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with <e1> azathioprine </e1> <e2> systemic lupus erythematosus </e2> (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"768": {"data": {"text": "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.", "entity1": "azathioprine", "entity2": "SLE", "span1": [138, 150], "span2": [70, 73]}, "bert_text": "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with <e1> azathioprine </e1> <e2> SLE </e2>) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"769": {"data": {"text": "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.", "entity1": "azathioprine", "entity2": "renal involvement", "span1": [138, 150], "span2": [80, 97]}, "bert_text": "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with <e1> azathioprine </e1> <e2> renal involvement </e2> and undergone periods of treatment with azathioprine and cyclophosphamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"770": {"data": {"text": "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.", "entity1": "cyclophosphamide", "entity2": "systemic lupus erythematosus", "span1": [155, 171], "span2": [40, 68]}, "bert_text": "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and <e1> cyclophosphamide </e1> <e2> systemic lupus erythematosus </e2> (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"771": {"data": {"text": "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.", "entity1": "cyclophosphamide", "entity2": "SLE", "span1": [155, 171], "span2": [70, 73]}, "bert_text": "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and <e1> cyclophosphamide </e1> <e2> SLE </e2>) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"772": {"data": {"text": "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.", "entity1": "cyclophosphamide", "entity2": "renal involvement", "span1": [155, 171], "span2": [80, 97]}, "bert_text": "Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and <e1> cyclophosphamide </e1> <e2> renal involvement </e2> and undergone periods of treatment with azathioprine and cyclophosphamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"773": {"data": {"text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\n", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [81, 92], "span2": [8, 22]}, "bert_text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"774": {"data": {"text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\n", "entity1": "doxorubicin", "entity2": "breast cancer", "span1": [81, 92], "span2": [223, 236]}, "bert_text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated <e1> doxorubicin </e1> and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic <e2> breast cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"775": {"data": {"text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\n", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [141, 152], "span2": [8, 22]}, "bert_text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"776": {"data": {"text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\n", "entity1": "doxorubicin", "entity2": "breast cancer", "span1": [141, 152], "span2": [223, 236]}, "bert_text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional <e1> doxorubicin </e1> and cyclophosphamide in a randomized, multicenter trial of metastatic <e2> breast cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"777": {"data": {"text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\n", "entity1": "cyclophosphamide", "entity2": "cardiotoxicity", "span1": [97, 113], "span2": [8, 22]}, "bert_text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and <e1> cyclophosphamide </e1> <e2> cardiotoxicity </e2> and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"778": {"data": {"text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\n", "entity1": "cyclophosphamide", "entity2": "breast cancer", "span1": [97, 113], "span2": [223, 236]}, "bert_text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and <e1> cyclophosphamide </e1> compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic <e2> breast cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"779": {"data": {"text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\n", "entity1": "cyclophosphamide", "entity2": "cardiotoxicity", "span1": [157, 173], "span2": [8, 22]}, "bert_text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and <e1> cyclophosphamide </e1> <e2> cardiotoxicity </e2> and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"780": {"data": {"text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\n", "entity1": "cyclophosphamide", "entity2": "breast cancer", "span1": [157, 173], "span2": [223, 236]}, "bert_text": "Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and <e1> cyclophosphamide </e1> in a randomized, multicenter trial of metastatic <e2> breast cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"781": {"data": {"text": "Seizure activity with imipenem therapy: incidence and risk factors.\n", "entity1": "imipenem", "entity2": "Seizure", "span1": [22, 30], "span2": [0, 7]}, "bert_text": "Seizure activity with <e1> imipenem </e1> <e2> Seizure </e2> activity with imipenem therapy: incidence and risk factors.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"782": {"data": {"text": "CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.", "entity1": "CB 3717", "entity2": "cytotoxicity", "span1": [0, 7], "span2": [110, 122]}, "bert_text": "<e1> CB 3717 </e1>, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose <e2> cytotoxicity </e2> is mediated solely through the inhibition of this enzyme.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"783": {"data": {"text": "CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.", "entity1": "N10-propargyl-5,8-dideazafolic acid", "entity2": "cytotoxicity", "span1": [9, 44], "span2": [110, 122]}, "bert_text": "CB 3717, <e1> N10-propargyl-5,8-dideazafolic acid </e1>, is a tight-binding inhibitor of thymidylate synthase (TS) whose <e2> cytotoxicity </e2> is mediated solely through the inhibition of this enzyme.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"784": {"data": {"text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.", "entity1": "steroid", "entity2": "atrophy", "span1": [106, 113], "span2": [91, 98]}, "bert_text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the <e1> steroid </e1> <e2> atrophy </e2> in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"785": {"data": {"text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.", "entity1": "steroid", "entity2": "diaphragmatic type IIa atrophy", "span1": [106, 113], "span2": [130, 160]}, "bert_text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the <e1> steroid </e1> groups and also <e2> diaphragmatic type IIa atrophy </e2> with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"786": {"data": {"text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.", "entity1": "steroid", "entity2": "necrosis", "span1": [106, 113], "span2": [252, 260]}, "bert_text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the <e1> steroid </e1> groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of <e2> necrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"787": {"data": {"text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.", "entity1": "T", "entity2": "atrophy", "span1": [166, 167], "span2": [91, 98]}, "bert_text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with <e1> T </e1> <e2> atrophy </e2> in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"788": {"data": {"text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.", "entity1": "T", "entity2": "diaphragmatic type IIa atrophy", "span1": [166, 167], "span2": [130, 160]}, "bert_text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with <e1> T </e1> <e2> diaphragmatic type IIa atrophy </e2> with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"789": {"data": {"text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.", "entity1": "T", "entity2": "necrosis", "span1": [166, 167], "span2": [252, 260]}, "bert_text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with <e1> T </e1>, whereas histologic examinations revealed a normal muscular pattern with absence of <e2> necrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"790": {"data": {"text": "Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.", "entity1": "Puromycin aminonucleoside", "entity2": "renal dysfunction", "span1": [0, 25], "span2": [34, 51]}, "bert_text": "<e1> Puromycin aminonucleoside </e1>-induced <e2> renal dysfunction </e2> and hyperlipidemia were also suppressed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"791": {"data": {"text": "Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.", "entity1": "Puromycin aminonucleoside", "entity2": "hyperlipidemia", "span1": [0, 25], "span2": [56, 70]}, "bert_text": "<e1> Puromycin aminonucleoside </e1>-induced renal dysfunction and <e2> hyperlipidemia </e2> were also suppressed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"792": {"data": {"text": "In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.", "entity1": "mesna", "entity2": "hemorrhagic cystitis", "span1": [122, 127], "span2": [202, 222]}, "bert_text": "In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with <e1> mesna </e1>, which neutralizes the hepatic metabolite of cyclophosphamide that causes <e2> hemorrhagic cystitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"793": {"data": {"text": "In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.", "entity1": "cyclophosphamide", "entity2": "hemorrhagic cystitis", "span1": [173, 189], "span2": [202, 222]}, "bert_text": "In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of <e1> cyclophosphamide </e1> that causes <e2> hemorrhagic cystitis </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"794": {"data": {"text": "These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [46, 54], "span2": [63, 74]}, "bert_text": "These results fail to support the notion that <e1> levodopa </e1>-induced <e2> dyskinesias </e2> are caused by overstimulation of a separate group of dopamine receptors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"795": {"data": {"text": "These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.", "entity1": "dopamine", "entity2": "dyskinesias", "span1": [128, 136], "span2": [63, 74]}, "bert_text": "These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of <e1> dopamine </e1> <e2> dyskinesias </e2> are caused by overstimulation of a separate group of dopamine receptors.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"796": {"data": {"text": "Pain responses in methadone-maintained opioid abusers.\n", "entity1": "methadone", "entity2": "Pain", "span1": [18, 27], "span2": [0, 4]}, "bert_text": "Pain responses in <e1> methadone </e1> <e2> Pain </e2> responses in methadone-maintained opioid abusers.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"797": {"data": {"text": "Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.", "entity1": "PB", "entity2": "epilepsy", "span1": [82, 84], "span2": [60, 68]}, "bert_text": "Here we report of two adult patients with a long history of epilepsy treated with <e1> PB </e1> <e2> epilepsy </e2> treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"798": {"data": {"text": "Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.", "entity1": "PB", "entity2": "cardiac arrest", "span1": [82, 84], "span2": [126, 140]}, "bert_text": "Here we report of two adult patients with a long history of epilepsy treated with <e1> PB </e1> who died suddenly: one as consequence of <e2> cardiac arrest </e2>, the other of acute bronchopneumonia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"799": {"data": {"text": "Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.", "entity1": "PB", "entity2": "bronchopneumonia", "span1": [82, 84], "span2": [161, 177]}, "bert_text": "Here we report of two adult patients with a long history of epilepsy treated with <e1> PB </e1> who died suddenly: one as consequence of cardiac arrest, the other of acute <e2> bronchopneumonia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"800": {"data": {"text": "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.\n", "entity1": "Valsartan", "entity2": "hypertension", "span1": [0, 9], "span2": [74, 86]}, "bert_text": "<e1> Valsartan </e1>, a new angiotensin II antagonist for the treatment of essential <e2> hypertension </e2>: a comparative study of the efficacy and safety against amlodipine.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"801": {"data": {"text": "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.\n", "entity1": "angiotensin II", "entity2": "hypertension", "span1": [17, 31], "span2": [74, 86]}, "bert_text": "Valsartan, a new <e1> angiotensin II </e1> antagonist for the treatment of essential <e2> hypertension </e2>: a comparative study of the efficacy and safety against amlodipine.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"802": {"data": {"text": "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.\n", "entity1": "amlodipine", "entity2": "hypertension", "span1": [143, 153], "span2": [74, 86]}, "bert_text": "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against <e1> amlodipine </e1> <e2> hypertension </e2>: a comparative study of the efficacy and safety against amlodipine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
	"803": {"data": {"text": "These results may suggest that NO is a proconvulsant mediator in lidocaine-induced convulsions.", "entity1": "NO", "entity2": "convulsions", "span1": [31, 33], "span2": [83, 94]}, "bert_text": "These results may suggest that <e1> NO </e1> is a proconvulsant mediator in lidocaine-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"804": {"data": {"text": "These results may suggest that NO is a proconvulsant mediator in lidocaine-induced convulsions.", "entity1": "lidocaine", "entity2": "convulsions", "span1": [65, 74], "span2": [83, 94]}, "bert_text": "These results may suggest that NO is a proconvulsant mediator in <e1> lidocaine </e1>-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"805": {"data": {"text": "The low-grade cardiotoxic changes were enhanced by the additional doxorubicin treatment.", "entity1": "doxorubicin", "entity2": "cardiotoxic", "span1": [66, 77], "span2": [14, 25]}, "bert_text": "The low-grade cardiotoxic changes were enhanced by the additional <e1> doxorubicin </e1> <e2> cardiotoxic </e2> changes were enhanced by the additional doxorubicin treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"806": {"data": {"text": "Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.", "entity1": "estrogens", "entity2": "ovarian failure", "span1": [27, 36], "span2": [41, 56]}, "bert_text": "Young women on replacement <e1> estrogens </e1> for <e2> ovarian failure </e2> after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"807": {"data": {"text": "Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.", "entity1": "estrogens", "entity2": "cancer", "span1": [27, 36], "span2": [63, 69]}, "bert_text": "Young women on replacement <e1> estrogens </e1> for ovarian failure after <e2> cancer </e2> therapy may also have increased risk of endometrial carcinoma and should be examined periodically.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"808": {"data": {"text": "Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.", "entity1": "estrogens", "entity2": "endometrial carcinoma", "span1": [27, 36], "span2": [110, 131]}, "bert_text": "Young women on replacement <e1> estrogens </e1> for ovarian failure after cancer therapy may also have increased risk of <e2> endometrial carcinoma </e2> and should be examined periodically.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"809": {"data": {"text": "Amiodarone pulmonary toxicity.\n", "entity1": "Amiodarone", "entity2": "pulmonary toxicity", "span1": [0, 10], "span2": [11, 29]}, "bert_text": "<e1> Amiodarone </e1> <e2> pulmonary toxicity </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"810": {"data": {"text": "Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.", "entity1": "lactate", "entity2": "lactic acidosis", "span1": [80, 87], "span2": [11, 26]}, "bert_text": "Nonketotic lactic acidosis was present in one and ketosis without a known serum <e1> lactate </e1> <e2> lactic acidosis </e2> was present in one and ketosis without a known serum lactate level was present in the other.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
	"811": {"data": {"text": "Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.", "entity1": "lactate", "entity2": "ketosis", "span1": [80, 87], "span2": [50, 57]}, "bert_text": "Nonketotic lactic acidosis was present in one and ketosis without a known serum <e1> lactate </e1> <e2> ketosis </e2> without a known serum lactate level was present in the other.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
	"812": {"data": {"text": "These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.", "entity1": "nicotine", "entity2": "locomotor hyperactivity", "span1": [35, 43], "span2": [65, 88]}, "bert_text": "These results suggest that chronic <e1> nicotine </e1>-treated rats develop <e2> locomotor hyperactivity </e2> in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"813": {"data": {"text": "These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.", "entity1": "nicotine", "entity2": "locomotor hyperactivity", "span1": [104, 112], "span2": [65, 88]}, "bert_text": "These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to <e1> nicotine </e1> <e2> locomotor hyperactivity </e2> in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
	"814": {"data": {"text": "These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.", "entity1": "DA", "entity2": "locomotor hyperactivity", "span1": [187, 189], "span2": [65, 88]}, "bert_text": "These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and <e1> DA </e1> <e2> locomotor hyperactivity </e2> in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
	"815": {"data": {"text": "These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.", "entity1": "DA", "entity2": "locomotor hyperactivity", "span1": [226, 228], "span2": [65, 88]}, "bert_text": "These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing <e1> DA </e1> <e2> locomotor hyperactivity </e2> in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
	"816": {"data": {"text": "Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/-", "entity1": "dexrazoxane", "entity2": "hematologic toxicity", "span1": [88, 99], "span2": [37, 57]}, "bert_text": "Because of their widespread use, the hematologic toxicity following coadministration of <e1> dexrazoxane </e1> <e2> hematologic toxicity </e2> following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"817": {"data": {"text": "Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/-", "entity1": "etoposide", "entity2": "hematologic toxicity", "span1": [238, 247], "span2": [37, 57]}, "bert_text": "Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to <e1> etoposide </e1> <e2> hematologic toxicity </e2> following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"818": {"data": {"text": "Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/-", "entity1": "daunorubicin", "entity2": "hematologic toxicity", "span1": [249, 261], "span2": [37, 57]}, "bert_text": "Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, <e1> daunorubicin </e1> <e2> hematologic toxicity </e2> following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"819": {"data": {"text": "Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/-", "entity1": "doxorubicin", "entity2": "hematologic toxicity", "span1": [267, 278], "span2": [37, 57]}, "bert_text": "Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and <e1> doxorubicin </e1> <e2> hematologic toxicity </e2> following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"820": {"data": {"text": "The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.", "entity1": "nomifensine", "entity2": "hyperactivity", "span1": [29, 40], "span2": [4, 17]}, "bert_text": "The hyperactivity induced by <e1> nomifensine </e1> <e2> hyperactivity </e2> induced by nomifensine in mice remained unaffected by fluvoxamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"821": {"data": {"text": "The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.", "entity1": "fluvoxamine", "entity2": "hyperactivity", "span1": [72, 83], "span2": [4, 17]}, "bert_text": "The hyperactivity induced by nomifensine in mice remained unaffected by <e1> fluvoxamine </e1> <e2> hyperactivity </e2> induced by nomifensine in mice remained unaffected by fluvoxamine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"822": {"data": {"text": "Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).", "entity1": "iopentol", "entity2": "ventricular fibrillation", "span1": [90, 98], "span2": [15, 39]}, "bert_text": "Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after <e1> iopentol </e1> <e2> ventricular fibrillation </e2> were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"823": {"data": {"text": "Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).", "entity1": "iohexol", "entity2": "ventricular fibrillation", "span1": [108, 115], "span2": [15, 39]}, "bert_text": "Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and <e1> iohexol </e1> <e2> ventricular fibrillation </e2> were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"824": {"data": {"text": "Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).", "entity1": "metrizoate", "entity2": "ventricular fibrillation", "span1": [132, 142], "span2": [15, 39]}, "bert_text": "Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after <e1> metrizoate </e1> <e2> ventricular fibrillation </e2> were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"825": {"data": {"text": "The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.", "entity1": "naloxone", "entity2": "hypotensive", "span1": [22, 30], "span2": [70, 81]}, "bert_text": "The opioid antagonist <e1> naloxone </e1> has been shown to block or reverse the <e2> hypotensive </e2> actions of captopril.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"826": {"data": {"text": ". MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.", "entity1": "MK-801", "entity2": "catalepsy", "span1": [2, 8], "span2": [51, 60]}, "bert_text": ". <e1> MK-801 </e1> (0.1 mg/kg) administration attenuated the <e2> catalepsy </e2> and tremor induced by reserpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"827": {"data": {"text": ". MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.", "entity1": "MK-801", "entity2": "tremor", "span1": [2, 8], "span2": [65, 71]}, "bert_text": ". <e1> MK-801 </e1> (0.1 mg/kg) administration attenuated the catalepsy and <e2> tremor </e2> induced by reserpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"828": {"data": {"text": ". MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.", "entity1": "reserpine", "entity2": "catalepsy", "span1": [83, 92], "span2": [51, 60]}, "bert_text": ". MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by <e1> reserpine </e1> <e2> catalepsy </e2> and tremor induced by reserpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"829": {"data": {"text": ". MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.", "entity1": "reserpine", "entity2": "tremor", "span1": [83, 92], "span2": [65, 71]}, "bert_text": ". MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by <e1> reserpine </e1> <e2> tremor </e2> induced by reserpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"830": {"data": {"text": "By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.", "entity1": "hydromorphone", "entity2": "pain", "span1": [188, 201], "span2": [88, 92]}, "bert_text": "By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (<e1> hydromorphone </e1> <e2> pain </e2> was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"831": {"data": {"text": "By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.", "entity1": "ketorolac", "entity2": "pain", "span1": [244, 253], "span2": [88, 92]}, "bert_text": "By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (<e1> ketorolac </e1> <e2> pain </e2> was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"832": {"data": {"text": "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "entity1": "reserpine", "entity2": "tremor", "span1": [18, 27], "span2": [166, 172]}, "bert_text": "Pretreatment with <e1> reserpine </e1> (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in <e2> tremor </e2> and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"833": {"data": {"text": "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "entity1": "reserpine", "entity2": "catalepsy", "span1": [18, 27], "span2": [177, 186]}, "bert_text": "Pretreatment with <e1> reserpine </e1> (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and <e2> catalepsy </e2>, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"834": {"data": {"text": "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "entity1": "reserpine", "entity2": "tremor", "span1": [272, 281], "span2": [166, 172]}, "bert_text": "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of <e1> reserpine </e1> <e2> tremor </e2> and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"835": {"data": {"text": "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "entity1": "reserpine", "entity2": "catalepsy", "span1": [272, 281], "span2": [177, 186]}, "bert_text": "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of <e1> reserpine </e1> <e2> catalepsy </e2>, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"836": {"data": {"text": "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "entity1": "MK-801", "entity2": "tremor", "span1": [196, 202], "span2": [166, 172]}, "bert_text": "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas <e1> MK-801 </e1> <e2> tremor </e2> and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"837": {"data": {"text": "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "entity1": "MK-801", "entity2": "catalepsy", "span1": [196, 202], "span2": [177, 186]}, "bert_text": "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas <e1> MK-801 </e1> <e2> catalepsy </e2>, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"838": {"data": {"text": "Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.\n", "entity1": "deoxycholic acid", "entity2": "cholestasis", "span1": [58, 74], "span2": [104, 115]}, "bert_text": "Increased sulfation and decreased 7alpha-hydroxylation of <e1> deoxycholic acid </e1> in ethinyl estradiol-induced <e2> cholestasis </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"839": {"data": {"text": "Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.\n", "entity1": "ethinyl estradiol", "entity2": "cholestasis", "span1": [78, 95], "span2": [104, 115]}, "bert_text": "Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in <e1> ethinyl estradiol </e1>-induced <e2> cholestasis </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"840": {"data": {"text": "We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.", "entity1": "cefotetan", "entity2": "hemolytic anemias", "span1": [38, 47], "span2": [56, 73]}, "bert_text": "We noticed that 10 of our 35 cases of <e1> cefotetan </e1>-induced <e2> hemolytic anemias </e2> were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"841": {"data": {"text": "We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.", "entity1": "cefotetan", "entity2": "hemolytic anemias", "span1": [108, 117], "span2": [56, 73]}, "bert_text": "We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received <e1> cefotetan </e1> <e2> hemolytic anemias </e2> were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"842": {"data": {"text": "Cocaine-induced brainstem seizures and behavior.\n", "entity1": "Cocaine", "entity2": "seizures", "span1": [0, 7], "span2": [26, 34]}, "bert_text": "<e1> Cocaine </e1>-induced brainstem <e2> seizures </e2> and behavior.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"843": {"data": {"text": "A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.", "entity1": "oxacillin", "entity2": "Staphylococcus aureus bacteremia", "span1": [39, 48], "span2": [73, 105]}, "bert_text": "A 67-year-old man who was treated with <e1> oxacillin </e1> for one week because of <e2> Staphylococcus aureus bacteremia </e2>, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"844": {"data": {"text": "A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.", "entity1": "oxacillin", "entity2": "renal failure", "span1": [39, 48], "span2": [117, 130]}, "bert_text": "A 67-year-old man who was treated with <e1> oxacillin </e1> for one week because of Staphylococcus aureus bacteremia, developed <e2> renal failure </e2> and diffuse, symmetric, palpable purpuric lesions on his feet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"845": {"data": {"text": "A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.", "entity1": "oxacillin", "entity2": "purpuric lesions", "span1": [39, 48], "span2": [164, 180]}, "bert_text": "A 67-year-old man who was treated with <e1> oxacillin </e1> for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable <e2> purpuric lesions </e2> on his feet.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"846": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "dexrazoxane", "entity2": "myelosuppression", "span1": [27, 38], "span2": [47, 63]}, "bert_text": "RESULTS: Nontoxic doses of <e1> dexrazoxane </e1> reduced <e2> myelosuppression </e2> and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"847": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "dexrazoxane", "entity2": "myelosuppression", "span1": [27, 38], "span2": [226, 242]}, "bert_text": "RESULTS: Nontoxic doses of <e1> dexrazoxane </e1> reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced <e2> myelosuppression </e2>, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"848": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "dexrazoxane", "entity2": "weight loss", "span1": [27, 38], "span2": [68, 79]}, "bert_text": "RESULTS: Nontoxic doses of <e1> dexrazoxane </e1> reduced myelosuppression and <e2> weight loss </e2> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"849": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "dexrazoxane", "entity2": "weight loss", "span1": [27, 38], "span2": [244, 255]}, "bert_text": "RESULTS: Nontoxic doses of <e1> dexrazoxane </e1> reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, <e2> weight loss </e2>, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"850": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "dexrazoxane", "entity2": "cytotoxicity", "span1": [27, 38], "span2": [274, 286]}, "bert_text": "RESULTS: Nontoxic doses of <e1> dexrazoxane </e1> reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro <e2> cytotoxicity </e2> from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"851": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "dexrazoxane", "entity2": "myelosuppression", "span1": [198, 209], "span2": [47, 63]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, <e1> dexrazoxane </e1> <e2> myelosuppression </e2> and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"852": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "dexrazoxane", "entity2": "myelosuppression", "span1": [198, 209], "span2": [226, 242]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, <e1> dexrazoxane </e1> neither reduced <e2> myelosuppression </e2>, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"853": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "dexrazoxane", "entity2": "weight loss", "span1": [198, 209], "span2": [68, 79]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, <e1> dexrazoxane </e1> <e2> weight loss </e2> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"854": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "dexrazoxane", "entity2": "weight loss", "span1": [198, 209], "span2": [244, 255]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, <e1> dexrazoxane </e1> neither reduced myelosuppression, <e2> weight loss </e2>, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"855": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "dexrazoxane", "entity2": "cytotoxicity", "span1": [198, 209], "span2": [274, 286]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, <e1> dexrazoxane </e1> neither reduced myelosuppression, weight loss, nor the in vitro <e2> cytotoxicity </e2> from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"856": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "daunorubicin", "entity2": "myelosuppression", "span1": [85, 97], "span2": [47, 63]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from <e1> daunorubicin </e1> <e2> myelosuppression </e2> and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"857": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "daunorubicin", "entity2": "myelosuppression", "span1": [85, 97], "span2": [226, 242]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from <e1> daunorubicin </e1> and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced <e2> myelosuppression </e2>, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"858": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "daunorubicin", "entity2": "weight loss", "span1": [85, 97], "span2": [68, 79]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from <e1> daunorubicin </e1> <e2> weight loss </e2> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"859": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "daunorubicin", "entity2": "weight loss", "span1": [85, 97], "span2": [244, 255]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from <e1> daunorubicin </e1> and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, <e2> weight loss </e2>, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"860": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "daunorubicin", "entity2": "cytotoxicity", "span1": [85, 97], "span2": [274, 286]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from <e1> daunorubicin </e1> and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro <e2> cytotoxicity </e2> from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"861": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "etoposide", "entity2": "myelosuppression", "span1": [102, 111], "span2": [47, 63]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and <e1> etoposide </e1> <e2> myelosuppression </e2> and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"862": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "etoposide", "entity2": "myelosuppression", "span1": [102, 111], "span2": [226, 242]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and <e1> etoposide </e1> in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced <e2> myelosuppression </e2>, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"863": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "etoposide", "entity2": "weight loss", "span1": [102, 111], "span2": [68, 79]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and <e1> etoposide </e1> <e2> weight loss </e2> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"864": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "etoposide", "entity2": "weight loss", "span1": [102, 111], "span2": [244, 255]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and <e1> etoposide </e1> in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, <e2> weight loss </e2>, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"865": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "etoposide", "entity2": "cytotoxicity", "span1": [102, 111], "span2": [274, 286]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and <e1> etoposide </e1> in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro <e2> cytotoxicity </e2> from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"866": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "doxorubicin", "entity2": "myelosuppression", "span1": [292, 303], "span2": [47, 63]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from <e1> doxorubicin </e1> <e2> myelosuppression </e2> and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"867": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "doxorubicin", "entity2": "myelosuppression", "span1": [292, 303], "span2": [226, 242]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from <e1> doxorubicin </e1> <e2> myelosuppression </e2>, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"868": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "doxorubicin", "entity2": "weight loss", "span1": [292, 303], "span2": [68, 79]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from <e1> doxorubicin </e1> <e2> weight loss </e2> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"869": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "doxorubicin", "entity2": "weight loss", "span1": [292, 303], "span2": [244, 255]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from <e1> doxorubicin </e1> <e2> weight loss </e2>, nor the in vitro cytotoxicity from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"870": {"data": {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity1": "doxorubicin", "entity2": "cytotoxicity", "span1": [292, 303], "span2": [274, 286]}, "bert_text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from <e1> doxorubicin </e1> <e2> cytotoxicity </e2> from doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"871": {"data": {"text": "We report the clinical and bioptic findings for a 57-year-old woman with severe chloroquine-induced myopathy.", "entity1": "chloroquine", "entity2": "myopathy", "span1": [80, 91], "span2": [100, 108]}, "bert_text": "We report the clinical and bioptic findings for a 57-year-old woman with severe <e1> chloroquine </e1>-induced <e2> myopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"872": {"data": {"text": "As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.", "entity1": "heroin", "entity2": "syncope", "span1": [3, 9], "span2": [106, 113]}, "bert_text": "As <e1> heroin </e1> addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of <e2> syncope </e2> to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"873": {"data": {"text": "As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.", "entity1": "heroin", "entity2": "TdP", "span1": [3, 9], "span2": [177, 180]}, "bert_text": "As <e1> heroin </e1> addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of <e2> TdP </e2> in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"874": {"data": {"text": "As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.", "entity1": "methadone", "entity2": "syncope", "span1": [306, 315], "span2": [106, 113]}, "bert_text": "As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of <e1> methadone </e1> <e2> syncope </e2> to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"875": {"data": {"text": "As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.", "entity1": "methadone", "entity2": "TdP", "span1": [306, 315], "span2": [177, 180]}, "bert_text": "As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of <e1> methadone </e1> <e2> TdP </e2> in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"876": {"data": {"text": "Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.\n", "entity1": "13-cis-retinoic acid", "entity2": "neuroblastoma", "span1": [17, 37], "span2": [55, 68]}, "bert_text": "Phase I trial of <e1> 13-cis-retinoic acid </e1> in children with <e2> neuroblastoma </e2> following bone marrow transplantation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"877": {"data": {"text": "PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.", "entity1": "13-cis-retinoic acid", "entity2": "neuroblastoma", "span1": [52, 72], "span2": [22, 35]}, "bert_text": "PURPOSE: Treatment of neuroblastoma cell lines with <e1> 13-cis-retinoic acid </e1> <e2> neuroblastoma </e2> cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
	"878": {"data": {"text": "PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.", "entity1": "cis-RA", "entity2": "neuroblastoma", "span1": [74, 80], "span2": [22, 35]}, "bert_text": "PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (<e1> cis-RA </e1> <e2> neuroblastoma </e2> cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
	"879": {"data": {"text": "There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.", "entity1": "sulindac", "entity2": "hearing loss", "span1": [83, 91], "span2": [137, 149]}, "bert_text": "There was no significant difference in the proportion of subjects in the DFMO plus <e1> sulindac </e1> group who experienced clinically significant <e2> hearing loss </e2> compared with the placebo group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"880": {"data": {"text": "A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.", "entity1": "lithium", "entity2": "tricuspid regurgitation", "span1": [107, 114], "span2": [23, 46]}, "bert_text": "A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum <e1> lithium </e1> <e2> tricuspid regurgitation </e2>, atrial flutter, congestive heart failure, and a high serum lithium level is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
	"881": {"data": {"text": "A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.", "entity1": "lithium", "entity2": "atrial flutter", "span1": [107, 114], "span2": [48, 62]}, "bert_text": "A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum <e1> lithium </e1> <e2> atrial flutter </e2>, congestive heart failure, and a high serum lithium level is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
	"882": {"data": {"text": "A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.", "entity1": "lithium", "entity2": "congestive heart failure", "span1": [107, 114], "span2": [64, 88]}, "bert_text": "A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum <e1> lithium </e1> <e2> congestive heart failure </e2>, and a high serum lithium level is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
	"883": {"data": {"text": "The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.", "entity1": "gentamicin", "entity2": "acute renal failure", "span1": [105, 115], "span2": [66, 85]}, "bert_text": "The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with <e1> gentamicin </e1> <e2> acute renal failure </e2> after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"884": {"data": {"text": "The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.", "entity1": "penicillin", "entity2": "acute renal failure", "span1": [134, 144], "span2": [66, 85]}, "bert_text": "The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and <e1> penicillin </e1> <e2> acute renal failure </e2> after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"885": {"data": {"text": "The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)", "entity1": "malondialdehyde", "entity2": "ischemic", "span1": [52, 67], "span2": [195, 203]}, "bert_text": "The present data indicate that the determination of <e1> malondialdehyde </e1>, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during <e2> ischemic </e2> phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"886": {"data": {"text": "The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)", "entity1": "nucleosides", "entity2": "ischemic", "span1": [85, 96], "span2": [195, 203]}, "bert_text": "The present data indicate that the determination of malondialdehyde, oxypurines, and <e1> nucleosides </e1> in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during <e2> ischemic </e2> phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"887": {"data": {"text": "Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.", "entity1": "puromycin aminonucleoside", "entity2": "hematological abnormalities", "span1": [43, 68], "span2": [77, 104]}, "bert_text": "Treatment with antithrombin attenuated the <e1> puromycin aminonucleoside </e1>-induced <e2> hematological abnormalities </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"888": {"data": {"text": "One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.", "entity1": "carbamazepine", "entity2": "sinus tachycardias", "span1": [75, 88], "span2": [28, 46]}, "bert_text": "One patient group developed sinus tachycardias in the setting of a massive <e1> carbamazepine </e1> <e2> sinus tachycardias </e2> in the setting of a massive carbamazepine overdose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"889": {"data": {"text": "One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.", "entity1": "carbamazepine", "entity2": "overdose", "span1": [75, 88], "span2": [89, 97]}, "bert_text": "One patient group developed sinus tachycardias in the setting of a massive <e1> carbamazepine </e1> <e2> overdose </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"890": {"data": {"text": "CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.", "entity1": "Cyclophosphamide", "entity2": "bladder tumor", "span1": [13, 29], "span2": [41, 54]}, "bert_text": "CONCLUSIONS: <e1> Cyclophosphamide </e1> associated <e2> bladder tumor </e2> is an aggressive disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"891": {"data": {"text": "CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.", "entity1": "Cyclophosphamide", "entity2": "aggressive disease", "span1": [13, 29], "span2": [61, 79]}, "bert_text": "CONCLUSIONS: <e1> Cyclophosphamide </e1> associated bladder tumor is an <e2> aggressive disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"892": {"data": {"text": "Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.", "entity1": "N-terminal pro brain natriuretic peptide", "entity2": "cardiovascular toxicity", "span1": [27, 67], "span2": [217, 240]}, "bert_text": "Diagnostic markers such as <e1> N-terminal pro brain natriuretic peptide </e1> (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious <e2> cardiovascular toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"893": {"data": {"text": "Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.", "entity1": "NT-proBNP", "entity2": "cardiovascular toxicity", "span1": [69, 78], "span2": [217, 240]}, "bert_text": "Diagnostic markers such as N-terminal pro brain natriuretic peptide (<e1> NT-proBNP </e1>) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious <e2> cardiovascular toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"894": {"data": {"text": "CONCLUSION: Lovastatin is highly effective and generally well tolerated as therapy for primary hypercholesterolemia in women.", "entity1": "Lovastatin", "entity2": "hypercholesterolemia", "span1": [12, 22], "span2": [95, 115]}, "bert_text": "CONCLUSION: <e1> Lovastatin </e1> is highly effective and generally well tolerated as therapy for primary <e2> hypercholesterolemia </e2> in women.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"895": {"data": {"text": "DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.\n", "entity1": "cyclophosphamide", "entity2": "myeloma", "span1": [47, 63], "span2": [166, 173]}, "bert_text": "DSMM XI study: dose definition for intravenous <e1> cyclophosphamide </e1> in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed <e2> myeloma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"896": {"data": {"text": "DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.\n", "entity1": "bortezomib", "entity2": "myeloma", "span1": [84, 94], "span2": [166, 173]}, "bert_text": "DSMM XI study: dose definition for intravenous cyclophosphamide in combination with <e1> bortezomib </e1>/dexamethasone for remission induction in patients with newly diagnosed <e2> myeloma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"897": {"data": {"text": "DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.\n", "entity1": "dexamethasone", "entity2": "myeloma", "span1": [95, 108], "span2": [166, 173]}, "bert_text": "DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/<e1> dexamethasone </e1> for remission induction in patients with newly diagnosed <e2> myeloma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
	"898": {"data": {"text": "Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.", "entity1": "Estrogens", "entity2": "cancers", "span1": [0, 9], "span2": [77, 84]}, "bert_text": "<e1> Estrogens </e1>, which have been associated with several types of human and animal <e2> cancers </e2>, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"899": {"data": {"text": "Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.", "entity1": "Estrogens", "entity2": "tumor", "span1": [0, 9], "span2": [97, 102]}, "bert_text": "<e1> Estrogens </e1>, which have been associated with several types of human and animal cancers, can induce <e2> tumor </e2> angiogenesis in the pituitary of Fischer 344 rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"900": {"data": {"text": "Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.\n", "entity1": "malondialdehyde", "entity2": "cerebral ischemia", "span1": [26, 41], "span2": [89, 106]}, "bert_text": "Time dependence of plasma <e1> malondialdehyde </e1>, oxypurines, and nucleosides during incomplete <e2> cerebral ischemia </e2> in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
	"901": {"data": {"text": "Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.\n", "entity1": "nucleosides", "entity2": "cerebral ischemia", "span1": [59, 70], "span2": [89, 106]}, "bert_text": "Time dependence of plasma malondialdehyde, oxypurines, and <e1> nucleosides </e1> during incomplete <e2> cerebral ischemia </e2> in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"902": {"data": {"text": "All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. epileptic onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively).", "entity1": "tacrine", "entity2": "epileptic", "span1": [29, 36], "span2": [114, 123]}, "bert_text": "All the animals treated with <e1> tacrine </e1>-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. <e2> epileptic </e2> onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"903": {"data": {"text": "A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.", "entity1": "sulindac", "entity2": "adenomatous polyps", "span1": [144, 152], "span2": [54, 72]}, "bert_text": "A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus <e1> sulindac </e1> <e2> adenomatous polyps </e2> after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"904": {"data": {"text": "The serum gentamicin concentration had reached toxic levels when anuria developed.", "entity1": "gentamicin", "entity2": "anuria", "span1": [10, 20], "span2": [65, 71]}, "bert_text": "The serum <e1> gentamicin </e1> concentration had reached toxic levels when <e2> anuria </e2> developed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
	"905": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "BHA", "entity2": "forestomach tumors", "span1": [19, 22], "span2": [211, 229]}, "bert_text": "In groups given 2% <e1> BHA </e1>, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of <e2> forestomach tumors </e2> (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
	"906": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "BHA", "entity2": "squamous cell papilloma", "span1": [19, 22], "span2": [231, 254]}, "bert_text": "In groups given 2% <e1> BHA </e1>, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (<e2> squamous cell papilloma </e2> and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"907": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "BHA", "entity2": "carcinoma", "span1": [19, 22], "span2": [259, 268]}, "bert_text": "In groups given 2% <e1> BHA </e1>, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and <e2> carcinoma </e2>) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"908": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "BHA", "entity2": "carcinoma", "span1": [19, 22], "span2": [296, 305]}, "bert_text": "In groups given 2% <e1> BHA </e1>, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with <e2> carcinoma </e2>) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"909": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "BHA", "entity2": "carcinoma", "span1": [19, 22], "span2": [336, 345]}, "bert_text": "In groups given 2% <e1> BHA </e1>, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with <e2> carcinoma </e2>) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"910": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "RA", "entity2": "forestomach tumors", "span1": [148, 150], "span2": [211, 229]}, "bert_text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% <e1> RA </e1> significantly (P less than 0.05) increased the incidence of <e2> forestomach tumors </e2> (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"911": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "RA", "entity2": "squamous cell papilloma", "span1": [148, 150], "span2": [231, 254]}, "bert_text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% <e1> RA </e1> significantly (P less than 0.05) increased the incidence of forestomach tumors (<e2> squamous cell papilloma </e2> and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"912": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "RA", "entity2": "carcinoma", "span1": [148, 150], "span2": [259, 268]}, "bert_text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% <e1> RA </e1> significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and <e2> carcinoma </e2>) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"913": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "RA", "entity2": "carcinoma", "span1": [148, 150], "span2": [296, 305]}, "bert_text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% <e1> RA </e1> significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with <e2> carcinoma </e2>) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"914": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "RA", "entity2": "carcinoma", "span1": [148, 150], "span2": [336, 345]}, "bert_text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% <e1> RA </e1> significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with <e2> carcinoma </e2>) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"915": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "RA", "entity2": "forestomach tumors", "span1": [366, 368], "span2": [211, 229]}, "bert_text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given <e1> RA </e1> <e2> forestomach tumors </e2> (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"916": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "RA", "entity2": "squamous cell papilloma", "span1": [366, 368], "span2": [231, 254]}, "bert_text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given <e1> RA </e1> <e2> squamous cell papilloma </e2> and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"917": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "RA", "entity2": "carcinoma", "span1": [366, 368], "span2": [259, 268]}, "bert_text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given <e1> RA </e1> <e2> carcinoma </e2>) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"918": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "RA", "entity2": "carcinoma", "span1": [366, 368], "span2": [296, 305]}, "bert_text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given <e1> RA </e1> <e2> carcinoma </e2>) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
	"919": {"data": {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity1": "RA", "entity2": "carcinoma", "span1": [366, 368], "span2": [336, 345]}, "bert_text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given <e1> RA </e1> <e2> carcinoma </e2>) in the group given RA-free water.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0}
}